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ABSTRACT
The Effect of Concomitant Ecstasy-Marijuana Use on
Auditory Verbal Learning and
Memory Performance
by
Kimberly M. Cramer
Dr. Douglas Ferraro, Examination Committee Chair
Professor of Psychology
University o f Nevada, Las Vegas
Previous research indicates that ecstasy users exhibit deficits of verbal learning and
memory. This research has not considered polydrug use in ecstasy users, especially
marijuana. Marijuana is an important confound because 90 percent of ecstasy users also
use marijuana. Several studies have suggested that marijuana use alters verbal memory
functioning; consequently, it is difficult to ascertain whether the observed memory
deficits in ecstasy users are attributable to ecstasy, marijuana, or other drug use. The
present study examined the effects of marijuana and ecstasy on verbal memory function.
Marijuana use was accounted for by recruiting concurrent ecstasy-marijuana users’ and
ecstasy-naïve marijuana-only users. Furthermore, the extent of marijuana use was
controlled for in the combined ecstasy-marijuana and marijuana-only groups by assigning
marijuana users to either the marijuana light or marijuana heavy experimental groups.
Recent animal findings suggest that at low frequencies marijuana may exert
neuroprotective effects against ecstasy-induced neurotoxicity. Alternatively, other animal
iii

findings have demonstrated negative synergistic effects between ecstasy and marijuana
and working memory performance. Polydrug use was controlled for by restricting other
drug use to not more than 15 occasions. Based upon responses to a drug use history
questionnaire, 109 students were retrospectively assigned to one o f five groups;
marijuana-only heavy users, marijuana-only light users, ecstasy-marijuana heavy users,
ecstasy-marijuana light users, and non-drug using controls. Participants were matched for
age, gender, education, and intelligence as measured by the Wechsler Adult Intelligence
Scale, Third Edition. Verbal learning and memory performance was assessed using the
Auditory Verbal Learning Test (AVLT) (Rey, 1964; Schmidt, 1996). The Biber Figure
Learning Test-Extended version (BFLT-E) was administered during the 20-minute delay
of the AVLT. AVLT performance was compared between the two marijuana-only groups
and the controls to determine the impact of marijuana use on mnemonic function. The
marijuana-only user groups were compared with the ecstasy-marijuana groups to evaluate
the effects o f ecstasy on verbal memory. Overall, findings in the present study suggest
that marijuana use more than ecstasy were associated with AVLT. Additionally, drug use
other than ecstasy and marijuana explained some of the impairment observed on the
AVLT and even more so for BFLT-E performance

IV

TABLE OF CONTENTS
ABSTRACT............................................................................................................................iii
LIST OF TABLES................................................................................................................ vii
LIST OF FIGURES....................................
ACKNOWLEDGEMENTS....................................................................................

viii
ix

CHAPTER 1 INTRODUCTION..........................................
1
Explicit Long-Term Verbal Memory Studies in Ecstasy Users......................................... 6
Explanations for the Diversity of Findings........................................................................14
The Marijuana Confound.....................................................................
15
Evidence Demonstrating Interactive Effects of MDMA and Marijuana........................ 18
The Proposed Investigation................................................................................................. 23
CHAPTER 2 REVIEW OF RELATED LITERATURE............................................... 25
History of M DM A...............
25
Neuropharmacology of M DM A........................................................................................ 26
The Serotonin System......................................................................................................... 28
Serotonergic Neuron Distribution and Pathways..............................................................29
Serotonergic Receptors....................................................................................................... 32
MDMA and Serotonin Receptors...................................................................................... 39
Neuropsychopharmacological Effects of MDMA in Experimental Animals................ 42
Acute Subjective Effects of MDMA in Humans..............................................................44
Long-Lasting Subjective Effects of Ecstasy in Humans.................................................. 44
Mechanisms of MDMA-Induced Neurotoxicity...............................................................45
Evidence of the Neurotoxic Effects of MDMA in Animals............................................ 49
Evidence of Neurotoxic Effects of MDMA in Humans.....................................
51
Evidence that MDMA Induces Residual Effects on Cognition...........................
55
Executive Function..............................................................................................................67
Methodological Challenges................................................................................................ 71
Directions for Future Research...........................................................................................74
Summary and Conclusions...................
76
Marijuana.....................................
77
Metabolism of Cannabinoids
...............................................................................78
Carmabinoid Receptors....................................................................................................... 79
Mechanisms of Action.........................................................................................................81
Does Marijuana Produce Dependence, Tolerance and Withdrawal?...............................82
Acute Physiological Effects o f M arijuana.........................................................................83

Acute Psychological Effects o f M arijuana....................................................................... 83
Appetite, Noiception and Anti-Emetic Acute Effects of Marijuana................................84
Acute Cognitive Effects of Marijuana...............................................................................85
Attention and Perception.........................................................................
Learning and Memory..................................................................................................... 86
Long-term Residual Effects of Marijuana Use on Neuropsychological Functioning... 88
Findings in Brain Imaging Studies................................................................................88
Behavioral Findings Related to the Residual Effects of Marijuana.................................90
Is Marijuana Neurotoxic?...................................................................................................96
Summary............................................................................................................................ 100
CHAPTER 3 METHODOLOGY.................................................................................. 102
Aim of the Proposed Study...............................................................................................102
Participants......................................................................................................................... 103
Experimental Groups
........................................................................
Dependent Measures..........................................................................................................108
Procedure............................................................................................
Predictions.......................................................................................................................... 117
Statistical Analyses............................................................................................................121
CHAPTER 4 RESULTS................................................................................................. 126
Descriptive Statistics..........................................................................................................126
AVLT Task Data................................................................................................................ 131
Regression Analyses..........................................................................................................152
CHAPTER 5

DISCUSSION........................................................................... ............. 155

APPENDIX I

TABLES.................................................................................................. 168

APPENDIX II

DRUG USE HISTORY QUESTIONNAIRE....................................... 180

REFERENCES..................................................................................................................... 182
VITA

........................................................................................................................ 229

VI

85

105

LIST OF TABLES
Table 1

Table 2
Table 3

Table 4
Table 5
Table 6
Table 7
Table 8
Table 9
Table 10
Table 11
Table 12
Table 13
Table 14
Table 15
Table 16

Well-controlled studies of verbal learning and memory in ecstasy users
with relatively strong control over the influence of drugs apart from
ecstasy......................................................................................................... 167
Verbal learning and memory studies that exercised less control over the
influence of drugs apart from ecstasy and other possible covariates.... 169
Cumulative lifetime dose (unless otherwise specified) of MDMA and
cannabis use in studies investigating long-term verbal memory
performance in ecstasy users.................................................................... 170
Different serotonin (5-HT) receptor subtypes...............................................32
Demographic characteristics in the control group and the drug user groups
126
Patterns of drug use by drug in the drug user groups and the control group
.................................................................................................................... 173
Mean total acquisition scores on the AVLT for each group......................132
Mean number of words recalled on the interference trial for the groups 134
Interference scores for males and females in each group.......................... 136
Proactive interference scores for males and females in each group
139
AVLT trial 6 (immediate recall) scores for each group............................. 140
Trial 7 (delayed recall) scores for each group............................................142
Recognition scores for each group............................................................... 144
Error association scores for males and females in each group................. 146
BFLT-E immediate recall scores for each group........................................148
BFLT-E extra responses for each group
....................................... 150

Vll

LIST OF FIGURES
Figure 1

Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14

Schematic drawing depicting the location of the serotonergic cell body
groups in a sagittal section of the rat central nervous system and their
major projections..............................................
30
Predictions for additive effects of ecstasy and marijuana use on the
number o f words recalled on the AVLT...................................................118
Predictions for positive synergistic effects between ecstasy and marijuana
use on the number of words recalled on the AVLT............................... 119
Predictions for negative synergistic effects between ecstasy and marijuana
use on the number of words recalled on the AVLT.................................120
Mean AVLT total acquisition scores and standard errors for each
group............................................................................................................ 133
Mean number of words recalled on the interference trial (List B) o f the
AVLT for each group................................................................................. 135
Observed means and standard errors for females and males in each group
on the interference trial of the A V LT....................................................... 137
Observed means and standard errors calculated for proactive interference
139
for each group......................................................................
Mean number of words recalled on AVLT trial 6 for each group
141
Mean number of words recalled on trial 7 of the AVLT for each group 143
Observed group means and standard errors for hits on the AVLT
recognition trial...................................................
145
Mean number of error associations made by males and females in each
group on the AVLT.....................................................................................147
Observed group means and standard errors for the BFLT-E immediate
recall trial
.............................................................................................. 149
The observed mean total number of extra responses made on BFLT-E
trials 1 through 7 and on interference trial B for each group..................151

V lll

ACKNOWLEDGEMENTS
The written pages included in this dissertation hold far more than the years of
study and work that I have put into this project. This project also reflects the many
wonderful relationships that I have formed with those who have become instrumental to
the completion o f my study.
To my advisor and committee chair, Dr. Douglas Ferraro, thank you for the
encouragement and the fact that you never stopped believing in me. Your patience and
compassion are deeply appreciated.
To my committee members. Dr. Daniel Allen, Dr. Laurel Pritchard,'and Dr. David
Beisecker, who were willing to devote their time and attention to my work during many
busy semesters.
To my husband, Eric Cramer, who has stood by my side through the many years of
frustration, joy, sadness, and happiness that encompass the course o f a graduate study.
To my friends, Mike and Helen Montgomery who have shown me the meaning of
true friendship and statistical analyses.
To all of my colleagues and professors who believed in me and showed me that
through hard work, I will persevere in my goal.

IX

CHAPTER 1

INTRODUCTION
Sought after for its tempered stimulant-hallucinogenic properties and reported
enhancement of social interaction, ecstasy’s popularity has risen to make it one of the
four most commonly used illicit drugs in the world (Christophersen, 2000). Ethnographic
data from the National Institute on Drug Abuse (NIDA) (2003) showed that ecstasy use is
spreading from dance parties and raves to high schools, colleges, and other social settings
frequented by adolescents and young adults. This is particularly alarming given that non
human primate and other animal studies suggest that the main psychoactive ingredient of
ecstasy, namely methylendioxymethamphetamine (MDMA), is neurotoxic upon central
serotonergic systems (e.g., Fischer et al., 1995; Ricaurte et al., 2000).
Taking MDMA leads to an acute massive neuronal release of serotonin, followed by a
period o f depletion before levels return to normal. Serotonin is thought to play a
prominent role in memory function and marked toxic effects of MDMA have been
observed in the hippocampus and prefrontal cortex. These areas are crucial to memory
and other cognitive functions (Sabol, Lew, Richards, Vosmer, & Seiden, 1996). This
suggests that MDMA may have long-term effects on memory and cognition.
In laboratory animals, high and repeated doses of MDMA produce widespread
degeneration of serotonergic axon terminals, with a concomitant depletion of serotonin in
brain regions such as the prefrontal cortex and hippocampus (Battaglia, Sharkey, Kuhar,
1

& de Souza, 1991; Ricaurte, DeLanney, Invin, & Langston, 1988; Sabol et al., 1996).
The hippocampus and the parahippocampus display relatively low rates of recovery after
abstinence from ecstasy and abnormal patterns of reinnervation are observed in the
hypothalamus and thalamus (Fischer et al., 1995; Hatzidimitriou et al., 1999; Ricaurte,
Martello, Katz, & Martello, 1992).
Corresponding with the animal evidence, neuroimaging studies in human ecstasy
users suggest MDMA use may be associated with structural alterations in serotonergic
functioning and therefore, may be neurotoxic. Functional magnetic resonance imaging
(fMRI), positron emission tomography (PET) and single photon emission tomography
(SPECT) studies have yielded evidence of long-term reductions in serotonergic
transporter densities (SERT) (McCann, Szabo, Scheffel, Dannals, & Ricaurte, 1998;
Reneman et al., 2001; Semple et al., 1999; Thomasius et al., 2003) and in cortical 5-HT2a
serotonergic receptor densities (Reneman, Majoie, Flick, & den Heeten, 2001),
deficiencies in cerebral metabolism (Chang et al., 1999; Chang et al., 2000; Obrocki et
al., 1999) and reduced cerebral spinal fluid (CSF) concentrations of 5-hydroxindoleacetic
acid (5-HIAA) (the major metabolite of serotonin; used as a marker for serotonergic
depletion) (McCann et al., 1999) in recreational ecstasy users. These data have been
interpreted as reflecting cumulative MDMA-induced damage to the serotonergic system,
with recent data pointing to partial recovery after prolonged abstinence (Buchert et al.,
2003; Gouzoulis-Mayfrank et al., 2002; Reneman et al., 2001; Semple et al., 1999;
Thomasius et al., 2003).
It remains unclear how these biological abnormalities might affect long-term
cognitive function since neuropsychological studies of ecstasy users have yielded

inconsistent results. On the one hand, studies indicate that users of ecstasy display
residual cognitive deficits, with a selective deficit of verbal learning and memory
impairment being most frequently observed in ecstasy users compared to controls on a
variety o f tasks (i.e., word list learning, prose recall, associative learning) (e.g.,
Bhattachery & Powell, 2001 ; Bolla, McCann, & Ricaurte, 1998; Curran & Travill, 1997;
Daumann et al., 2004; Fox, Toplis et al., 2001; Gouzoulis-Mayfrank et al., 2000;
Gouzoulis-Mayfrank et al., 2003; Krystal et al., 1992; McCann et al., 1999; McCardle et
al., 2004; Montgomery, Fisk, & Necombe, 2005; Morgan, 1999; Parrott & Lasky, 1998;
Quednow et al., 2006; Reneman et al., 2001; Thomasius et al., 2003; Yip & Lee, 2005).
Delayed and inunediate measures of recall performance in particular appear to be most
adversely affected in ecstasy users (Bhattachery & Powell, 2001; Bolla et al., 1998;
Curran & Travill, 1997; Curran & Verheyden, 2003; Fox, Toplis et al., 2001; GouzoulisMayfrank et al., 2000; Krystal & Price, 1992; McCardle et al., 2004; Montgomery, Fisk,
& Necombe, 2005; Morgan, 1999; Parrott & Lasky, 1998; Quednow et al., 2006;
Reneman et al., 2001; Rodgers, 2000, Thomasius et al., 2003; Yip & Lee, 2005).
Moreover, verbal memory performance in ecstasy users has been found to be
negatively associated with cumulative MDMA consumption (e.g., Bhattachary & Powell,
2001; Bolla et al., 1998; Curran & Travill, 1997; Fox, Toplis et al., 2001; GouzoulisMayfrank et al., 2000; Krystal & Price, 1992; Quednow et al., 2006; Thomasius et al.,
2003; Yip & Lee, 2005; Zakzanis & Young, 2001), levels of 5-hydroxyindoleacetic acid
(5-HIAA) depletion (5-HIAA is the major metabolite of serotonin) (Bolla et al., 1998;
McCann et al., 1998) and reduced serotonergic transporter (SERT) binding and
availability (Reneman et al., 2001; Semple et al., 1999; Thomasius et al., 2003).

On the other hand, a minority of studies have reported no differences between ecstasy
users and controls with regard to verbal memory performance (e.g., Back-Madruga et al.,
2003; Croft et al., 2001; Dafters, Hoshi, & Talbot, 2004; Fox, Parrott, & Turner, 2001;
Halpem et al., 2004; Lamers et al., 2006; Morgan, 1998; Parrott, 2000; Semple et al.,
1999). Some o f these studies have compared combined users of ecstasy and marijuana
with marijuana-only users and found an association between low memory performance
and the concomitant use o f marijuana rather than ecstasy (e.g., Croft et al., 2001 ; Dafters
et al., 2004; Gouzoulis-Mayfrank et al., 2000; Lamers et al., 2006; Thomasius et al.,
2003). Other studies have failed to find significant differences in verbal memory
performance when they compared ecstasy users with polydrug users matched for similar
patterns of drug use (Back-Madruga et al., 2003; Fox, Parrott et al., 2001; Halpem et al.,
2004; Semple et al., 1999; Simon & Mattick, 2002)
Interpretation o f the positive findings of verbal memory deficits are questionable,
however, because they are complicated by methodological shortcomings and potentially
confounding variables that may have contributed to the deficits observed. First, a number
of the earlier memory studies that demonstrate impairment did not adequately match
samples o f ecstasy users and control participants with regard to pre-morbid cognitive
ability, education level, gender and age. More recent studies have attempted to correct for
such differences by matching participants. With regard to pre-morbid intellectual ability,
researchers have either matched participants or adjusted for some measure of verbal
intelligence, since this measure is relatively immune to cortical insults.
Secondly, previous research provides little specific consideration for the concomitant
use o f other illicit drugs by ecstasy users, especially marijuana (e.g., Bolla et al., 1992;

Curran & Travill, 1997; Krystal et al., 1992; Parrott & Lasky, 1998). Marijuana use is a
particular problem for MDMA research because it is common for ecstasy users to
consume marijuana to enhance the MDMA-induced euphoria, as well as to mitigate the
unpleasant come-down effects that follow when the euphoria begins to diminish (Parrott,
2001). Subsequently, most ecstasy users have used marijuana more or less regularly
before they started taking ecstasy and continue using marijuana parallel to their use of
ecstasy (Gouzoulis-Mayfrank & Daumann, 2006). Strote et al. (2002) observed that 92
percent o f college students who had taken ecstasy also used marijuana. Moreover, a
recent survey showed that every novice ecstasy user (cumulative dose one to nine pills)
had smoked marijuana at least once during the preceding month and 32 percent had
smoked marijuana on five or more occasions during the preceding month. In addition, the
more pills these novice users had taken, the more frequently they had smoked marijuana
before (Scholey et al., 2004). Previous studies yielded similar results with rates o f 90 to
100 percent for co-use of marijuana in ecstasy users (Rodgers, 2000; Schuster et al.,
1998; Winstock et al., 2001). Thus, a large number of ecstasy users have also used a
substantial quantity of marijuana, making it difficult to recruit ecstasy users who have not
also used marijuana.
In addition, a number of neuropsychological studies have reported that habitual use of
marijuana may alter cognitive functioning, particularly verbal memory ability (e.g.. Block
& Gonheim, 1993; Fletcher et al., 1996; Hall & Solowij, 1998; Messinis et al., 2006;
Millsaps et al., 1994; Pope et al., 1996; Solowij et al., 2002). Furthermore, the severity of
marijuana-induced impairment appears to depend on the duration and the frequency of
marijuana use (e.g.. Hall & Solowij, 1998; Solowij et al., 2002). To some degree then, the

question remains as to whether cognitive deficits in ecstasy users are attributable to
ecstasy itself or to marijuana. Because most studies addressing MDMA neurotoxicity
have not controlled for marijuana use, more studies are needed to investigate the separate
effects of ecstasy and marijuana on verbal learning and memory performance.
The aim of the proposed study was to assess whether ecstasy users exhibit deficits in
explicit long-term verbal memory performance while accounting for concomitant use of
marijuana and other illicit dmgs, as well as intelligence. To delineate the respective
effects of marijuana and ecstasy on memory function, concomitant ecstasy-marijuana
users were compared to ecstasy-naive marijuana-only users approximately matched for
age, gender, level of education and intelligence. Furthermore, based on recent animal data
illustrating interactive effects of ecstasy and marijuana, the extent o f marijuana use was
manipulated to examine whether marijuana used in low and high recreational doses with
ecstasy exerts additive, supra-additive and/or subtractive effects on verbal memory
performance. Other illicit drug and alcohol use was accounted for by instituting strict
inclusion criteria.

Explicit Long-Term Verbal Memory Studies in Ecstasy Users
Behavioral studies o f ecstasy users have been hampered by the impossibility of using
double-blind, placebo-controlled, repeated dose regimens on ethical grounds and by
difficulty finding suitable control populations with which to compare ecstasy users (Croft
et al., 2001 ; Dafters et al., 2004). The fact that ecstasy users are usually polydrug users,
particularly with a long history of marijuana use has led some researchers to abandon the
traditional non-drug using control group, resorting instead to controlling for non-ecstasy

drug use by statistical adjustments of levels of other drug use (Curran & Verheyden,
2003; Dafters et al., 1999; Fox et al., 2001; Halpem et al., 2004; McCardle et al., 2004;
Mongomery et al., 2005; Quednow et al., 2006; Reneman et al., 2001; Simon & Mattick,
2002; Thomasius et al., 2003; Verkes et al., 2001). Others have attempted to compare
ecstasy users with ecstasy -naive users with otherwise comparable drug use histories
(e.g., Croft et al., 2001; Dafters et al., 2004; Gouzoulis-Mayfrank et al., 2000; Lamers et
al., 2006; McCann et al., 1999; Morgan, 1998, 1999; Morgan et al., 2002; Quednow et
al., 2006; Rogers, 2000; Thomasius et al., 2003).
Tables 1 and 2 (see Appendix I) summarize previous findings regarding ecstasyrelated performance on explicit long-term verbal memory tests. The studies are split into
two tables because they vary in the degree of specificity with which any cohort
differences can be attributed to ecstasy. With the exception of the ecstasy users recruited
by Yip and Lee (2005), Gouzoulis-Mayfrank et al. (2000) and Halpem et al. (2004), the
majority of ecstasy users in studies also used a variety of other drugs and alcohol. This is
tolerated in this field of research because it is generally considered impractical to obtain
samples that do not use alcohol and other drugs. Consequently, evidence with the greatest
degree o f specificity to ecstasy comes from studies that statistically control for the use of
other drugs and/or compare ecstasy users to a control group of individuals who have
similar drug use patterns, but have never used ecstasy.
Additionally, studies with a high degree of specificity to the long-term effects of
ecstasy control for other potential covariates by excluding individuals with a history of
relevant psychiatric conditions and by statistical controlling for and/or matching cohorts
on gender, age, estimated pre-morbid intelligence and level of education.

The studies in Table 1 exercised a relatively higher degree of control over possible
confounding variables compared to those in Table 2, namely other illicit drug use and
pre-morbid IQ. Thus, the degree of assurance with which one can derive conclusions
from these data is greater for the studies reported in Table 1 than in Table 2. Hence, the
verbal memory findings reported in Table 2 must be interpreted with caution.
Both tables report the findings of immediate and delayed recall performance and in
some cases other measures of memory performance (e.g., recognition). Delayed recall
performance is the measure that is most specific to explicit verbal memory and is
typically assessed after a 20- or 30-minute delay. Presumably, delayed recall performance
represents one’s ability to encode, store and retrieve incoming information. A number of
studies have examined the impact of recreational ecstasy use on delayed recall
performance in ecstasy users. While significant deficits in ecstasy users have been
observed using a variety o f tests, the results are far from consistent across studies.
O f the studies in Table 1 that assessed delayed memory performance, seven reported
a significant deficit in ecstasy users compared to other dmg users (except when noted).
Despite being statistically significant, the size of the deficit detected in ecstasy users
compared to controls was quite small, typically seven percent to 28 percent, such that
ecstasy users only recall one or two words less than controls on a list of 15 words (e.g.,
Curran & Verheyden, 2003; Fox, Toplis et al., 2001; McCardle et al., 2004). Larger
deficits in ecstasy users were found by Reneman et al. (2001,22 percent, ecstasy users =
10.1 words versus polydrug users = 13.1 words on the AVLT), as well as Yip and Lee
(2005,61 percent, ecstasy users = 5.28 words versus non-drug users = 13.52 words on the
AVLT).
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Yip and Lee’s (2005) study deserves particular consideration, not just because large
deficits in both immediate and delayed recall performance were observed in ecstasy
users, but because a large sample of ecstasy users was tested (N = 100). Moreover, the
ecstasy users recruited were unusual in that they were relatively “pure” ecstasy users.
They were “pure” in the sense that they did not report any history of substance abuse
other than ecstasy use. The authors attributed recruitment of such subjects to the fact that
the use of ecstasy had only recently become a popular trend in Hong Kong.
What’s more interesting is that Yip and Lee (2005) observed deficits in ecstasy users
with relatively low lifetime ecstasy consumption. Ecstasy users had on average consumed
35.8 tablets (range 16 to 60 tablets). The only other study to report significant deficits in
ecstasy users with such a low average use of ecstasy was McCardle et al. (2004), but the
deficit detected was only seven percent (ecstasy users =11.18 words versus polydrug
users =12.13 words on the AVLT). In comparison, deficits of 28 percent were obtained
by Curran and Verheyden (2003) in users with an average lifetime dose of 707 tablets
(ecstasy users = 5.81 words versus polydrug users = 8.06 words on the RBMT-Prose
Recall) and Fox, Toplis et al. (2001) in users with an average lifetime dose of 811.5
tablets (ecstasy users = 10.6 words versus polydrug users = 12.7 words on the AVLT).
Others have not found a statistically significant deficit in users who have also used
several hundred ecstasy tablets in their lifetime (e.g., Semple et al., 1999; Simon &
Mattick, 2002). For example, ecstasy users in Simon and Mattick’s (2002) study had
consumed a mean lifetime 258 tablets, whereas in Semple et al., (1999) the mean lifetime
consumption of ecstasy users was 672 tablets. Although Semple and colleagues (1999)
did not find significant differences in delayed recall, they did obtain an association

between lifetime numbers of ecstasy tablets and verbal memory performance. Larger
lifetime doses of ecstasy were associated with reduced verbal memory performance in the
CVLT.
Other evidence for ecstasy-related verbal memory impairment has been provided by
four studies (e.g., Fox, Toplis et al., 2001; Gouzoulis-Mayfrank et al., 2000; Quednow et
al., 2006; Thomasius et al., 2003) that too, observed dose-related impairment between
some measure o f ecstasy use and the delayed recall performance. For example,
Gouzoulis-Mayfrank et al. (2000), Quednow et al. (2006) and Thomasius et al. (2003)
observed a negative association between cumulative lifetime consumption and delayed
recall scores as measured by the Auditory Verbal Learning Test (AVLT). That is, heavier
ecstasy use was associated with lower delayed recall scores. With the exception of
Gouzoulis-Mayfrank et al. (2000) (M = 93 tablets), cumulative lifetime consumption of
ecstasy was high (e.g.. Fox et al., M = 811 tablets; Quednow et al., M = 457 tablets;
Thomasius et al., M = 1,033 tablets). Fox and colleagues (2001) also found that delayed
recall scores were negatively associated with both the usual and largest number of ecstasy
tablets consumed on any one occasion.
Lifetime consumption of marijuana has also been observed to be associated with
AVLT immediate memory performance (Fox, Toplis et al., 2001; Gouzoulis-Mayfrank et
al., 2000; Morgan, 1999; Quednow et al., 2006; Thomasius et al., 2003). For example, the
extent o f marijuana use was associated with performance on AVLT-Trial two in the Fox,
Toplis et al. (2001) study, whereas in Gouzoulis-Mayfrank et al. (2000) younger age of
onset o f marijuana use and higher frequency of use were associated with learning
performance or sum of AVLT Trials one through five. Thomasius and colleagues (2003)
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found the amount of marijuana smoked in the year prior to testing best predicted AVLTTrial six performance (immediate recall of interference list B) (R^ = 0.05, p = 0.023).
In addition to cumulative lifetime consumption, an association between duration of
abstinence from MDMA and delayed recall scores has been observed (Bhattachary &
Powell, 2001). This is suggestive of some degree of recovery of function with cessation
of ecstasy use. However, studies of ecstasy users who have been abstinent for at least one
year have demonstrated persistent mnemonic deficits (Curran & Verheyden, 2003;
Reneman et al., 2001). These findings suggest that the after effects of ecstasy use may be
long lasting or permanent. A single, small scale longitudinal study of ecstasy users (N =
15) found that continued use of ecstasy over a one-year follow up period was associated
with progression o f deficits in both immediate and delayed verbal memory (Zakzanis &
Young, 2001).
The reported frequency of ecstasy use at baseline ranged from one to 55 tablets (mean
= 19 tablets) (Zakzanis & Young, 2001). At the one-year follow-up, this increased from a
minimum o f three tablets to reportedly as many as 225 tablets (mean = 55 tablets).
Average use in the ecstasy users had gone up by an average of 4 tablets per month, but
the use of various other illicit drugs also increased over the same period complicating the
conclusions about ecstasy’s long-term effects on memory. While this study is far from a
final say on the matter, its longitudinal design is more convincing than simple
comparison group testing.
Like Zakzanis and Young (2001), findings of significant verbal memory deficits in
ecstasy users in six other studies in Table 2 are complicated by the absence of statistical
evaluation o f the potential influence of other drugs (Bhattachery & Powell, 2001 ; Bolla et
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al., 1998; Krystal et al., 1992; Morgan, 1999; Parrott & Lasky, 1998; Reneman, Majoie et
al., 2001). This makes it difficult to identify the relative contribution o f these substances
to verbal long-term impairment. Consequently, these findings must be treated with more
caution because drug use other than ecstasy may have contributed to the observed
deficits.
In contrast to the number o f significant findings for delayed recall, five of the
relatively well controlled studies in Table 1 failed to detect a difference between ecstasy
users and controls on delayed verbal memory or detected a difference that failed to
remain significant after controlling for other drug use and/or other covariates (Croft et al.,
2001; Dafters et al., 2004; Halpem et al., 2004; Lamers et al., 2006; Semple et al., 1999;
Simon & Mattick, 2002). For example, Dafters and colleagues (2004) compared the
verbal memory performance o f subjects who used both ecstasy and marijuana, marijuanaonly, and neither drug, on the Rivermead Behavioral Memory Test (RBMT), which
involved the recall of an audio taped story after a 30-minute delay. In addition, free recall
performance o f 30 words (i.e., subjects listen to 30 words and are instructed to recall as
many as they can remember) was tested. All the drug user groups displayed significantly
impaired memory fimction compared to the non-drug users. However, there were no
significant differences between subjects who used ecstasy-marijuana and those who used
only marijuana.
Likewise, Lamers et al. (2006) and Croft et al. (2001) found that combined ecstasymarijuana users and marijuana-only users did not differ from each other in their delayed
recall performance. A variety of tests were used to assess delayed recall performance,
including the AVLT (Lamers et al., 2006), Coughlan List Test (Croft et al., 2001) and the
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Weschler Memory Scale III test (WMS-III) (Simon & Mattick, 2002). In addition, the
sample sizes o f the Lamers et al. (2006) and Croft et al. (2001) studies were relatively
small (Lamers et al., 2006, ecstasy-marijuana users N = 11, marijuana-only users N = 15,
non-drug users N = 15). The sample size in the Simon and Mattick (2002) study was
larger (ecstasy users N = 40, marijuana-only users N = 37). Taken together, these results
provide very little support for an effect of ecstasy use on delayed verbal memory
performance. These studies suggest that marijuana use, rather than MDMA use, may
better account for many of the verbal memory deficits among ecstasy users reported
elsewhere in the literature.
The majority o f studies in Tables 1 and 2 also assessed immediate recall. Immediate
recall performance presumably reflects some combination of long-term memory and
working memory performance because there is no inhibition of the use o f working
memory to retain items between study and test (Fox, Toplis et al., 2001). In the AVLT,
for example, the number of words recalled on trial six (the trial immediately following
recall o f words from interference list B) is typically used to represent participants
immediate recall score. However, trials one through five have also been interpreted to
reflect immediate recall performance.
Like the delayed recall memory results, there has been a mix of significant and non
significant results across studies with regard to immediate recall performance (e.g., 13
studies have found deficits, whereas 13 studies have not). Yip and Lee (2005) have
observed the most profound deficit in ecstasy users immediate recall performance (51
percent). On average, the ecstasy user group recalled 5.20 words whereas the non-users
recalled an average of 10.51 words. Mean recognition performance in the ecstasy users

13

was also significantly impaired relative to non-users (ecstasy users M = 5.64 v. non-users
M = 12.80 words) (Yip & Lee, 2005).
Negative correlations between inunediate recall scores and patterns o f ecstasy use
have also been observed. For example, Reneman Lavalaye et al. (2001) found that
immediate recall scores on the AVLT were lower in ecstasy users who had reported
greater lifetime consumption and/or used higher lifetime doses of ecstasy. Furthermore,
Thomasius et al. (2003) showed that immediate recall on the first trial was best predicted
by the average number of exposures to ecstasy.
Immediate recall deficits have often been observed in relatively heavy ecstasy users.
For example, Quednow and colleagues (2006) demonstrated immediate memory deficits
in ecstasy users with more than 450 tablets per lifetime. Studies showing no or only weak
impairment in immediate recall (e.g., Back-Madruga et al., 2003; Croft et al., 2001;
Gouzoulis-Mayfrank et al., 2000; McCardle et al., 2004; Simon & Mattick, 2002) in
ecstasy users examined mostly users with a lifetime dose lower than 100 tablets.
However, ecstasy users in the Simon and Mattick (2002) study had consumed a
somewhat higher dose of 258 tablets.

Explanations for the Diversity o f Findings
Several factors may contribute to the diversity of findings. y\mong them are failure to
comprehensively to assess intelligence and control for IQ differences between groups,
lack o f a normal control group in some studies, age and/or educational differences
between subjects and controls and relatively small sample sizes. One of the most crucial
influencing factors to the diversity of finding is the relative use of marijuana and ecstasy.
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Table 3 (see Appendix I) summarizes the mean lifetime consumption o f ecstasy users in
the verbal memory studies reviewed in Tables 1 and 2. As Table 3 depicts, there is a great
deal of variability across studies with regard to cumulative MDMA exposure. Moreover,
verbal memory deficits have been detected in ecstasy users who have used a small
number o f tablets (mean = 20 tablets, Rodgers, 2000), whereas others have failed to find
deficits in ecstasy users who have consumed a substantial number of tablets (mean = 672
tablets, Semple et al., 1999). In addition, in some studies the extent of use of marijuana
was significantly greater than ecstasy use. For example, in Croft et al. (2001a), the mean
lifetime use o f marijuana was 10,964 occasions, whereas the use of ecstasy was 41
occasions. Similarly, participants in Simon and Mattick’s (2002) study (ecstasy users and
marijuana-only users) were also heavy marijuana users, with a mean 67.9 joints smoked
per month in the ecstasy user group and a mean 62.6 joints smoked per month in the
marijuana-only group, but generally lighter ecstasy users (mean lifetime exposure 258
tablets). It could be posited that the higher use of marijuana may have contributed to
these researchers finding that the verbal memory deficits were related to marijuana, rather
than ecstasy.

The Marijuana Confound
Marijuana may confound MDMA studies in two ways. First, the main psychoactive
constituent of marijuana, delta-9- tetrahydrocannabinol (THC), has been shown to
interact with the dopamine system (Tanda et al., 2000) and dopamine has been shown
largely to determine MDMA-related serotonin impairment in rats (Aguirre et al., 1998;
Sprague et al., 1998; Stone et al., 1989). Thus, marijuana may interact with MDMA in
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determining serotonin deficit in recreational users. Second, rat hippocampus is impaired
following chronic marijuana administration (Ameri et al., 1999; Scallet, 1991) and as the
hippocampus plays a significant role in memory (Sun et al., 1999), marijuana may also
impair neurocognitive function.
Brain imaging studies o f marijuana users have demonstrated altered function, blood
flow, and metabolism in prefrontal and cerebellar regions (Block et al., 1999; Loeber &
Yurgelun-Todd, 1999; Lundqvist, 2005). Thus, marijuana produces various metabolic
changes in the brain. Long-term marijuana users appear to have lower resting levels of
regional cerebral blood flow (rCBF) compared with non-smokers. Marijuana increases
rCBF and brain metabolism in experienced users, while it decreases rCBF in non-users.
These effects have been particularly apparent in frontal cortical areas. Decreases in rCBF
were localized to brain regions that mediate sensory processing and attention.
Studies using a challenge paradigm indicate that even after an extended washout
period, specific differential patterns o f cortical activation exist in subjects with a history
of heavy marijuana use. During a challenge paradigm, smokers who completed a 24-hour
washout showed diminished activation in the dorsolateral prefrontal cortex (DLPFC).
The effect remained diminished after 28 days of washout, although some increase in the
DLPFC activation was noted, relative to the 24-hour time point (Yurgelun-Todd et al.,
1999). Memory-related blood flow in frequent marijuana users showed decreases relative
to controls in the prefrontal cortex, increases in memory-relevant regions of the
cerebellum, and altered lateralization in the hippocampus (Block et al., 2002). The
greatest differences between users and controls occurred in brain activity related to
episodic memory encoding.
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Behavioral studies corroborate the brain imaging data and provide good consensus
that heavy marijuana use produces residual deficits on measures such as memory o f word
lists (Fletcher et al., 1996; Pope & Yurgelun-Todd, 1996; Pope et al., 1995, 2001 ;
Solowij et al., 2002) and complex attention tasks (Fletcher et al., 1996; Pope et al., 2001)
that may last for many days after cessation. For example. Pope and colleagues (2001)
found persistent deficits among users who conunenced marijuana use prior to the age o f
17. Bolla et al. (2002) found dose-related decrements in neuropsychological performance
after 28 days o f abstinence using a very similar neuropsychological test battery. Solowij
and colleagues (1995) have observed partial recovery, but with persistence of some
selective attention deficits after a mean, abstinence of two years, however, at present,
consensus is still lacking on the question o f whether increasing duration of marijuana
exposure causes increasing cognitive deficits. To date, the results o f different studies
indicate that marijuana-associated cognitive deficits may be reversible and related to
recent marijuana exposure (Pope et al., 2002).
In summary, both neuropsychological assessment studies and studies based on brain
imaging techniques indicate that heavy chronic marijuana use may be associated with
dysfunction on tests of verbal memory that were found previously to differentiate ecstasy
users from controls (e.g.. Block & Gonheim, 1993; Bolla et al., 2002; Fletcher et al.,
1996; Fried, Watkinson, James, & Gray, 2002; Hall & Solowij, 1998; Messinis et al.,
2006; Pope et al., 2001; Solowij et al., 2002). This raises the question of whether the
adverse cognitive profiles of ecstasy users who also concomitantly use marijuana, are
more closely associated with the extent of marijuana use rather than ecstasy use. To date.
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investigations regarding the contribution of marijuana to the long-term memory effects of
MDMA have yielded inconsistent findings.

Evidence Demonstrating Interactive Effects o f MDMA and Marijuana
The potential mechanism(s) by which MDMA and marijuana interact is not well
known. Parrott and colleagues (2004) have suggested that the effects of marijuana and
MDMA may interact when taken together. This notion has been partially based on the
acute profiles of MDMA and marijuana, which are opposite in certain crucial aspects. For
example, MDMA is a powerful central nervous system (CNS) stimulant whereas
marijuana has sedative and relaxant properties. MDMA is hyperthermic, whereas
marijuana is hypothermic, MDMA increases oxidative stress while cannabinoids are
powerful antioxidants (Croxford, 2003). This led Parrott et al. (2004) to generate the
tentative hypothesis that when taken together marijuana may act to ameliorate the
stimulatory effects of ecstasy. Furthermore, they suggested that if marijuana does reduce
the acute neuronal over-stimulation induced by ecstasy, it may then also attenuate
MDMA-induced neurotoxicity (Parrott et al., 2004). There is animal evidence which
lends support to the notion that marijuana may interact with MDMA to mitigate MDMAinduced neurotoxicity.
Morley and colleagues (2004) found that administration of the main psychoactive
constituent o f marijuana, delta 9 tetrahydrocannabinol (THC), or the synthetic
cannabinoid CP 55940, in male wistar rats attenuated the hyperthermic and serotonin
depleting effects of MDMA, which previously have been found to cause neurotoxicity.
MDMA alone, THC alone, a combination of MDMA-THC, a synthetic cannabinoid
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agonist CP 55940 and a cannabinoid antagonist SR 141716 were administered in repeated
injections every four hours for two days. Body temperature, locomotor activity,
emergence (a measure of anxiety), social interaction, and neurochemical analyses in the
hippocampus, amygdala, and prefrontal cortex (known to be depleted of serotonin when
MDMA is taken) were assessed.
With regard to body temperature, MDMA alone caused hyperthermia whereas THC
caused modest hypothermia. Interestingly, the co-administration of MDMA-THC
induced greater hypothermia than THC given alone, particularly within the first two
hours of testing. A similar robust hypothermia was also evident when the effect of
synthetic cannabinoid CP 55940 was combined with MDMA. Co-administration of the
CBi antagonist SR 141716 prevented this hypothermia suggesting the involvement of
CBi receptors in the effect.
In addition, in the MDMA-THC group, THC at a high dose (2.5 mg/kg every four
hours for two days) partially prevented the depletion o f serotonin and 5-HIAA in each of
the prefrontal cortex, amygdala and hippocampus compared to when MDMA was given
alone. Subsequently, the combination of MDMA-THC tended to decrease MDMAinduced hyperactivity and increases in anxiety seen in the emergence test. These findings
were taken as evidence that THC when combined with MDMA provided some degree of
neuroprotection against MDMA-related neurotoxicity.
Morley and colleagues (2004) have suggested that the mechanism of neuroprotection
may be due to THC’s antioxidant properties, possibly by counteracting MDMA-induced
oxidative stress (Morley et al., 2004). There is evidence which suggests that THC has a
structural resemblance to the powerful antioxidant vitamin E (Chen & Buck, 2000).
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Furthermore, cannabinoids have been found to exert antioxidant effects in vitro and are
neuroprotective in animal models of stroke (Leker et al., 1999; Mishima et al., 2005).
However, Morley and colleagues (2004) caution that their findings do not suggest
that human MDMA users should resort to consuming THC to minimize harm. Firstly, the
protective doses of THC used in their study were high and these effects are unlikely to be
obtained with the relatively small amounts of THC typically consumed during
recreational marijuana use. Secondly, the effect of cannabinoids on MDMA-induced
neurotoxicity in cannabinoid tolerant animals is not known. Thus, protection from the
neurotoxic effects of MDMA may not necessarily be obtained in frequent marijuana
users. Finally, the neuroprotective effects of THC were by no means complete and were
in fact only partial in all brain regions examined.
Croft et al. (2001) has also suggested that marijuana may exert neuroprotective
effects against MDMA-induced neurotoxicity by inducing dopamine down regulation.
Marijuana indirectly augments levels of dopamine in the mesocortical pathway (Diana,
Melis, & Gessa, 1998). A possible mechanism explaining this increase in dopamine
levels is through an indirect excitatory action of marijuana on the ventral tegmental area
(VTA) dopaminergic neurons, the main ascending dopaminergic projection to the nucleus
accumbens (Cheer et al., 2004). Cannabinoid receptor (CBi) agonists have been found to
enhance the firing rate of dopaminergic neurons (Cheer et al., 2003) via a reduction of
afferent GABAergic transmission (Szabo et al., 2002). Marijuana binds to CB, receptors
located on pre-synaptic glutamatergic neurons that project to the nucleus accumbens,
effectively controlling the firing of the nucleus accumbens GABAergic neurons, which in
turn inhibit the dopaminergic neurons of the VTA. Via the reduction of excitatory
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transmission in the nucleus accumbens, marijuana could disinhibit dopamine cells of the
VTA, increase their firing rate, and trigger the release of dopamine in the nucleus
accumbens (Robbe et al., 2001).
Long-term over stimulation of dopamine decreases the number of receptors (down
regulation) and the remaining receptors become desensitized. Down regulation is thought
to be an underlying mechanism for psychodynamic tolerance, where exposure to a drug
causes less response than previously obtained.
In contrast to the hypothesis that marijuana attenuates MDMA-induced neurotoxicity,
there are other animal data which suggest that ecstasy and marijuana may interact to
produce greater impairment than that which is observed when either drug is used alone.
Young, McGregor, and Mallet (2005) tested working memory using a double-Y maze
task in male wistar rats. The double-Y maze task involved the presentation of two
consecutive tasks on each trial: a spatial discrimination task in the first “Y”, followed by
a delayed alternation task in the second “Y”. The spatial discrimination component of the
double-Y maze requires the use of reference memory only, whereas the delayed
alternation component also requires the use of working memory (Mallet & Beninger,
1993).
Low (THC 0.25 mg/kg and MDMA 1.25 mg/kg), medium (THC 0.5 mg/kg and
MDMA 2.5 mg/kg), and high (THC 1.0 mg/kg and MDMA 5.0 mg/kg) drug doses were
administered alone and together. At low doses, THC and MDMA alone did not impair
memory. Combined however THC and MDMA significantly impaired working memory,
which was evidenced by impaired choice accuracy in the delayed alternation component,
but no effect in the spatial discrimination component of the maze task. At medium doses,
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the administration of THC or MDMA alone or in combination had no significant effect in
the spatial discrimination task of the double-Y maze. THC, but not MDMA significantly
impaired choice accuracy in the delayed alternation component. The combined drug
treatment led to a further impairment of choice accuracy in the delayed alternation. At
high doses, THC and MDMA treatments alone both caused increased errors in the
delayed alternation component, with THC causing greater impairment than MDMA. Co
administration of THC and MDMA rendered the rats incapable of completing either maze
task. These findings provide strong evidence of a synergistic interaction of THC and
MDMA on memory fimction.
To summarize. Young and colleagues findings revealed that MDMA alone did not
significantly affect memory at the low or medium doses tested (which are within a dose
range relevant to human consumption), but MDMA at these doses interacted with THC to
produce an impairment of memory that was greater than that observed with THC alone.
MDMA and THC acted synergistically to impair memory.
Young and colleagues (2005) posited that the neurochemical basis for the observed
synergistic effects o f THC and MDMA may involve dopamine. THC primarily exerts its
effects via activation of cannabinoid CBi receptors, which are predominately located on
pre-synaptic hippocampal neurons (Tsou et al., 1998). THC is known to increase
dopamine production in several areas including prefrontal mesocortical areas, strongly
connected with working memory function (Bergson et al., 2003). MDMA has direct
action on the serotonin, dopamine, and norepinephrine neurotransmitter systems (Climko
et al., 1986), suggesting that an interaction of the two drugs may occur within the
dopamine system.
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The Proposed Investigation
Most investigations examining explicit long-term verbal memory function in
recreational ecstasy users have not controlled for other illicit drug use. Marijuana use is a
particular problem for MDMA research because it is common for ecstasy users to
consume marijuana to alleviate the residual negative effects that result from taking
ecstasy. Thus, a large number of ecstasy users have also used a substantial quantity of
marijuana. This is problematic because marijuana use by itself has been associated with
deficits on tests o f verbal learning and memory previously found to differentiate ecstasy
users from controls (e.g., Bolla et al., 2002; Hall & Solowij, 1998; Pope et al., 1996;
Solowij et al., 2002). These findings suggest that at least some of the widely reported
deficits in memory performance in ecstasy users might be attributable to marijuana rather
than ecstasy.
The primary aim of the proposed study was to delineate the respective effects of
marijuana and ecstasy on verbal learning and memory performance. The Auditory Verbal
Learning Test (AVLT) (Rey, 1964; Schmidt, 1996) was used to assess verbal memory
performance. Participants completed a drug use history questionnaire, which explored
participants’ prior illicit drug use and demographic information.
Illicit drug use beyond ecstasy and marijuana was controlled for by setting strict
criteria that limited other drug use to 15 or fewer occasions in a lifetime. Additionally, to
control for individual differences participants were matched for age, gender, and level of
education. Participants also were matched on intelligence, which was assessed using the
vocabulary subtest of the Wechsler Adult Intelligence Scale, Third Edition (WAIS-III)
(Wechsler, 1997).
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Concurrent ecstasy-marijuana users, ecstasy-naïve marijuana-only users and non-drug
users were recruited for participation. The extent of marijuana use was controlled for in
the drug user groups by classifying marijuana use as either light or heavy. Categorization
of marijuana use as light or heavy was based on retrospective examination o f participants
self-report data collected from the drug use history questionnaire. The marijuana use
criterion resembled that used by Fried, Watkinson, James, and Gray (2002). Heavy
marijuana use was defined as using marijuana five or more times per week and light
marijuana use was defined as using marijuana fewer than five times a week.
Moreover, the comparison o f heavy and light marijuana users in the concurrent
ecstasy-marijuana and marijuana-only users enabled the assessment o f potential
interactive effects of combined marijuana and ecstasy use. The rationale for examining
the interactive effects o f these two drugs is found in recent animal findings. One set of
findings has suggested that marijuana at high doses may exert positive neuroprotective
effects against MDMA-induced neurotoxicity (Morley et al., 2004). In contrast, another
set o f animal findings has demonstrated a negative synergistic disruption in working
memory performance by co-administration of THC and MDMA (Young et al., 2005).
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CHAPTER 2

REVIEW OF RELATED LITERATURE

History o f MDMA
The German pharmaceutical company Merck first synthesized MDMA in 1912.
MDMA was incidentally created as a by-product while trying to synthesize a different
drug. For reasons that have been lost over time, Merck did little to explore its properties
as a drug. In fact, there was little interest in MDMA until the 1950s when the U.S. Army
studied it as a potential chemical warfare agent that would temporarily disable enemy
troops. In the 1970s, despite a lack of any meaningful controlled clinical trials, many
psychotherapists used it as a therapeutic agent. The use of MDMA as an adjunct to
therapy was based on the notion that MDMA lowers defensiveness and heightens the
effects o f physical contact, which purportedly allows users to achieve important healing
insights about their problems (Rochester & Kirchner, 1999).
In the 1980s, MDMA earned a new nickname, ecstasy (also XTC or E), given to it by
the newest group to experiment with it, our nation’s youth. At about the same time that
MDMA first appeared as a so called “party” or “club” drug at raves or all-night dance
parties, evidence was emerging that this compound was not benign, and could cause
damaging effects on serotonergic neurons.
In 1985, MDMA was found to have toxic effects on brain serotonin neurons in
rodents (Ricaurte et al., 1985). Subsequently, the U.S. Drug Enforcement Agency (DEA)
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added MDMA to the Schedule I list of drugs having high abuse potential with no
accepted medical use. Despite MDMA’s classification as a Schedule I drug, it continues
to be used illegally.

Neuropharmacology o f MDMA
MDMA is a derivative o f methamphetamine (known by such street names as “speed,”
“crystal,” and “meth”) and its parent compound amphetamine. Ecstasy differs from
amphetamine and methamphetamine in that it has a methylenedioxy (-0-CH 2-0-) group
attached to positions three and four o f the aromatic ring of the amphetamine molecule
(i.e., it is ring substituted). In this respect, it resembles the structure of the hallucinogenic
material mescaline (Nichols, 1986; Shulgin, 1986). As a result, the pharmacological
effects of MDMA are a blend of those of the amphetamines and hallucinogenic
mescaline. 3,4-methylenedioxyamphetamine (MDA) and methylenedioxiethylamphetamine (MDEA) are also amphetamine-mescaline derivatives (i.e., they are similar
in chemical structure to MDMA) and therefore, produce pharmacological effects similar
to MDMA. This group of substances is frequently referred to as “designer drugs” because
when illicit laboratories began to produce them for non-medical use, the blend of
amphetamine-like and mescaline-like effects was intentionally sought and could be
achieved reliably by the appropriate design of the drug molecule (Kalant, 2001).
MDMA blocks the reuptake of serotonin by binding with a high affinity to the
serotonergic transporters (SERTS). This action is similar to serotonin specific reuptake
inhibitors (SSRIs), such as anti-depressants like fluoxetine (Prozac), sertraline (Zoloft),
and paroxetine (Paxil). Unlike SSRIs, but similar to the action of the amphetamines,
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MDMA appears to enter the nerve terminal itself, either through passive diffusion or
directly through the SERT, by exchange diffusion (a concentration gradient that involves
the reversal o f the normal inward bound direction of serotonin with MDMA) and causes
the release of serotonin. This release is calcium-independent (i.e., independent of the
firing of the serotonin neuron) and appears to come from cytoplasmic stores rather than
from synaptic vesicles. The released serotonin then enters the synaptic cleft through the
serotonin transporter, by exchange diffusion with MDMA. MDMA acts on serotonin
release in much the same way as amphetamines act on dopamine release.
It is thought that the movement of serotonin into the synaptic cleft, and the
subsequent action of serotonin on pre- and post-synaptic binding sites is central to
MDMA's neuropharmacology. MDMA has potency for the serotonin 5-HT2a, muscarinic
Ml, adrenergic alpha (a- 2) and histamine Hi receptors (Nichols et al., 1982; Berger et al.,
1992b). Animal studies indicate that 5 -HT2 receptors might be involved in MDMA’s
effects because 5 -HT2 antagonists reduced several effects of MDMA, such as MDMAinduced serotonergic neurotoxicity, acute hyperthermia and disruption of sensorimotor
gating (Schmidt et al. 1990). 5-HT2a receptors have been implicated in the hallucinogenic
effects o f classic psychedelic drugs such as LSD (Vollenweider et al. 1998). It is possible
that some o f MDMA's psychedelic effects occur because of interactions with this
receptor. The a -2 adrenergic receptor also may be associated with some of the
cardiovascular effects of MDMA (Berger et al., 1992).
MDMA also triggers the releases o f dopamine, which may be central to both its
psychological action and to its neurotoxicity in animal studies (Johnson et al., 1991). In
mice, MDMA produces a selective long-term loss of dopamine nerve endings (Miller &
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0 ’Callaghan, 1994). Pre-treatment of an animal with a drug that blocks dopamine
release, appears to block MDMA neurotoxicity (Colado, 0 ’ Shea, & Green, 2004). Also,
serotonin specific releasing agents, which are non-dopaminergic have been synthesized
and been found to be devoid of MDMA's neurotoxicity and psychological effects in
animals. MDMA tends to indirectly inhibit the firing and release of dopamine in
nigrostriatal dopamine neurons (i.e., neurons projecting from the substantia nigra to the
striatum) due to local serotonin release (Colado, O’ Shea, & Green, 2004).
In summary, MDMA affects serotonin similarly to the way that amphetamines affect
dopamine, by inhibiting the reuptake and causing the release o f serotonin. This effect is
somewhat similar to the effect that SSRI antidepressant drugs have. Subsequently,
MDMA influences the 5-HT2a (psychedelic) and a -2 adrenergic (cardiovascular) receptor
sites. MDMA’s effects on dopamine appear, at this point, to be involved both with its
neurotoxicity and psychological effects.

The Serotonin System
Serotonin, also called 5-hydroxytryptamine or 5-HT is found in mast cells, blood
platelets, intestinal tissue, and especially in the brain. In the brain, serotonin acts as a
primary neurotransmitter. It is synthesized from tryptophan through the intermediate 5hydroxytryptophan in the axon terminals of serotonin neurons. After serotonin is
manufactured, it is stored in sacks called synaptic vesicles located in the 5-HT axon
terminals. These vesicles release their serotonin into the synaptic cleft via exocytosis (the
excretion of neurotransmitter through the membrane of a pre-synaptic terminal and into
the synaptic cleft), in response to the firing of the serotonin neurons.
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In the synaptic cleft, the serotonin neurotransmitter exerts its action on both presynaptic and post-synaptic receptor sites (sites on the serotonin neuron itself and on the
neuron with which it is communicating). Serotonin is then taken back into the presynaptic serotonin neuron (from the synaptic cleft) via a reuptake pump referred to as the
synaptic membrane serotonin transporter (SERT). Thus, the concentration o f serotonin in
the synaptic cleft is controlled directly by its reuptake into the pre-synaptic terminal.
Serotonin that is reclaimed is again stored in the vesicles or metabolized by monoamine
oxidase (MAO-A) into 5-hydroxyindileacetic acid (5-HIAA).

Serotonergic Neuron Distribution and Pathways
Serotonergic neurons are widely distributed in pathways throughout the CNS. As
Figure 1 depicts, the largest group of serotonergic neurons is B7, which is continuous
with a smaller group of serotonergic cells, B6. Groups B6 and B7 often are considered
together as the dorsal raphe nucleus, with B6 being its caudal (tail or hind end) extension.
Another prominent serotonergic cell body group is B8, which corresponds to the median
raphe nucleus. Group B9, part of the ventrolateral tegmentum of the pons and midbrain,
forms a lateral extension of the median raphe and therefore is not considered one of the
midline raphe nuclei. Ascending serotonergic projections innervating the cerebral cortex
and other regions of the forebrain arise primarily from the dorsal raphe, median raphe and
B9 cell group.
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Figure 1.
Schematic drawing depicting the location of the serotonergic cell body
groups in a sagittal section o f the rat central nervous system and their major projections.
Serotonergic cell bodies are located within the B cell groups of Dahlstrom and Fuxe
(1964), from which they project caudally to the spinal cord and rostrally to many
forebrain structures. OT, olfactory tuberculum; Sept, septum; C. Put, nucleus caudateputamen; G. Pal, globus pallidus; T, thalamus; H, habenula; S. Nigra, substantia nigra.
(Modified from Consolazione & Cuello, 1982).

Two distinct ascending projections arise from the rostral (head or front end)
serotonergic system. The two main ascending serotonergic pathways emerging from the
midbrain raphe nuclei to the forebrain are the dorsal periventricular path and the ventral
tegmental radiations. Both pathways converge in the caudal hypothalamus, where they
join the medial forebrain bundle. Axons of both dopaminergic and noradrenergic neurons
run through the medial forebrain bundle as well.

Ascending projections from the raphe nuclei to forebrain structures are organized in a
topographical manner. The dorsal and median raphe nuclei give rise to distinct
projections to forebrain regions. The median raphe projects heavily to the hippocampus.
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septum and hypothalamus, whereas the striatum is innervated predominantly by the
dorsal raphe nuclei. The dorsal and median raphe nuclei send overlapping neuronal
projections to the neocortex.
Within the dorsal and median raphe, cells are organized in particular zones or groups
that send axons to specific areas of the brain. For example, the frontal cortex receives
heavy innervation from the rostral and lateral sub-regions of the dorsal raphe nucleus.
Raphe neurons send collateral axons to areas of the brain that are related in function, such
as the amygdala and hippocampus or the substantia nigra and caudate putamen. The
specific and highly organized innervation o f forebrain structures by raphe neurons
implies independent functions of sets of serotonergic neurons dependent on their origin
and terminal projections, as opposed to a nonselective or general role for serotonin in the
CNS.
The existence of specific pathways projecting from the raphe nuclei to the forebrain
and the density of serotonin receptors in these and other areas, such as the hippocampus,
amygdala and cortex, supports the growing body of evidence implicating serotonin in the
processes o f learning and memory (Buhot, 1997; Buhot, Martin, & Segu, 2000). Spoont
(1992) has proposed that serotonin may play a role in cognition and that extreme
deviations of serotonin activity can result in biases in cognitive processing. There is also
evidence that suggests that serotonin is particularly likely to be involved in learning (e.g..
Hunter, 1988), visuospatial memory (Wenk, 1997), visual discrimination, associative
functions and aspects of planning (Park et al., 1994), and general memory consolidation
and retrieval (Meneses & Hong, 1994).
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Serotonin has been also implicated in the regulation of mood, anxiety, aggression,
impulsiveness, sexual activity, appetite, sleep, pain, circadian and seasonal rhythms,
motor activity, and body temperature (Morgan, 2000). Transient reductions in serotonin
activity, induced by tryptophan depletion have been reported to produce a rapid lowering
o f mood in normal males (Young et al., 1985) and relapse in recently remitted depressed
patients (Delgado et al., 1990). Furthermore, there is evidence that disorders o f central
serotonergic neurotransmission, as reflected by low levels 5-HIAA (the major metabolite
o f serotonin) are associated with anxiety disorders (e.g., Garvey et al., 1995) and
impulsive and aggressive personality traits (e.g., Linnoila et al., 1993).

Serotonergic Receptors
Over the past decade, more than 14 different serotonin receptors have been located in
the central and peripheral nervous system (CNS/PNS) (see Table 4). Researchers have
also cloned serotonin receptors through molecular biological techniques, which has
facilitated the identification o f new therapeutic targets and aided an understanding o f the
multiple roles played by 5-HT in the brain.

Table 4

Different serotonin (5-HT) receptor subtypes
5-HT,
5-HTy^
5-HT,b
5-HT,d
5-HT,e
5-H T,F

5-HT2

5-HT3

5-HT2A
5-HT2B
5-HT2C

5-HT3A
5-HT3B

5-HT4

5-HT;
5-HT5A
5-HT5B
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5-HT6

Serotonergic receptors are divided into seven distinct classes based on their structural
and operational characteristics. With the exception of the 5 -HT3 receptor, a ligand gated
ion channel, all other 5-HT receptors are G-protein coupled seven transmembrane (or
heptahelical) receptors that activate an intracellular second messenger cascade. Binding
of serotonin to the receptor causes a conformational change in the intracellular domain of
the receptor, which then affects its interaction with the GTP-binding G-protein on the
cytosolic side of the plasma membrane. The occupied receptor causes replacement of the
GDP bound to the alpha subunit of the G-protein by GTP, activating the G-protein. This
activated G- protein regulates an enzyme which generates an intracellular second
messenger. If the G- protein is a stimulatory G-protein, it acts on the membrane bound
enzyme to increase the concentration o f the intracellular second messenger, while an
inhibitory G-protein acts to decrease the second messenger concentration (e.g., Linnoila
et al., 1993).
At least five receptor subtypes have been classified within the family o f 5-HTi
receptors (5-HTia, 5-HTib, 5-HTid, 5-HTie, 5-HTif). They exhibit high affinity for
serotonin and cause the cell membrane to hyperpolarize, which keeps the neuron from
firing (Bames & Sharp, 1999). Selective agonist (a drug that binds to a receptor of a cell
and triggers a response by the cell) for 5-HT, receptors include 8-hydroxy-2-di-npropylamino-tetralin (8-OH-DPAT), which modulate adenylyl cyclase activity in the
hippocampus. 5-HT,A receptors are found in the hippocampus, cerebral cortex, raphe
nuclei, thalamus and amygdala.
The cell body of 5-HT,a receptor functions as an autoreceptor sensing the
extracellular serotonin concentration and modulating the firing rate o f the neurons of the
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raphe nuclei (Hamon et al, 1999). When activated, 5-HTja autoreceptors inhibit firing
and consequently inhibit subsequent release o f serotonin from distal axon terminals.
5-HTia ligands with agonist activity seem to possess anti-anxiety, anti-depressant,
anti-aggressive, as well as anti-craving, anti-cataleptic, anti-emetic and neuroprotective
properties. For example, Buspirone is a 5-HT ia agonist that is useful in the management
of anxiety. The main therapeutic potential of 5-HT ia receptors has been in the treatment
of anxiety and depression. Work with 5-HT ia (partial) agonists indicates that the anti
anxiety actions o f 5-HT ia may involve primarily pre-synaptic somatodendritic 5-HT ia
receptors (leading to reduced release of 5-HT in terminal areas), whereas the anti
depressant action of 5-HT, Aagents may primarily involve post-synaptic 5-HT ia
receptors. 5-HT ia receptors also may be involved in obsessive-compulsive disorders,
impulsivity, sexual behavior, appetite control, thermoregulation, and cardiovascular
function.
5-HTib receptors were one of the first 5-HTi-like receptors to be described. It was
later shown that the distribution and second messenger coupling o f 5-HT,B receptors in
rodent brain was similar to that of 5-HTm receptors in mammalian brain, leading to
speculation that 5-HTib and 5-HTid receptors might constitute species variants of the
same receptor. 5-HTib receptors are located pre-synaptically where they control the
release o f 5-HT and post-synaptically where the highest density o f 5-HTib receptors in
rat and mouse brain is found in the substantia nigra, globus pallidus, and dorsal
subiculum. 5-HTib receptors are negatively coupled to adenylate cyclase.
Rodent 5-HT ib receptors play a role in thermoregulation, respiration, appetite control,
sexual behavior, aggression, and anxiety (Liechti et al., 2000). Past studies, however,
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utilized agents that are now recognized as lacking selectivity for 5-HTib receptors. In
addition, the possible existence of multiple populations of 5-HTib receptors and the
relationship between 5-HTib and 5-HTid receptors has raised new questions.
Nonetheless, recent studies support a role for 5-HT ib receptors in the regulation of sleep,
sensorimotor inhibition, and to some extent, locomotor activity (Vollenweider et al.,
1998).
Another method for obtaining information about 5-HTib receptors is by use of 5HT ib receptor knock-out mice (Schmidt et al., 1990). Such mutant mice failed to display
any obvious developmental or behavioral deficit but supported earlier suggestions that 5HTIB receptors might be involved in locomotor activity and aggressive behavior.
5-HT id receptors are widely distributed throughout the CNS (Liechti et al., 2000) and
are negatively coupled to inhibit adenylate cyclase activity. The clinical significance o f 5HT id receptors remains largely unknown. There has been speculation that these receptors
might be involved in anxiety, depression, and other neuropsychiatrie disorders, but this
remains for the most part to be substantiated. With the availability o f the 5-HT id
antagonists, it has been shown for example that GR127935 blocks the effect o f anti
depressants in the mouse tail suspension test. Further, the localization o f 5-HT id
receptors in human brain is thought to be consistent with potential involvement in
Huntington's disease (Slassi et al., 2004). The causes of migraine headaches are
unknown, but appear to include dilation o f the cerebral blood vessels. Both 5-HT,g and 5HT id receptors mediate vasoconstriction, and 5-HT id agonists (e.g., sumatriptan) are
useful in the treatment o f migraine headaches (Whale et al., 2000). Sumatriptan also
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called Imitrix is effective after the onset o f migraine headaches, yet is not as effective in
preventing migraines.
The 5 -HT2 receptor family consists of three specific receptor subtypes (5-HT2a, 5HT2B, and 5-HT2c). 5-HT2a receptors (originally referred to as 5 -HT2 receptors) were
among the first 5-HT receptors to be identified. The 5 -HT2 receptor family stimulates
phosphoinositide-specific phospholipase C. 5-HT2Areceptors are widely distributed at
varying densities throughout the brain, with the highest density is in the neocortex.
Relative to 5-HT] receptors, 5 -HT2 receptors exhibit slightly lower affinity for serotonin.
In the CNS, the 5-HT2a receptors function to suppress cell firing, as well as inhibit
neurotransmitter release (e.g., dopamine, acetylcholine, noradrenaline).
5 -HT2A receptors

display a high homology with 5 -HT2C receptors. Moreover, recent

evidence suggests some o f the roles attributed to the 5-HT2a receptors may in fact be
mediated by 5-HT2c receptors. This suggestion was partly based on the finding that 5HT2A ligands bind nearly equally well at both types of receptors. Nevertheless, 5 -HT2A
receptors are believed to play a role in appetite control, thermoregulation, and sleep. They
are also involved, along with various other 5-HT receptor populations, in cardiovascular
function and muscle contraction.
In addition, 5 -HT2A receptors have also received considerable attention from a
neuropsychiatrie standpoint. Various anti-psychotic agents and anti-depressants bind with
relatively high affinity at 5 -HT2Areceptors (Vollenweider et al., 1998). Although there is
no direct correlation between their receptor affinities and clinically effective doses,
evidence is strong that these disorders involve, at least to some extent, 5-HT2a (or
perhaps 5-HT2c) receptors (Liechti et al., 2000). For example, chronic administration of
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5-HT2A antagonists results in a paradoxical down-regulation of 5-HT2a receptors, such a
down-regulation would be of benefit in the treatment of depression. There also are
indications that 5-HT2a antagonists (a drug that blocks an action) possess anxiolytic
properties. For example, ritanserin produced anti-anxiety effect in humans. 5-HT2a
receptors are also involved in the actions of the classical hallucinogens (e.g., LSD,
mescaline, MDMA) (Sanders-Bush, Burries, & Knoth, 1988).
5 -HT2Creceptors

(once referred to as 5-HT2a) have been found in low densities in

various brain regions o f different animal species. 5-HT2c receptors may play a greater
role than 5-HT2a receptors in migraine (Liechti et al., 2000). On the basis o f a significant
correlation between migraine prophylactic activity and binding affinity, 5-HT2c receptors
may be involved in the initiation o f migraine attacks (Whale et al., 2001). For the most
part, the specific role of 5-HT2b receptors is unknown.
The 5 -HT 3 receptors are different fi’om the other serotonin receptors in that they are
non-selective sodium-potassium ion channel receptors, which allow them to alter fast
synaptic transmission. They are found in both the PNS and CNS. In the CNS, 5 -HT 3
receptors are localized in the entorhinal cortex, fi’ontal cortex, and hippocampus.
5 -HT3 antagonists

(e.g., ondansetron, granisetron, tropisetron) have proven clinically

effective for the treatment of chemotherapy-induced or radiation-induced nausea and
vomiting. Preclinical studies suggest that 5 -HT 3 antagonists may enhance memory and be
of benefit in the treatment of anxiety, depression, pain, and dementia. In addition, 5 -HT 3
receptors can control dopamine release and may also be involved in acetylcholine release
and control o f the GABAergic system. Dopamine itself acts as a 5 -HT3 partial agonist.
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5-HT4 receptors are localized on neurons and may mediate slow excitatory responses
to serotonin. It has been suggested that 5 -HT4 agonists may restore deficits in cognitive
function and may be useful as anxiolytics or in the treatment of dopamine-related
disorders. The marked decrease in 5 -HT4 receptors in patients with Alzheimer's disease
suggests the 5 -HT4 receptors may be involved in memory and learning (Peroutka,
Newman, & Harris, 1988). A high density of 5 -HT4 receptors in the nucleus accumbens
has led some researchers to speculate that these receptors may be involved in the reward
system and may influence self-administration behavior (e.g., Geyer, 1994).
The 5 -HT 5 class of serotonin receptors has been found to not have a high efficiency
of coupling to G-proteins. This suggests these may in fact be coupled to ion channels.
The pharmacological function o f 5-HTs receptors is currently unknown. It has been
speculated that on the basis of their localization they may be involved in motor control,
feeding, anxiety, depression, learning, memory consolidation, adaptive behavior, and
brain development (Liechti & Vollenweider, 2000). 5-HT sa receptors may also be
involved in a neuronally-driven mechanism for regulating astrocyte physiology, with
relevance to gliosis (Liechti et al., 2000). Disruption of 5-HT neuron-glial interactions
(i.e., gliosis) may be involved in the development of certain CNS pathologies, including
Alzheimer's disease, Down's syndrome, and some drug-induced developmental deficits
(Liechti et al., 2000).
5-HTô receptors are found primarily in the CNS and recent evidence suggests that
these play a role in many neuropsychiatrie disorders (Vollenweider et al., 1999). This is
because numerous anti-depressants (clomipramine, amitriptylamine) and antipsychotic
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agents (rilapine, clozapine, olanzapine) bind with a high affinity for these type of
receptors acting as antagonists (Glennon, Dukat, & Westkaemper, 1999).
The newest classes of 5-HT receptors (5-HT?A and 5-HT?B) are thought to be
involved in both mood and learning, as well as in neuroendocrine and vegetative
behaviors. It has recently been found that these two receptors also have a high affinity for
many anti-depressants and anti-psychotic agents (Naughton, Mulrooney, & Leonard,
2000).

MDMA and Serotonin Receptors
MDMA causes a profound release of serotonin by binding with high affinity to the
serotonin transporter (SERT). The binding of MDMA to the SERT inhibits the reuptake
of serotonin into the serotonin neurons, consequently flooding the brain with serotonin.
Recent studies suggest that the body responds to these extraordinarily high levels of
serotonin by decreasing the amount o f serotonin receptors in the brain. When serotonin
levels return to normal, but there are less 5-HT receptors in the brain this may lead to
changes in behavior (Rutty & Milroy, 1998).
Indeed, the major effect associated with the long-term abuse o f the drug ecstasy has
been the development o f clinical depression in frequent users (e.g. Parrott, 2004;
Thomasius et al., 2003). As MDMA affects serotonin release, and since serotonin has
long been known to be linked to depression, it was assumed that MDMA eventually
caused a lower production in the amount o f serotonin released. If this were true, then
treatment with anti-depressants should have fixed the problem.

39

Most anti-depressants are known as SSRI's, or selective serotonin reuptake inhibitors.
This class o f drugs works in that they inhibit the reuptake of serotonin back into the nerve
terminal, therefore increasing the amount o f available synaptic 5-HT, and thus, reversing
depression (Connor et al, 2001). However, in ecstasy users, the administration of SSRI's
had no effect, suggesting that the problem was not in the serotonin levels after all, as the
increased serotonin levels did not provide the expected results.
After studies found that even high levels of SSRI administration didn't work to
decrease depression, it was then postulated that the problem wasn't in the levels of
serotonin, but in the 5-HT receptors. Autopsy observations on humans who have died
from complications o f ecstasy use (heart failure, heat stroke, seizures) found that their
serotonin levels were normal (as measured by high performance liquid chromatography
or HPLC), further suggesting that the problem was in the serotonin receptors. However, it
still wasn't known if the 5-HT receptors were merely dysfunctional or if they had actually
been completely depleted. However, evidence now exists that it is actually in the number
of receptors, as studies in rodents have found a reduction in post-synaptic 5-HT receptors
following MDMA dosage (e.g., Battaglia et al., 1991).
The depletion of serotonin receptors is much like Type II Diabetes Mellitus, in that
the ligand is present in normal amounts, but the low concentration o f receptors is what
causes the problems. Therefore, anti-depressants show no effect, as the increased levels
of serotonin aren't any help because the receptors aren't present to take up the ligand
(Colado et al., 2004).
The mild hallucinogen-like perceptual effects of MDMA appear to be due to
serotonergic 5-HT%A receptor stimulation whereas MDMA-induced hyperactivity is
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mediated in part by 5-HT]g and 5-HTzA receptors. In contrast, the stimulation o f 5-HT2c
receptors results in inhibition of the expression o f MDMA-stimulated hyperactivity
(Liechti & Vollenweider, 2000).
The positive mood effects of MDMA may be related in part to dopaminergic D;
receptor stimulation. Serotonin neurons innervate dopamine nigrostriatal and
mesocorticolimbic circuits, including the projection from dopamine cell bodies in the
substantia nigra (SN) and ventral tegmental area (VTA) to the dorsal striatum and nucleus
accumbens. These pathways are known to be critical in mediating the behavioral effects
of psychostimulants.
The 5-HTib, 5-HT2a, and 5-HT2c are among the 5-HT receptors that have been
suggested to control brain dopamine function and also play a role in the behavioral effects
of MDMA. The 5-HT] g and its homolog, 5-HT]d function pre-synaptically as an
inhibitory autoreceptor (a receptor located on pre-synaptic nerve cell terminals and serves
as a part o f a feedback loop in signal transduction; it is sensitive only to those
neurotransmitters or hormones that are released by the neuron in whose membrane the
autoreceptor sits) and post-synaptically as an inhibitory heteroreceptor (a receptor
regulating the synthesis and/or the release o f neurotransmitter(s) other than its own
ligand) to control release o f neurotransmitters (Barnes & Sharp, 1999). Localization and
lesion studies support the hypothesis that 5-HT]g are localized on the axon terminals of Yaminobutyric acid (GABA) efferents projecting from the striatum and nucleus
accumbens. 5-HTig receptors provide inhibitory feedback to the origins o f nigrostriatal
and mesoaccumbens dopamine pathways (e.g., Brocke et al., 2000).
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Stimulation of 5-HTig by direct (5-HT) or indirect agonists (e.g., cocaine) has been
shown to inhibit GAB A release from terminals that innervate dopamine neurons in the
substantia nigra (Johnson etal., 1998) and VTA suggesting an important role for the 5HTig in the control of dopamine function. In support of this hypothesis, microdialysis
studies have shown that 5-HTig agonists facilitate release of dopamine in the nucleus
accumbens (Parsons et al., 1999) and striatum (Ng et al., 1993).

Neuropsychopharmacological Effects o f MDMA in Experimental Animals
The effect of MDMA on brain concentrations of serotonin is biphasic in the rodent
brain, and can be divided into acute and long-lasting phases. An acute, reversible phase
of serotonin depletion occurs within three to six hours after drug administration, after
which serotonin concentrations return to normal values (Schmidt, 1987). A long-lasting
depletion of serotonin occurs two to three days after drug treatment, and this depletion of
serotonin is evident in most brain regions containing serotonin terminals (Sabol et al.,
1996). There is only a partial recovery to control concentrations of serotonin after
depletion produced by MDMA. Serotonin concentrations remain depleted in most brain
regions up to one year following MDMA administration (Lew et al., 1996; Sabol et al.,
1996).
MDMA administration in rats also results in hyperthermia or an increase in core body
temperature (Colado et al., 1993; Dafters, 1994; Gordon, Wilkinson, O'Callaghan, &
Miller, 1991). Hyperthermia is related to the ambient temperature. Both Gordon et al.
(1991) and Dafters (1994) showed that at normal (24“C) and high (30“C) ambient
temperatures, MDMA administration resulted in an increase in temperature of
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approximately 2.0°C, whereas administering the drug to animals that had been kept at
low ambient temperature (11 ®C) for 24-hours before injection resulted in a fall in
temperature. Transferring the rats to a low temperature room 30-minutes after drug
administration attenuated the temperature rise (Dafters, 1994).
Hyperthermia that follows MDMA administration was once thought to be serotonin
receptor-mediated, however, more recent data suggests that it is a consequence o f
dopamine release (Meehan et al., 2002a; Sugimoto et al., 2001). Support for this proposal
comes from findings that show that selective serotonin receptor antagonists do not block
MDMA-induced hyperthermia (Meehan et al., 2002a). In addition, it has been shown that
the administration of Prozac almost totally inhibited the increase in extracellular
serotonin levels, but had no effect on the hyperthermic response in the same animals
(Berger et al., 1992; Malberg et al., 1996; Schmidt et al., 1990). What is more, Meehan
and colleagues (2002a) observed that a dopamine D| receptor antagonist (SCH 23390),
dose-dependently inhibited MDMA-induced hyperthermia. These researchers postulated
that MDMA might be producing hyperthermia, by enhancing the release o f dopamine,
which then acts on dopamine Di receptors.
Another major consequence o f MDMA administration in rats is the appearance of
hyperactivity and the “serotonin behavioral syndrome” (Grahame-Smith, 1971a; Colado
et al., 1993; Slikker et al., 1989). The syndrome consists of hyperactivity accompanied
by, head-weaving, piloerection, fore-paw treading, penile erection, ejaculation, and
salivation (Green et al., 2003). Callaway et al. (1990) reported that MDMA produced a
dose-related increase in locomotor activity that was prevented by pretreatment with
Prozac. This finding shows that serotonin release plays a key role in the behavioral
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effects o f MDMA. In addition, Kehne et ai. (1996a) demonstrated a reduction o f the
MDMA-induced locomotor response following pretreatment with a serotonin 5-HT2a
receptor antagonist, indicating the importance of 5-HT2a receptors in the expression of
MDMA-induced locomotor responses.

Acute Subjective Effects o f MDMA in Humans
Commonly consumed in oral tablet form, the average recreational dose of ecstasy is
between one and two tablets, each containing approximately 6 0 -1 2 0 milligrams (mg) of
MDMA (Morgan, 2000). Most individuals use the drtig on weekends, once a week or less
because tolerance to its positive effects develops rapidly (Peroutka, Newman, & Harris,
1988; Solowij, Hall, & Lee, 1992).
Recreational users typically describe a range of positive moods while on MDMA,
including euphoria, feelings of intimacy and closeness to others, heightened arousal, selfconfidence, increased sensory sensitivity, increased depth of emotion, and decreased
appetite (Curran & Travill, 1997; Davison & Parrott, 1997; Parrott, 1997; Peroutka et al.,
1988). The commonly reported acute adverse physiological side effects include increased
heart rate, jaw clenching, bruxism (tooth grinding), pupil dilation, gait instability, and
nausea (Davison & Parrott, 1997; Petroutka et al., 1988).

Long-Lasting Subjective Effects o f Ecstasy in Humans
Following the acute subjective effects, ecstasy users generally report a 24- to 48-hour
period characterized by the persistence of an array of negative moods, such as feelings of
lethargy, irritability, aggression, and depression. The negative moods presumably
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develop as a consequence o f central serotonergic depletion. This cycle of positive moods
while on the drug and negative moods afterward was confirmed in a prospective study by
Curran and Travill (1997). Twelve recreational MDMA users were compared with 12
alcohol users (controls), at a Saturday night dance club, over a period o f four days
following consumption. MDMA users reported comparatively better moods on the
Saturday night (i.e., day one), and worse moods in the days afterwards, at which point
some participants scored within the range of clinical depression. In contrast, alcohol users
showed less pronounced changes, which followed a U-shaped curve, with the lowest
point being day two.

Mechanisms o f MDMA-Induced Neurotoxicity
MDMA predominately causes serotonin to be released from its storage sites in
neurons, thereby, dramatically increasing brain activity. An acute dose of MDMA can
release around 80 percent o f central serotonin stores within four hours of administration
(Green, Cross, & Goodwin, 1995). Through the release of large amounts of serotonin,
MDMA causes a significant depletion of central serotonin stores, which can take two
weeks or longer to replenish (Green et al., 2003).
Neurotoxicity appears to develop because MDMA interferes with the synthesis of
serotonin neurons. That is, MDMA triggers both oxidative and metabolic stress in
serotonergic neurons, which adversely affects the ability of these neurons to produce
serotonin. For example. Stone, Johnson, Hanson, and Gibb (1989) found that MDMAinduced oxidation rapidly destroyed tryptophan hydroxylase (an enzyme essential for the
synthesis o f serotonin), which causes a long-term depletion of serotonin in affected
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neurons, and eventual cell death, particularly in the striatum and the cortex (Ricaurte et
al., 1985).
It appears that oxidation is triggered by MDMA binding to the serotonin transporter
and by MDMA-induced release of dopamine. Researchers have discovered that blocking
either dopamine release or MDMA binding to the serotonin transporter blocks the
production o f free radicals (a usually short-lived, highly reactive molecular fragment that
contained one or more impaired electrons) and the destruction of tryptophan hydroxylase.
In addition, investigators have shown that the formation of reactive oxygen triggered by
MDMA and other amphetamine derivatives increases with body temperature, which
explains observations that hyperthermia increases MDMA-induced toxicity.
Other evidence that MDMA induces oxidative stress comes from studies that have
measured the levels of the major metabolite of serotonin, 5-HIAA, and the serotonin
transporter. These studies have observed that 5-HIAA and the serotonin transporter levels
decrease markedly after MDMA administration and appear to remain low for months
after exposure. For example, in a study of rhesus monkeys, Taffe and colleagues (2001)
found that a four-day course of twice daily injections of a moderate dose of MDMA
produced four-to-five fold reductions in cortical serotonin levels 17 months after
exposure.
MDMA may also produce neurotoxicity by triggering the production of hydroxl
radicals, which cause an acute depletion of brain serotonin. Shankaran, Yamamoto, and
Gudelsky (1999) measured the production of hydroxl radicals within the brains of rats
given MDMA. These investigators found that following MDMA injection, there was an
immediate rise in hydroxl radicals, in serotonergic neurons in the striatum.
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What is more, MDMA leads to a reduction in antioxidant (enzymes that prevent the
formation o f hydroxl radicals) levels. For example, experimenters found decreased levels
of the antioxidants ascorbic acid (vitamin C) and vitamin E in the striatum of rat brains
following MDMA administration. Subsequent studies, however, have found that
artificially boosting the levels o f antioxidant enzymes may reduce MDMA’s damaging
effects on serotonergic and also dopaminergic neurons (e.g.. Cadet & Thiriet, 2001). It
also appears that drugs, such as Prozac, which inhibits the serotonin transporter
specifically, may decrease the number o f free radicals produced by MDMA use. For
example, in the Shankaran et al. (1999) study mentioned above, researchers administered
Prozac an hour prior to MDMA injection and observed a dramatic reduction in hydroxl
radical formation and in the amount o f serotonin released in the striatum. MDMAinduced dopamine release in the striatum was also suppressed. The same effect was seen
even when Prozac was administered four hours after MDMA. This finding suggests that
these neurotoxic effects involve MDMA’s actions at the serotonin transporter.
Histological studies have provided more dramatic evidence for the serotonin
neurotoxicity produced by MDMA. Two weeks after receiving 20 mg/km o f MDMA,
twice daily for four days, tissue taken from rat brains showed a substantial decrease in
neurons containing serotonin. Furthermore, the axons of these neurons appeared to be
missing. More recently, investigators observed similar findings in squirrel monkeys
showing that the loss o f serotonin axons from four-day exposure to MDMA was severe
18 months after exposure and persisted seven years later (Hatzidimitriou, McCann, &
Ricaurte, 1999).
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Further examination of this structural damage suggests that MDMA “prunes” or
reduces in number serotonin axons and axon terminals in some brain regions, like the
striatum, while sparing others, such as the amygdala (Ricaurte, 2001). This pattern is a
hallmark of axon pruning, since neurons will often grow replacement axon terminals
upstream o f the damaged terminals. Taken together, these results provide evidence not
only of MDMA’s neurotoxicity but of the brain attempting to rewire the serotonin system
after damage.
Finally, the regulation of serotonin receptors may also be involved in the mechanism
of neurotoxicity. During the acute action of MDMA, there is an adaptive down regulation
of serotonin receptors in the cerebral cortex (Sprague, Everman, & Nichols, 1998). This
may lead to many of the conditions associated with low serotonin levels, primarily
depression, even after brain serotonin levels have been restored, due to the inability of
serotonin to bind to its down regulated receptors (Morgan, 2000). In contrast, in long
term users, in the drug-free state, there is upregulation of receptors (an adaptive response
to the decrease in serotonin release) (Reneman et al., 2000).
Although it was initially thought that the development of toxicity required multiple
exposures to relatively high doses o f MDMA, studies in rats (Cami et al., 2000) have
shown that even a single exposure can produce some neuronal damage. Neurotoxic
effects found in non-human primates are long lasting and possibly permanent. Monkeys,
for example, have shown decrements in serotonin levels for as long as 18 months after
MDMA intake (Ricaurte et al., 1992). Repeated exposures to MDMA increase the
behavioral and biochemical responses o f the animals to the drug and sensitization seems
to occur after repeated exposure to low doses (Rodgers, 2000).
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Evidence o f the Neurotoxic Effects o f MDMA in Animals
In animals, there is extensive evidence that MDMA causes dose-related reductions of
brain serotonin and 5-HIAA concentrations, the density of serotonin uptake sites, and the
activity o f tryptophan hydroxylase. These neurochemical deficits, which last well beyond
the period o f drug administration, have been correlated with the disappearance of
serotonin axons, suggesting that they are related to axonal damage. Moreover, it appears
that MDMA damages only those serotonergic axons in the cortical region o f the brain, in
particular, those that arise from the dorsal raphe nucleus (Green et al., 2003).
The profile of neurodegenerative changes produced by MDMA is remarkably
consistent across a variety o f species, including rats, mice, guinea pigs, and non-human
primates. Mice appear to be less sensitive to MDMA neurotoxicity, whereas non-human
primates show more MDMA-induced serotonergic damage.
The magnitude ^ d duration of MDMA’s effects are dependent on the dose and the
number of injections given. Single doses (20 mg/kg or more) or several more moderate
doses, typically 5 mg/kg twice daily for four consecutive days (Battaglia et al., 1988;
Colado et al., 1993; O’Shea et al., 1998; Ricaurte et al., 1992) produce marked depletion
of serotonin and 5-HIAA. The neurotoxic effects are evident for up to one year after drug
administration in rats (Battaglia et al., 1987), and have been observed up to seven years
after drug administration in non-human primates (Hatzidimitriou et al., 1999). The lowest
MDMA dose that elicited long-term structural damage in non-human primates was
5mg/kg twice daily, for four consecutive days (Ricaurte et al., 1992). This is higher and
more frequent dosing than is typical in human recreational users. However, principles of
interspecies scaling suggest that a dose of 5 mg/kg of MDMA, in a squirrel monkey, is
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equivalent to 1.4 mg/kg in humans (Ricaurte et al., 2000). Furthermore, it has been
reported that up to one third of recreational users “binge” by taking several tablets at once
or over a period of hours to days (Topp et al., 1999).
With regard to regional brain sensitivity to the neurotoxic effects of MDMA, areas
rich in serotonin terminals, such as the cerebral cortex, show more severe deficits than
brain regions containing fibers of passage (e.g., hypothalamus) or cell bodies (brain stem)
(Commins et al., 1987; Steele et al., 1994). In particular, repeated administration of
MDMA has been found to produce especially long-lasting degeneration of serotonin
axons and decreases in brain serotonin and 5-HIAA concentrations in many regions of
the forebrain. These include the neocortex (prefrontal cortex), hippocampus, caudate
nucleus, putamen, and many thalamic nuclei (Hatzidimitriou et al., 1999; Ricaurte et al.,
1992).
Following MDMA injury, there is evidence of a lasting reorganization o f ascending
serotonin axon projections. Projections to distant forebrain sites like the dorsal prefrontal
cortex, exhibit little or no evidence o f recovery, while projections to more proximal
targets, such as the hypothalamus, recover fully, and in excess (Fischer et al., 1995).
Moreover, Fischer and colleagues (1995) reported that altered reinnervation patterns
develop much more frequently in MDMA-treated primates than in MDMA-treated
rodents.
Similar evidence has also been obtained using positron emission tomography (PET).
Scheffel and colleagues (1998) utilized a radioligand (a radio active chemical marker
which binds to certain cells and is used to allow areas inside the brain to be mapped or
measured) that selectively labels the serotonin transporter to investigate the long-term
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neurotoxic effects in a baboon that had been administered 5 mg/kg MDMA, twice daily
for four consecutive days. In agreement with the results of Fischer et al. (1995), PET
scans nine and thirteen months post-MDMA showed regional differences in the recovery
of serotonin transporters. For example, an increase in transporters was observed in the
hypothalamus whereas a persistent decrease in transporters occurred in the prefrontal
cortex.
Taken together, the available animal evidence, which focus on the neurotoxic effects
of MDMA, suggests that repeated administration of high oral doses o f MDMA may
produce long-term reductions in serotonin activity and degeneration of serotonin axons.
In particular, non-human primates show increased sensitivity to such effects, with a lesser
tendency for reinnervation to occur in cortical serotonin systems.

Evidence o f Neurotoxic Effects o f MDMA in Humans
The neurotoxic dose o f MDMA in non-human primates approaches the dose of
MDMA typically taken by recreational users (Ricaurte & McCann, 1992). This raises the
concern that human MDMA users might also incur MDMA-induced serotonin damage.
Since there are no currently available methods for directly evaluating the status of
serotonin neurons in living humans, studies of MDMA’s neurotoxic potential in humans
rely on indirect methods. These methods include measurements o f the concentration of 5HIAA in cerebral spinal fluid (CSF) (levels of serotonin metabolites in the CSF reflect
the amount o f release during neuronal activity in the brain), quantification of serotonin
transporter density, neuroendocrine challenge (the administration o f drugs that stimulate
serotonergic pathways, and a variety of neuroimaging techniques.
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The earliest study to measure 5-HIAA concentrations in CSF failed to find evidence
of reduced levels of 5-HIAA in recreational users (Peroutka et al., 1987). More recent
data, however, has reported significantly lower levels of CSF 5-HIAA in recreational
ecstasy users compared to polydrug users who had never used ecstasy (e.g., Bolla et al.,
1998; McCann et al., 1994; 1999; Ricaurte et al., 1990).
In addition to a marked reduction in 5-HIAA levels, investigators have consistently
observed decreases in the number of serotonin transporters in MDMA users. Serotonin
transporters are sites on the pre-synaptic axons and axon terminals of serotonin neurons
that reabsorb serotonin from the synapse. They are considered to be a reliable marker of
serotonin neurotoxic changes (Renenman et al., 2001). Thomasius and colleagues (2003)
utilized single photon emission computed tomography (SPECT) to measure serotonin
transporter densities in 30 current and 31 ex-MDMA users (with MDMA abstinence of at
least five months), and 29 polydrug and 30 drug naïve controls. Current ecstasy users
showed significantly reduced distribution volume ratios of serotonin transporter
availability in the mesencephalon and caudate nucleus. Furthermore, regression analyses
indicated that the number of ecstasy tablets taken, best-predicted serotonergic alterations.
Similarly, Reneman et al. (2001) compared serotonin transporter densities in 22
recent MDMA users, 16 ex-MDMA users (individuals who had stopped using MDMA
for more than one year), and 13 drug naive controls. These investigators found that recent
MDMA users showed global decreases in cortical serotonin transporter densities (nine
percent reduction), whereas ex-MDMA users densities did not differ from those of
controls. Semple, Ebmeier, Glabus, O’Carroll, and Johnstone (1999) also reported a ten
percent reduction in serotonin transporter densities in the occipital cortex of recent
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MDMA users. In addition, recent MDMA users showed a widespread reduction of
cortical serotonin transporter binding. What is more, decrease correlated with the extent
of previous use. Semple and colleagues (1999) observation of reduced transporter binding
corroborate earlier PET findings (McCann et al., 1998).
There is also evidence that brain atrophy might occur in association with chronic
ecstasy use. Magnetic resonance spectroscopy (MRS) has been used to investigate myo
inositol concentrations, a specific marker of glial cell density and neuronal damage.
Increases in the number o f glial cells are indicative of brain injury (Kalant, 2001). Chang
et al. (2001) reported that myo-inositol concentrations were elevated in the parietal white
matter o f heavy ecstasy users compared to that of drug naïve subjects. A significant effect
o f the cumulative lifetime ecstasy dose on the parietal white matter and in the occipital
cortex was also observed. Similarly, the duration o f MDMA use was related to myo
inositol in the parietal white matter, as well as in the frontal cortex.
There is also neuroimaging evidence that the hippocampus, amygdala, and frontal
region o f the cortex may be particularly affected by extensive exposure to ecstasy.
Obrocki et al. (1999) employed positron emission tomography (PET) to investigate
regional brain glucose metabolism in seven heavy ecstasy users, who had used between
12 and 840 single doses and had remained drug free for 2 - 16 months. The ecstasy users
exhibited bilaterally reduced glucose metabolic uptake in the hippocampus, amygdala,
and cingulate cortex. Moreover, glucose metabolism was significantly more affected in
MDMA users who began taking the drug before age 18.
Other evidence of potential MDMA-induced brain alterations is provided by
functional magnetic resonance imaging (fMRI) and evoked potential studies. For
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example, Cowan and colleagues (2001) found that MDMA users showed less brain
activity in the visual cortex following a light flash than did drug-naive control subjects.
Subsequently, a comparison o f the auditory evoked potentials of heavy ecstasy users with
those o f two matched control groups, a non-user and a marijuana-user group found that
ecstasy users demonstrated altered patterns of cortical brain activation relative to both
control groups (Tuchtenhagen et al., 2000). Specifically, ecstasy users (who had been
dmg free for seven days to a year) exhibited an increase in the amplitude o f the tangential
N1/P2 source activity, with higher stimulus intensities. High intensity dependence of the
tangential N1/P2 source activity has been associated with low levels of serotonergic
neurotransmission in humans (Hergerl & Juckel, 1993).
A major limitation o f these studies is that, even if they demonstrate decreased
numbers o f serotonin cells and reduced serotonin system function in the brains of
MDMA users, they cannot prove that the MDMA use necessarily caused the changes.
The alterations in serotonin function may have been present before the drug use began or,
alternatively, they may have contributed to the initiation o f drug use (Kalant, 2001).
However, several studies have shown that the degree of change in serotonin function is
proportional to the duration and intensity of the preceding use of MDMA. This finding is
more compatible with the MDMA use being the cause rather than the consequence of
impaired serotonin function.
Although none of the studies whether animal or human have proven without a doubt
that MDMA is exerting long-term or permanent neurotoxic effects on serotonergic
neurons, all of the experimental results presented above appear to converge on that
notion. Evidence from both animal and human studies strongly suggest that MDMA
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produces a lasting decrease in serotonergic activity by permanently disrupting its neuron
terminals. The animal and human MDMA studies carried out thus far have made a great
deal of progress toward clarifying MDMA’s neurotoxic effects. However, much more
still needs to be done in order to elucidate the whole MDMA picture, including its exact
neurotoxic effects and the dosages, which bring about those effects. Nevertheless, the
fuzzy MDMA picture painted so far is enough to raise real concerns over the escalating
MDMA usage seen in the 1990’s and 2000’s. In conclusion, individuals who use MDMA
as a recreational drug may be putting themselves at risk of developing permanent brain
serotonergic system injuries.

Evidence that MDMA Induces Residual Effects on Cognition
If MDMA induces neurotoxic effects in serotonergic neurons, functional changes can
be expected in psychological functions that are related to serotonergic processes.
Learning and memory are two such processes. There is some evidence that repeated
treatment o f rats with high doses of MDMA produces persistent impairments in learning
and memory. For instance, MDMA-induced 73 percent depletion of neocortical
serotonin, which resulted in a mild impairment of the ability to develop an efficient
search strategy in a place-havigation task (Robinson et al., 1993). Furthermore, a
selective, delay-dependent deficit in delayed non-match to place performance developed
12 days after rats were exposed to high doses of MDMA for three days (Marston et al.,
1999).
There is evidence that suggests human recreational MDMA users may display
residual cognitive dysfunction. Some studies have observed that recreational ecstasy
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users perform more poorly than other drug users and non-drug users on tests of visualspatial and verbal working memory, as well as executive function (e.g.. Fox et al., 2002;
Gouzoulis-Mayffank et al., 2000; Montgomery et al., 2005; Morgan, 2002; von Gesuau et
al., 2004; Wareing et al., 2004; Wareing et al., 2000; Zakzanis & Yoimg, 2001).
However, the most robust finding in the MDMA literature is that recreational ecstasy
users exhibit a selective deficit in verbal learning and memory performance (e.g.,
Bhattachery & Powell, 2001; Bolla et al., 1998; Curran & Verheyden, 2003; Fox et al.,
2001; Gouzoulis-Mayfrank et al., 2000; Krystal et al., 1992; McCann et al., 2001;
McCardle et al., 2004; Morgan, 1999; Parrott & Lasky, 1998; Parrott et al., 1998;
Quednow et al., 2006; Reneman et al., 2001 ; Rodgers, 2000; Verkes et al., 2001 ; Yip &
Lee, 2005; Zakzanis & Yoimg, 2001). Moreover, there appears to be a dose-dependent
relationship between memory problems and extent of ecstasy use, such that higher
cumulative lifetime dose of ecstasy is associated with lower memory scores.
Bolla et al. (1998) compared 24 abstinent MDMA users who had used MDMA on at
least 25 occasions (and had abstained from use for >2 weeks) and 24 control subjects
matched for age, gender, level of education, vocabulary score, and prior drug use (had no
self-reported prior use of MDMA, but other drugs were used). Subjects were assessed on
the Rey-Auditory Verbal Learning Test (AVLT), the Wechsler Memory Scale-Revised
(WMS-R) and the Rey-Osterrieth Complex Figure (RCF) tasks. Bolla and colleagues
(1998) found that greater use o f MDMA (in terms of total mg/per month) was associated
with greater impairments in immediate verbal memory and delayed visual memory. The
relation among CSF 5-HIAA, average total MDMA per dose per month, and memory
function were also analyzed. The mean concentration of 5-HIAA in the CSF was lower in
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the MDMA users compared to control subjects and CSF 5-HIAA levels decreased with
increasing MDMA dose. Furthermore, the lower CSF 5-HIAA concentrations resulted in
worse memory performance. These data suggest that MDMA-induced brain serotonin
neurotoxicity might account for the observed memory deficits.
Morgan (1999) utilized subtests of the Rivermead Behavioral Memory Test (RBMT),
to investigate immediate and delayed recall. He asked MDMA users and controls to listen
to a brief, audio-taped news story o f five sentences and 65 words and then write down as
much o f what they had heard as possible, immediately after the story and again 40
minutes later. Members o f the MDMA group, all o f whom had taken the drug on at least
20 occasions, but were abstinent from all psychoactive drugs on the day o f the study,
scored substantially lower than either the polydrug group or non-drug group on both
immediate and delayed recall. Though the analysis found that there was no correlation
between the amount o f MDMA taken over an individual’s lifetime and memory
performance, there was a trend suggesting that the immediate recall abilities might be
related to the average dose taken per occasion.
Other neuropsychological test batteries yield similar findings with regard to cognitive
fimction. For example, McCann et al. (1999) assessed cognitive performance in 22
MDMA users (who had used MDMA on at least 25 separate occasions) and 23 control
subjects (who had never used MDMA) using a computerized version o f the Walter Reed
Army Institute of Research Performance Assessment Battery (WRAIR PAB).
The test battery consisted of seven tests designed to assess a variety o f psychomotor
and cognitive fimctions, including the Time Wall task, the Serial Add and Subtract test,
the Logical Reasoning Task, the Manikin task. Code Substitution, the Matching to
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Sample task, and the Delayed Recall test. CSF 5-HIAA measures were also obtained.
Compared to control subjects, MDMA users who had abstained from drug use for at least
three weeks had impaired performance deficits on four of seven cognitive tests in the
WRAIR PAB. Specifically, performance deficits were found on a sustained attention task
requiring arithmetic calculations, a task requiring visual discrimination and working
memory, a short-term memory task, and a task of semantic recognition and verbal
reasoning. Performance deficits on the working memory task were directly associated
with the extent of prior MDMA use. Significant reductions in CSF 5-HIAA (the major
metabolite o f 5-HT) concentrations were also observed in ecstasy users relative to
controls. McCann et al.’s (1999) findings extend those from previous investigations
demonstrating deficits in verbal and visual memory in MDMA users to include a variety
of different psychomotor, perceptive and cognitive tasks (e.g., Curran & Travill, 1997;
Parrott et al., 1998).
The evidence that impaired serotonergic function may be associated with memory
deficits in recreational ecstasy users is further extended by correlations between
alterations in cortical serotonin 5-HT2a receptor binding (Reneman et al., 2000), altered
D-fenfluramine-induced cortisol responses (Verkes et al., 2001), altered tryptophan
metabolism (Curran & Verheyden, 2003), and memory deficits. For example, Reneman
et al. (2000) demonstrated higher overall serotonin 5-HT2a receptor binding ratios in the
brains o f an ecstasy user group compared to control subjects. These differences reached
statistical significance in the occipital cortex, and the authors suggested that the increased
binding was due to MDMA-induced serotonin depletion resulting in an upregulation of
serotonin 5-HT2a receptors. The ecstasy users also demonstrated a significant impairment
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in delayed recall as measured by the AVLT, which directly correlated with the increase in
serotonin 5-HT2a receptor binding ratios (Reneman et al., 2000). Verkes et al. (2001)
demonstrated a significantly reduced cortisol response to D-fenfluramine in ecstasy users
compared to control subjects. In addition, ecstasy users also had significantly longer
reaction times to visual and auditory stimuli, lower visual recall, and lower working
memory scores. The reduced cortisol response was demonstrated to correlate
significantly with visual recall scores, indicating a significant association between
chronic ecstasy use, diminished memory performance, and serotonergic neuroendocrine
functional deficits (Verkes et al., 2001).
Furthermore, Curran and Verheyden (2003) observed increased plasma tryptophan
levels following a tryptophan challenge (an indirect method of assessing the integrity of
serotonin function) in ex-ecstasy users (ex-users had stopped using ecstasy for at least a
year and on average, 2.4 years), which correlated very highly with ex-users poorer
immediate and delayed prose recall. Elevated plasma levels of tryptophan may imply
there is a disruption in tryptophan metabolism in ex-ecstasy users. If tryptophan is not
metabolized into serotonin, then the concentration of tryptophan in the brain will
increase, thereby reducing the transport gradient between the brain and plasma resulting
in elevated levels of plasma tryptophan (Curran & Verheyden, 2003). This decreased
metabolism may, therefore, reflect alterations in serotonin function in ex-users. In
conjunction with findings from non-human primates (Hatzidimitriou et al., 1999), it is
possible that this relates to degeneration o f serotonin axonal terminals.
Other memory investigations have attempted to assess whether long-term ecstasy use
or long-term marijuana use is responsible for the memory impairment often observed in
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recreational ecstasy users (e.g., Croft et al., 2001; Dafters et al., 2004; GouzoulisMayffank et al., 2000; Halpem et al., 2004; Lamers et al., 2006; Quednow et al., 2006;
Rodgers, 2000; Simon & Mattick, 2002). For example, in a well-controlled study,
Gouzoulis-Mayffank et al. (2000) compared three groups of 28 subjects; ecstasy users
(average lifetime dose of 93 tablets), marijuana users, and non-drug users. The marijuana
group had the same exposure to marijuana as the ecstasy group, but no other regular drug
use. The groups were well-matched for age, sex and education (with slightly lower
education in ecstasy users).
A cognitive test battery was administered. Memory was assessed using a German
version o f the AVLT (delayed recall was not assessed), the digit span forward/backward
task to tap working memory and a visual memory task. Test scores in all three groups
were within the normal range. Ecstasy users scored significantly lower than non-drug
controls in immediate verbal and visual recall and in working memory (digit span
backward), and required more repetitions to learn the AVLT word list. Subsequently, the
ecstasy group also performed worse than the marijuana users in immediate visual recall
and required more repetitions to learn the word list. Ecstasy users further showed poorer
performance than the other two groups in tests of selective attention, logical thinking,
problem solving and general knowledge. Decreasing immediate verbal recall and
working memory performance correlated with increasing lifetime doses of ecstasy. An
increasing ffequency of marijuana use correlated with an increasing number o f repetitions
required to learn the word list. Taken together, theses findings indicate that poorer
memory performance in ecstasy users may not be solely accounted for by concomitant
marijuana use.
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Like Gouzoulis-Mayfrank et al. (2001), findings from Rodgers (2000) study suggest
that marijuana use may be responsible for some proportion of the impairment seen in
ecstasy users verbal memory performance. Three groups of 15 subjects were recruited:
ecstasy users (mean ecstasy use o f 20 tablets), exclusive marijuana users, and non-drug
users. All groups were matched for age, sex and education. Marijuana and ecstasy users
were matched for their marijuana use. The marijuana users had consumed marijuana four
days a week for about 11 years and the ecstasy users had consumed marijuana for about
ten years. With regard to drugs other than ecstasy and marijuana, the ecstasy group was
not matched to the other groups.
Memory was assessed with the Wechsler Memory Scale (WMS), which includes
measures for verbal and visual memory (both immediate and delayed). A further series of
tasks assessed basic and complex reaction time. Ecstasy users scored lower than controls
in one test of immediate verbal recall, which required them to retell brief stories from
memory, but not in another one that required memorizing associated word pairs.
Marijuana users showed the same pattern of significantly lower scores in the former, but
not the latter test for immediate verbal recall. Ecstasy users were also substantially worse
than controls and marijuana users in tests of verbal and visual delayed recall. In the
delayed story recall condition, both ecstasy and marijuana users scored significantly
worse than controls. No group differences were found in tests of immediate visual
memory, attention, and basic and complex reaction time.
One major concern with this study is in the extent o f use of marijuana and ecstasy in
the ecstasy users. The ecstasy users were very light users of ecstasy (mean = 20 tablets),
but very heavy users o f marijuana. It seems more appropriate to say that this study tested
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regular marijuana users with an occasional use of ecstasy, then to speak o f ecstasy users
with concomitant marijuana use. From this perspective, the fact that the additional light
ecstasy use in one of the marijuana groups was associated with lower scores in delayed
memory performance above those seen in exclusive marijuana users seems remarkable.
The main suggestion offered by this work is that marijuana use could be responsible for
some proportion of the lowered memory scores (particularly in immediate verbal recall),
but that additional, even moderate ecstasy use, can extend the impact on memory to
include delayed memory performance.
This view is in partial agreement with Gouzoulis-Mayfrank et al. (2000) who reported
that marijuana use is likely to have affected cognition and to have contributed to some
extent to the poorer performance o f ecstasy users. However, in the Gouzoulis-Mayfrank
et al. study, marijuana users did not perform significantly worse than non-drug controls.
The reason for this may be that their use o f marijuana, although comparable in frequency
to the marijuana users in Rodgers’ (2000) study had spanned only three years compared
to 11 years.
Croft et al. (2001) compared the cognitive performance of 11 ecstasy users with
concomitant marijuana use with 18 ecstasy-naive marijuana users and 31 non-drug user
controls. Ecstasy and marijuana users had both used a substantial amount o f marijuana
(10,965

V.

7,762 lifetime joints). Long-term memory performance was assessed using the

Coughlin List and Design Learning Test and a facial recognition test. Other cognitive
tests were included in the test battery (forward/backward digit span, verbal fluency,
spatial associative learning, the Stroop test, a pegboard test). The only difference between
ecstasy users and marijuana users were higher scores in design learning and the pegboard
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test in the ecstasy group. The pooled ecstasy and marijuana groups performed worse than
the non-drug controls in tests for auditory verbal learning, immediate and delayed recall,
forward and backward digit span, face recognition, as well as in non-memory tests
including spatial associative learning, verbal fluency, and the Stroop test for speed of
processing.
Most interestingly, when statistically removing the effect of marijuana use none of
the significant differences remained except for in the Stroop test for speed o f processing.
This means all but one difference in cognitive test performance between the drug using
subjects and the controls could be statistically accounted for by marijuana use, while
ecstasy use only accounted for the difference in the Stroop test. This finding suggests that
concomitant marijuana use may be responsible for much, if not all of the cognitive
differences between ecstasy users and control subjects that have been reported thus far.
However, an alternative explanation for this result is that MDMA did cause cognitive
impairment, but the lack of difference between the MDMA-marijuana and marijuanaonly group was due to some interaction between the drugs. Croft et al. (2001) have
suggested that marijuana might attenuate the effects of ecstasy through marijuana-related
dopamine down regulation thereby exerting neuroprotection against MDMA-induced
serotonergic deficits.
Nevertheless, the Croft et al. (2001) study clearly shows the need to adequately
control for marijuana use in fiiture studies. In that respect it adds to the studies of
Rodgers (2000) and Gouzoulis-Mayfrank et al. (2000) that already demonstrated an
involvement o f marijuana in verbal memory deficits found in ecstasy users. However, an
important difference with the latter studies is that Croft et al. (2001) found no relative
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impairment o f the ecstasy users compared to the marijuana users, while GouzoulisMayfrank et al. (2000) and Rodgers (2000) found poorer verbal learning and recall, as
well as visual recall in ecstasy plus marijuana users compared to marijuana but not
ecstasy users. Thus, although the jury is still out on this, it seems that the putative effects
of ecstasy use on cognitive performance can extend beyond those of marijuana use (given
the particularly careful methodology of the Gouzoulis-Mayfrank et al. (2000) study).
However, this does not preclude the possibility that a substantial part of the observed
cognitive differences may be the consequence of regular marijuana use.
Other, more recent investigations corroborate Croft et al.’s (2001) finding of no
significant differences between ecstasy and marijuana users verbal memory performance,
after controlling for marijuana use (e.g., Dafters et al., 2004; Halpem et al., 2004; Lamers
et al., 2006; Simon & Mattick, 2002). These investigations have found that marijuana
users, whether or not they also used ecstasy, exhibit significant impairment in memory
fimction when compared to the non-drug user controls. However, there is no significant
difference between the ecstasy and marijuana users.
There are, o f course well-designed investigations that have controlled for marijuana
use and demonstrated verbal memory deficits are more closely associated with ecstasy
use, rather than marijuana. For example. Yip and Lee (2005) observed large deficits in
both immediate and delayed recall performance on a Chinese version of the AVLT, in a
large sample of ecstasy users (N = 100). Moreover, these researchers were able to recruit
exclusive ecstasy users (no other illicit drug use) because ecstasy use had only recently
become a popular trend in Hong Kong.
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What’s more interesting is that Yip and Lee (2005) observed deficits in ecstasy users
with relatively low lifetime ecstasy consumption. Ecstasy users had on average consumed
35.8 tablets (range 16 to 60 tablets). The only other study to report significant deficits in
ecstasy users with such a low average use of ecstasy was McCardle et al. (2004), but the
deficit detected was only 7 percent (ecstasy users = 11.18 words versus polydrug users =
12.13 words on the AVLT).
Like Yip and Lee (2005), Quednow et al. (2006) conducted a well-designed study
that supports the claim that deficits in delayed recall performance in recreational ecstasy
users are attributable to ecstasy use instead of marijuana. Quednow and colleagues (2006)
examined AVLT performance in three groups of 19 male participants: abstinent ecstasy
users, abstinent marijuana users and non-drug users. The comparison with a control group
of marijuana users allowed these researchers to estimate the influence of concomitant
marijuana use in ecstasy users.
Ecstasy users showed widespread marked verbal deficits compared to non-drug user
controls, as well as compared to marijuana users, whereas marijuana users’ memory
performance did not differ from controls subjects. Ecstasy users revealed impairments in
learning, consolidation, recall and recognition. In addition to that, they have also
displayed a worse organization of memory information which is reflected in a high
inconsistency of recall and a diminished retroactive interference, which is expressed by a
high loss after interference. The ecstasy users also did show slightly worse performance
in the supraspan (AVLT-trial 1), which may indicate a moderate deficit in working
memory. These results remained significant after statistically covarying for marijuana use
and verbal IQ.
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Taken together, the findings are mixed with regard to whether long-term ecstasy use
or long-term marijuana use is responsible for the changes sometimes observed in ecstasy
users. Interpretation o f the positive findings of verbal memory deficits are questionable,
however, because they are complicated by methodological shortcomings and potentially
confounding variables that may have contributed to the deficits observed. For instance, a
number o f the earlier memory studies that demonstrated impairment did not adequately
match samples of ecstasy users and control participants with regard to pre-morbid
intellectual function, education level, gender and age. More recent studies have attempted
to correct for such differences by matching participants.
In addition, much o f the earlier research provides little specific consideration for the
concomitant use of other illicit drugs by ecstasy users, especially marijuana. A large
number o f ecstasy users have also used a substantial quantity of marijuana.
Neuropsychological studies have reported that the heavy chronic use of marijuana may
produce subtle deficits in attention and verbal learning and memory (e.g.. Block &
Gonheim, 1993; Fletcher et al., 1996; Hall & Solowij, 1998; Messinis et al., 2005;
Millsaps et al., 1994; Pope et al., 1996; Solowij et al., 2002). The severity o f marijuanainduced impairment appears to depend on the duration and the frequency o f marijuana
use (e.g.. Holla et al., 1998; Hall & Solowij, 1998; Solowij et al., 2002). To some degree
then, the question remains as to whether cognitive deficits in ecstasy users are attributable
to ecstasy itself or to marijuana.
Alternatively, recent work with male wistar rats suggests that MDMA and THC (the
main psychoactive component in marijuana) may interact synergistically, such that the
combined effect of MDMA and THC is greater than the sum of their individual effects
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(Morley et al., 2004; Young et al., 2005). For instance. Young and colleagues (2005)
observed a greater acute impairment in working memory performance in rats that were
co-administered both MDMA and THC relative to rats that received either drug alone.
In contrast, Morley et al.’s (2004) findings revealed positive synergistic effects of
MDMA and THC. When THC was administered with MDMA, THC at high doses
attenuated the typical negative effects associated with MDMA up to six weeks following
drug administration. For example, Morley et al. (2004) found that THC reduced body
temperature, serotonin depletion in the hippocampus, amygdala and prefi^ontal cortex, as
well as reduced anxiety.

Executive Function
Executive functions are general-purpose control mechanisms that modulate the
operation of various cognitive subprocesses and thereby regulate the dynamics of human
cognition (Miyake, Friedman, Emerson, Witzki, & Howerter, 2000). It is proposed that
these functions make possible the anticipation o f and establishment of goals, the
designing o f plans, the self-regulation and monitoring of tasks, the appropriate selection
of, organization and sequencing of behaviors in space and time, the monitoring of
behavior with regard to affective and motivational states, adaptive decision-making, and
effective execution and feedback (Damasio, 1994).
Executive functions have been neuroanatomically associated with different neural
interaction pathways involving the prefrontal cortex (Roberts, Robbins, & Weiskrantz,
1998). In particular, the dorsolateral portion of the prefrontal cortex (DLPFC) is the area
that seems to be involved in executive function. Moreover, the psychopharmacological
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literature suggests that DLPFC function is underpinned by dopaminergic systems, which
are in turn modulated by serotonin activity. Given that MDMA affects serotonin activity,
this raises the possibility that MDMA disrupts the modulating role of serotonin in the
DLPFC.
Indeed, there is evidence, which suggests that MDMA use may be associated with
selective impairments in executive function, and like the findings on memory
performance, it appears that increases in MDMA consumption might relate to more
pronounced impairment in executive function. For example, in their assessment of 26
MDMA users (a minimum consumption of 10 ecstasy tablets was required with at least
one occasion in the most recent year) and 33 non-users, von Geusau et al. (2004) found
that MDMA users performed significantly worse on tasks that tapped cognitive flexibility
(i.e., Dots-Triangles test and Local-Global test). Moreover, male MDMA users
performed poorly on the cognitive flexibility task and made more perseverative errors
whereas no significant difference were found in female MDMA users relative to control
subjects. Significant differences between male MDMA users and controls were also
found on the complex executive function tasks (i.e., WCST and Tower of London
(TOL)). In the WCST, users performed worse on virtually all the dependent measures
(e.g., total number of correct responses, number of perseverative errors). This finding is
consistent with those reported by Fox et al. (2001), who also observed more errors of
perseveration in MDMA users on the TOL task.
Verdejo-Garcia et al. (2005) analyzed the relationship between severity of
consumption of different drugs and performance on tasks sensitive to impairment in the
executive subprocesses o f working memory, response inhibition, cognitive flexibility,
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and abstract reasoning in a sample of 38 detoxified polydrug abusers. A significant effect
of MDMA was found on the working memory and analogical reasoning components of
executive function.
In another study, Zdczanis and Young (2002) observed that MDMA users scored
appreciably lower on the Behavioral Assessment of Dysexecutive Syndrome, a test
designed to measure mental organization, planning strategies, thinking ahead, mental rule
formation, and the estimation o f temporal activities. In addition, several significant
product moment correlations were found suggesting that increases in MDMA
consumption may relate to more pronounced impairment in executive function. Similarly,
Semple et al. (1999), using the Spatial Working Memory subtest of the Cambridge
Neuropsychological Test Automated Battery (CANTAB), Trail Making Test (Part B),
phonemic word fluency, and the Stroop task to examine executive function in abstinent
ecstasy users found that larger lifetime doses of MDMA were associated with more errors
on the Spatial Working Memory test.
Wareing and colleagues (2000; 2004), utilizing a random letter-generating task
sensitive to the central executive of working memory, also showed that recreational users
of MDMA generated fewer letters and exhibited a greater degree of redundancy and a
greater number of intrusions. Subsequently, Gouzoulis-Mayfrank et al. (2000),
employing a digit span backward task demonstrated impairments that persisted for at
least six months after abstinence in ecstasy users.
In contrast to the above-mentioned findings, other researchers have failed to observe
impairments in executive function in MDMA users. For instance. Fox et al. (2002)
examined the neuropsychological performance of 20 MDMA polydrug abusers and 20
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non-MDMA polydrug abusers who had never taken ecstasy, on a computer-assisted
neuropsychological battery designed to assess memory and executive functioning. Both
groups had remained abstinent for a minimum period of two weeks. Their results showed
significant differences in performance of the polydrug ecstasy abusers on tasks of visual
short-term memory, working memory, and verbal fluency. Although working memory
and fluency processes have been associated with prefrontal executive deficits, the
polydrug ecstasy group did not show significant impairments on other tasks designed to
evaluate planning, impulse control, or decision-making abilities. The authors interpreted
their results in terms of a selective profile of temporal dysfunction.
Subsequently, Gouzoulis-Mayfrank et al. (2003) compared the performance of 60
abstinent MDMA users (30 heavy users and 30 moderate users) and 30 non-user controls
on tests aimed to judge general intelligence, memory, working memory, and executive
control processes. They reported that heavy ecstasy users were significantly impaired
compared to moderate users and healthy controls, in the general intelligence and memory
domains whereas these users did not show significant impairments on tests of planning,
impulse control, and working memory. However, memory deficits were still significant
when general intelligence was included as a covariate and they were significantly related
to a measure o f frequency of MDMA use.
Likewise, Thomasius et al. (2003) compared a group of 31 former ecstasy users who
quit using ecstasy at least 20 weeks before the study, a group of 29 polydrug users who
had never taken ecstasy and were asked to abstain from consumption for at least six days
and a group o f 30 healthy controls on neuropsychological tests of intelligence, learning,
and memory, divided attention, impulse control, and mental flexibility. Results showed
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that former ecstasy abusers were significantly more impaired in memory functions and
that polydrug, non-MDMA users made significantly more preservative errors on the
WCST. Finally, no significant group differences were detected on premorbid intelligence
and complex attention. Finally, Simon and Mattick (2002) did not detect significant
differences between 40 ecstasy users asked to abstain for a minimum of 24-hours and a
group o f 37 controls and novice ecstasy users on the Wechsler Memory Scale-Ill (WSMIII).
Taken together, the available evidence seems to suggest that sustained MDMA
consumption incurs a selective impairment on the cognitive flexibility component of
executive function (as shown by performance on switch tasks and the WCST). Moreover,
heavy ecstasy users appear to exhibit greater impairment, relative to moderate users and
drug naive controls. Thus, the recreational use o f ecstasy may result in deficiencies in the
adaptive ability to adjust behavior in response to changing environmental demands.

Methodological Challenges
While the neuropsychological data strongly suggests that MDMA damages the central
serotonergic system and produces long-lasting behavioral deficits, there are a number of
methodological challenges. These challenges are not unique to MDMA investigations but
are common problems in all drug research involving human subjects. Nevertheless, this
makes it difficult to unequivocally prove a cause and effect relationship between MDMA
use and specific psychological damage in humans.
A fundamental difficulty in such research is knowing how to interpret the causality of
associations between outcome measures and recreational use of MDMA. Any differences
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between MDMA users and nonusers could indicate either a persistent effect of exposure
to the drug or pre-existing differences between the two groups. It is possible that there is
a biologically vulnerable set of individuals whose use of MDMA and other psychoactive
substances reflects preexisting predispositions to such use. High levels of impulsivity and
other related personality traits could be a predisposing factor. Individuals with low
serotonergic function may be more impulsive and thus more predisposed to using
MDMA and other drugs (Ricaurte et al., 2000). In fact, they may be equally depressed
and predisposed to using drugs (Reneman et al., 2000). Furthermore, differences in
memory function and indirect measures of serotonin activity (e.g., 5-HI A A levels in CSF
and serotonin transporter density) between MDMA users and non-users may also have
existed before the onset o f substance use. For example, individuals with low 5-HIAA
levels may both have memory problems and be predisposed to MDMA use (McGuie,
Cope, & Fahy, 1994).
Another major concern is that few clinically based controlled prospective studies
have been performed. Most of the controlled studies have been conducted,
retrospectively, on small numbers of subjects, who have consumed widely varying
amounts o f MDMA tablets. Given that there is little quality control of street drugs, most
investigations provide only an estimate at best when calculating each subjects MDMA
intake. Thus, there has been no control over MDMA administration nor has there been
confirmation o f the dose or purity of MDMA consumed. Published reports (e.g., Schifano
et al., 1998; Wolff, Hay, Sherlock, & Conner, 1995), however do suggest that the
majority of tablets sold as “ecstasy” in fact contain MDMA.
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The method of self-report, which relies on the drug user’s recollection of prior drug
experience, is also an issue. Self-report of drug taking behavior in drug users is
notoriously unreliable (Parrott, 2000). Memory for how much and how often MDMA is
actually consumed over many years is likely to be undependable.
Most ecstasy users are polydrug users, which raises the possibility that one or several
o f these other drugs are responsible for decrements in performance. MDMA users have a
tendency to use a variety of illicit substances, including amphetamine, cocaine, ketamine,
LSD, sedatives (e.g., opiates), and especially, marijuana (Fox et al., 2001; Milani et al.,
2000). Preliminary investigations of recreational MDMA users did not collect data on
other illicit substances (e.g., Curran & Travill, 1997; Parrott, 1997). Researchers have
since refined their methodology to control for the problem of polydrug use by using a
control group comprising individuals who have never used MDMA, but who otherwise
have closely matched histories of using other drugs of abuse.
The recruitment o f subjects is another methodological concern. MDMA users tend to
be exclusively recruited through targeted sampling techniques, by advertising for
volunteers or through word of mouth. This is problematic because it introduces an
unknown bias into each study, since it is possible that these self-referred individuals are
not representative of MDMA users as a whole. Ideally, researchers would like to be able
to study MDMA’s effects in drug naïve individuals, but, given the ethical issues involved
in conducting such studies, there is little likelihood of studying MDMA’s effects on
substantial numbers of volunteers.
Finally, the applicability of the animal neurotoxicity evidence to human subjects has
been contested, largely because the dosage used in animal experiments is perceived to be
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much higher than that taken by humans (Ricaurte et al., 2000). The lowest MDMA dose
reported to elicit long-term structural damage in serotonergic neurons of non-human
primates is 10 mg/kg subcutaneously daily for four days (Gouzoulis-Mayfrank et al.,
2000). According to principles o f interspecies scaling, this is equivalent to 1.4 mg/kg in
humans (Ricaurte et al., 2000), an amount similar to that used for recreational purposes
(Burgess, O’Donohue, & Gill, 2000).
Despite the many methodological concerns, the pattern of cognitive dysfunction seen
in the frontal cortex (i.e., impulsivity and impaired higher executive processing) and the
hippocampus (i.e., memory deficits) in human MDMA users is consistent with damage
that has been found in animals exposed to MDMA (Volkow et al., 2001).

Directions for Future Research
All of the methodological shortcomings with the previous research, outlined earlier,
should be addressed in future studies. It might be possible, in the future, to randomly
select a large sample of individuals with different patterns of drug use and then
investigate the persistent psychological consequences of a variety of different illicit drugs
simultaneously. Researchers should also attempt to corroborate self-reported current drug
use and prior drug use with urine and hair analysis. If it is not possible to recruit
exclusive ecstasy users, investigators should consider employing a design that facilitates
the statistical control of previous use of other illicit drugs (e.g., Morgan, 1999).
A prospective, randomized study of the chronic effects of pharmaceutical MDMA
would be necessary to definitively determine its persistent effects on human behavior, but
ethical and legal constraints prevent such a study, at least in the United States. It may be
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possible in the future, however, to conduct a prospective study on the long-term
psychological consequences of recreational MDMA use. For example, it might be
possible to assess a large sample of adolescents before they have taken ecstasy and then
again at subsequent time points, on the assumption that some proportion will go on to
experiment with the drug. However, this type of study is not without ethical issues.
Future research should also explicitly investigate which aspect o f recreational ecstasy
use plays the most significant role in determining subsequent persistent psychological
problems. The results of some of the studies reviewed earlier suggest that a gross
estimate of lifelong exposure to ecstasy can predict the risk of future persistent
psychological problems. But it is likely that the pattern of use also plays a significant
role. For example, Topp et al. (1999) have reported that young, female polydrug users,
and those who have binged on ecstasy for 48 hours or more, appeared most at risk for
experiencing harm that they attributed to their ecstasy use. Thus, it was useful to further
investigate the relationship between ecstasy exposure variables, (for example, total past
ecstasy dose, average monthly dose, frequency of use, and bingeing) and cognitive
dysfunction and determine if risk factors for the development o f ecstasy-related cognitive
deficits can be identified (for example, gender, IQ, and psychiatric history).
There is also a pressing need for more information concerning the longevity of the
psychological impairments exhibited by heavy ecstasy users. Clearly, longitudinal studies
designed to follow ecstasy users, both as they continue to use the drug and after they have
stopped using it are needed. Such studies would give important insight into how age and
length of use affect ecstasy’s acute and long-term neurochemical toxicity. In addition,
such studies would allow researchers to determine if deficits appear later in life, long
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after use stops, or if adverse effects diminish over time. Such studies, if designed with
regular assessment intervals, might also allow researchers to develop better measures of
MDMA toxicity, and to more accurately determine how much drug is used and in what
circumstances.
In addition, little is presently known about the decline of serotonergic function in
humans over the life span. One possible direction for future research would be to
compare markers of serotonin transporter binding in healthy young individuals with those
of healthy older individuals with SPECT or PET. Finally, other neuroimaging techniques,
such as fMRI and EEG are required to investigate the effects of experimentally
manipulated serotonin neurotransmission on brain activity and cognitive function in
ecstasy users.

Summary and Conclusions
Since the late 1980s recreational use of ecstasy has become increasingly popular. We
now know much about the pharmacology o f this drug in experimental animals, both in
terms o f its acute actions and its longer-term neurotoxic effects. In general, MDMA’s
effects are consistent across species, with the exception of the mouse. Importantly, its
acute effects in humans are also very similar to those seen in experimental animals. What
is uncertain is whether the clear and consistent long-term neurotoxic effects seen in
animals can and do occur in humans. There are data suggesting that damage may occur in
the human brain and this should be cause for concern. It appears that adverse effects
(both acute and long-term) are related to both dose and frequency of administration.

76

The major problems in investigating the effects of MDMA are the facts that
prospective studies are generally unethical, so retrospective studies must be performed,
the purity o f the ingested drug, the doses taken, and frequency of administration are
unknown, and many of the subjects are polydrug users either by choice or unknowingly
because o f the impure nature of the tablets ingested.

Marijuana
Marijuana or marijuana has been used for centuries, for its medicinal and euphoric
properties, and its fibers, to make hemp cloth and paper. Medicinally, between 1850 and
1942, it was prescribed in the United States Pharmacopeia as a remedy for a variety of
ailments including gout, tetanus, depression, and cramps (Farthing, 1992). Today, it is
used for reducing intraocular pressure due to glaucoma, as an anti-emetic to relieve
nausea associated with chemotherapy and as an appetite stimulant for AIDS patients.
Recreationally, marijuana is the most widely used illicit drug, especially among young
adults (Chan, Hinds, Impey, & Storm, 1998). According to the 2003 National Survey on
Drug Use and Health (NSDUH), more than 94 million Americans (40 percent) age 12
and older have tried marijuana at least once.
Marijuana contains chemicals called cannabinoids, including cannabinol, cannabidiol,
cannabinolidic acids, caimabigerol, cannabichromene, and several isomers of delta 9
tetrahydrocannabinol (THC). One of these isomers, delta 9-THC is believed to be
responsible for most of the characteristic psychoactive effects of marijuana.
Marijuana refers to the leaves and flowering tops of the marijuana plant. The buds of
the marijuana plant are often preferred because of their higher THC content. Hashish
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consists of the THC-rich resinous secretions o f the plant, which are collected, dried,
compressed and smoked. Hashish oil is produced by extracting the cannabinoids from
plant material with a solvent. In the U.S., marijuana, hashish and hashish oil are Schedule
I controlled substances.
Smoking remains the most efficient means of delivering THC and experienced users
can titrate the dose by adjusting the frequency and depth of inhalation. A typical joint
contains between 0.5 grams and one gram of marijuana. As little as two to three
milligrams o f available THC will produce a “high” in occasional users, but regular users
may smoke five or more joints a day (Iversen, 2003). THC or marijuana extracts may
also be taken orally in fat-containing foods (e.g., brownies), but marijuana is mostly
smoked because this is the easiest way to achieve the desired psychoactive effects.

Metabolism o f Cannabinoids
Different methods of using marijuana lead to differing absorption, metabolism and
excretion o f THC. When smoked, THC is absorbed from the lungs into the bloodstream
within minutes. It is first metabolized in the lungs, and then in the liver where it is
transformed into a number of metabolites. THC rapidly disappears from the blood plasma
and is taken up in fat where it remains with a half life decay rate of five to seven days.
This means that after a single dose of THC, less than one percent of the primary active
ingredient remains in fatty tissue after approximately 35 to 50 days (Nahas, 1984). When
swallowed, THC takes one to three hours to enter the bloodstream delaying the onset o f
psychoactive effects (Tart, 1970).
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THC and its metabolites account for most o f the psychological effects of marijuana.
Peak blood levels of THC are usually reached within ten minutes of smoking and decline
to about five to ten percent o f their initial level within an hour. This rate o f decline
reflects the rapid conversion of THC to its metabolites and the distribution of THC to
fatty tissues including the brain. THC and its metabolites are lipophilic or highly fat
soluble and readily cross the blood-brain barrier. They may remain in the fatty tissues of
the body for long periods of time. THC and its metabolites accumulate in the body
because o f their slow rate of clearance. Thus, they may be detected in the blood for
several days and traces may persist for several weeks.
The acute toxicity of cannabinoids is very low. There are no confirmed published
cases worldwide of human deaths from marijuana poisoning, and the dose of THC
required to produce 50 percent mortality in rodents is extremely high compared with
other commonly used drugs (Degenhardt, Hall, & Lynskey, 2003).

Cannabinoid Receptors
Two types of G-protein-linked cannabinoid receptors (CBi and CB 2) have been
identified. CBi receptors are expressed predominantly in neurons of the CNS, while CB 2
peripheral cannabinoid receptors appear to play an important immunomodulatory role the
PNS.
Cannabinoid receptor activation is linked to inhibition of adenylate cyclase activity
(Hewlett et al., 1991). Advances in cannabinoid pharmacology have generated a number
of selective agonists and antagonists for these receptor subtypes (Pertwee, 1997). One of
these compounds rimonabant (SR141716A), which acts selectively to block CBi
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receptors has been widely used in studies of the actions of cannabinoids in the CNS
(Rinaldi-Carmona et al., 1998).
The distribution of cannabinoid receptors was first mapped in the rat brain by
Herkenham et al. (1991). The mapping studies in the rat brain showed that CBi receptors
are mainly localized to axons and nerve terminals in the CNS and are largely absent from
the neuronal soma and dendrites. Consequently, cannabinoid receptors are predominantly
pre-synaptic rather than post-synaptic.
In both animals and humans, there are high densities of CB| receptors in the fi'ontal
regions of the cerebral cortex, the basal ganglia and in the cerebellum. A high density of
cannabinoid receptors in the caudate nucleus and the cerebellum are consistent with the
marked effects of cannabinoids on motor behavior. In addition, CBi receptors are found
in particularly high densities in the limbic forebrain, including in the hypothalamus, the
anterior cingulate cortex and the hippocampus (Herkenham et al., 1991). CBi receptor
density is highest in the hippocampus, the brain structure known to be involved in human
memory processes (Pertwee, 1999).
Within the hippocampus, CBi receptors are expressed at especially high densities in
the dentate gyrus, CAl, and CA3 regions (Herkenham et al., 1991; Matsuda et al., 1990;
Tsou et al., 1998). Furthermore, immunohistological staining has demonstrated that CB,
receptors are found primarily on hippocampal GABAergic intemeurons (Katona et al.,
1999; Marciano & Lutz, 1999; Tsou et al., 1999). High densities of CB| receptors in
limbic brain regions correlate with cannabinoids effects on perception, cognition,
memory, learning, endocrine function, food intake, and regulation of body temperature
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(Hall & Pacula, 2003). CB2 receptors have been localized in the spleen, thymus and
tonsils and on mast cells and plasmocytes (Matsuda et al., 1990).
In addition to cannabinoid receptors, the brain produces its own cannabinoid
substances called endocannabinoids. Endocannabinoids are neurotransmitters that bind to
the same receptors as marijuana, however, these compounds act with much shorter
duration compared to marijuana because they are rapidly degraded by specific enzymes
in the brain cells. Two endocannabinoid ligands, anandamide and 2-arachidonylglycerol
(2-AG) have been identified suggesting the existence of a cannabinoid neuromodulatory
system. Together with the cannabinoid receptors, this carmabimimetic system is thought
to have a widespread role in fine-tuning a variety of brain fimctions, including
nociception, control o f movement, memory and neuroendocrine regulation (Iversen,
2003).
It is noteworthy that the highest levels of anandamide are expressed in the
hippocampus (Felder et al., 1996). Interestingly, Tomaso and colleagues (1996) have
speculated that part o f the pleasure of chocolate comes from anandamide. These
researchers discovered three compounds in dark chocolate strongly resemble
anandamide.

Mechanisms o f Action

Marijuana exerts its effects in the CNS by binding to the CBi receptor. The CBi
receptor modifies the activity of several intracellular enzymes, particularly cyclic AMP
(cAMP) whose activity is reduced. Less cAMP means less protein kinase A and the
reduced activity of this enzyme affects the potassium and calcium channels, so as to
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reduce the amount of neurotransmitters released. Consequently, the general excitability o f
the brain’s neural networks is reduced.
However, in the reward circuit just as in the case of other drugs more dopamine is
released. The reward circuit includes the ventral tegmental area (VTA), which is
connected to the nucleus accumbens and the prefrontal cortex in the pathway where they
communicate through neurons. The paradoxical increase in dopamine is explained by the
fact that the dopaminergic neurons in this circuit do not have CBi receptors, but are
normally inhibited by GABA neurons that do have them. Marijuana removes this
inhibition by the GABAergic neurons and thereby activates the dopamine neurons.

Does Marijuana Produce Dependence, Tolerance and Withdrawal?

Animals develop tolerance to the effects of repeated doses of THC (Compton et al.,
1991) and studies suggest that cannabinoids may affect the same reward system as
alcohol, cocaine and opioids (Wickelgreen, 1998). Heavy smokers of marijuana also
develop tolerance to its subjective and cardiovascular effects (Compton et al., 1991) and
some report withdrawal symptoms on the abrupt cessation of marijuana use (Compton et
al., 1991 ; Weisbeck et al., 1996). Studies in clinical and non-clinical samples of long
term marijuana users have reported withdrawal symptoms, such as anxiety, insomnia,
appetite disturbance and depression (e.g., Copeland, Swift, & Rees, 2001; Stephens,
Roffman, & Simpson, 1994).
Also, there is evidence that a marijuana dependence syndrome occurs with heavy
chronic use in individuals who report problems in controlling their use and who continue
to use the drug despite experiencing adverse personal consequences (Hall, Solowij, &
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Lemon, 1994). Marijuana dependence is the most common form of drug dependence after
alcohol and tobacco in the U.S (NIDA, 2006). About one in ten of those who ever use
marijuana become dependent on it at some time during their four or five years of heaviest
use (Anthony, Warner, & Kessler, 1994). This risk is more like the equivalent risk for
alcohol (15 percent) than for nicotine (32 percent) or opioids (23 percent).

Acute Physiological Effects o f Marijuana

The most immediate physiological effect of smoking marijuana is an increase in heart
rate by 20 to 50 percent within a few minutes to a quarter of an hour of smoking (Chesher
& Hall, 1999). Changes in blood pressure also occur. These depend upon posture, that is,
blood pressure is increased while the person is sitting and decreases while they are
standing. A sudden change from lying down to standing up may produce postural
hypotension and a feeling of lightheadedness and faintness that is often the earliest
indication o f intoxication in naïve users (Maykut, 1984).
Marijuana reliably induces a swelling of the minor conjunctival blood vessels in the
membranes around the eye, producing a slight “blood-shot” appearance, termed
conjunctival congestion. This is similar to that seen with alcohol. A reduction in
intraocular (within the eye) fluid pressure has also been reported with marijuana and may
have therapeutic significance (Adler & Geller, 1986).

Acute Psychological Effects o f Marijuana

A variety of psychological effects are produced by marijuana. At low doses,
marijuana typically induces euphoria and relaxation, perceptual alterations, time
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distortion, and the intensification o f ordinary experiences, such as eating, watching films,
and listening to music (Jaffe, 1985). However, at high doses marijuana use often results
in confusion, amnesia, delusions, hallucinations, anxiety and agitation, especially by
users who are unfamiliar with the effects of marijuana (Jaffe, 1985; Hall & Solowij,
1998).
Psychotic symptoms, such as delusions and hallucinations, are very rare experiences
that may occur at very high doses o f THC and in susceptible individuals at lower doses
(Thomas, 1993). More experienced users may report these effects after swallowing
marijuana because its effects may be more pronounced and o f longer duration than they
usually experience after smoking (Hall & Pacula, 2003).

Appetite, Noiception and Anti-Emetic Acute Effects o f Marijuana

Marijuana intoxication produces an increase in appetite that results in increased food
intake, with a preference for sweet foods, even in subjects who were previously satiated
(Hubbard, Franco, & Onaivi, 1999). This effect has been confirmed under labortatory
conditions (e.g., Hollister & Gillespie, 1970; Mattes et al., 1994). For example, controlled
clinical trials in patients suffering from AIDS-related wasting syndrome showed that
THC (dronabinol) had significant beneficial effects on counteracting appetite loss and
reductions in body weight in (Beal et al., 1995).
Anti-nausea and anti-emetic effects of THC and other cannabinoids also have been
well demonstrated (e.g., Zimmerman, 1998). Studies in experimental animals have
confirmed that the anti-emetic effects of cannabinoids are mediated through CB,
receptors (Darmani, 2002).
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In addition to its effects on appetite, marijuana intoxication diminishes pain
perception and increases pain tolerance. These analgesic effects involve actions at a
number of different levels, including peripheral sensory neurons (Lynch & Taylor, 2005),
spinal cord (Neeleman, 2000) and central pathways (Cichewicz, Martin, Smith, & Welch,
1999). In the brain and spinal cord, a cannabinoid interaction with the opioidergic system
may act to modulate the perception o f painful stimuli (Pertwee, 2001). Cannabinoids
ameliorate pain by modulating rostral ventromedial medulla (RVM) neuron activity in
the brainstem in a manner similar to morphine (Meng et al., 1998). Cannabinoids also
inhibit synaptic transmission in the midbrain. This area forms part of a descending
antinociceptive pathway that via the RVM modulates nociceptive transmission at the
level o f the spinal cord (Fields, Heinricher, & Mason, 1991).

Acute Cognitive Effects o f Marijuana
Attention and Perception

Marijuana intoxication produces minor distortions in sensory awareness, including
some reports of heightened sensory perception (Hollister, 1986). In monkeys, acute
marijuana exposure had no serious deleterious effects on simple visual discrimination
tasks (Schwartz et al., 1989). However, there are reports of significant effects of
cannabinoids on attention processes in both humans and animals.
THC produced dose-dependent effects on both the accuracy and latency of responses
to differential tone discrimination (e.g., Campbell et al., 1986) and on signal detection
performance in rats (e.g., Heyser, Hampson, & Deadwyler, 1993). The performance of
monkeys trained to respond in a choice reaction time task was significantly disrupted by
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acute exposure to marijuana smoke (Paule et ai., 1992). In humans, marijuana
intoxication produced detrimental effects on both attention span and divided attention
tasks (e.g., Chait & Pierre, 1992; Hall & Solowij, 1998; Solowij et al., 2002).
These data suggest that cannabinoid receptor activation does not appear to affect the
performance of tasks that do not require focused attention or persistent detailed
perception. On the other hand, discriminatory processes may become susceptible to the
influence of cannabinoid agonists when more sustained or divided attention is necessary.
In general, in animal models the outcome of cannabinoid receptor activation on attention
or perception tasks is thought to resemble that of hippocampal lesions (Irving et al.,
2000).

Learning and Memory

The main acute effects of cannabinoids on cognition in humans relate to the
disruption o f short-term memory (Chait & Pierri, 1992; Miller & Branconnier, 1983).
Marijuana produces dose-related memory impairment in the ability to freely recall words
from a list. Free recall is impaired both immediately after list presentation (immediate
recall) and 20 or 30 minutes following list presentation (delayed recall). In the case of
immediate free recall, words presented at the end of a list are more likely to be recalled
than those presented earlier in the list, suggesting that some aspect of memory storage has
been disrupted (Chait & Pierre, 1992). This pattern of memory deficits seen following
marijuana intoxication is similar to that seen in patients with hippocampal dysfunction
induced by encephalitis, Korsakoff’s syndrome, or Alzheimer’s disease (Miller &
Branconnier, 1983).
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Experiments in animals also demonstrate cannabinoid-mediated memory deficits and
these are related to impairment of the function of the hippocampus, a structure that is
intimately involved in the processes that underlie learning and memory (Sullivan, 2000).
Studies have shown that activation of cannabinoid receptors produces memory deficits
similar to those produced by neurochemical lesions of the hippocampus (Hampson &
Deadwyler, 1999). Such lesions impair performance in short-term spatial memory tasks
learned prior to the lesion.
In rats, THC reduced exploratory parameters and motor activity and caused more
errors in maze tests and problems with information retention (Sullivan, 2000). In
monkeys, the administration of THC prior to testing impairs performance on delayed
non-match-to-sample memory task, in which the animal must identify which of a
presented pair of objects was displayed 15-minutes earlier (Aigner, 1988). In contrast,
cannabinoids have no effect on concurrent discrimination learning, during which the
drugged animal must learn over several sessions separated by 24-hours, to identify which
of two objects is always paired with food. This differential effect of THC on delayed nonmatch-to-sample performance and concurrent discrimination learning is similar to the
pattern of deficits seen after amygdalo-hippocampal lesions in monkeys (Aigner, 1988).
Most behavioral and physiological effects of THC return to baseline levels within
three to six hours after exposure (Chait & Pierri, 1992; Hollister, 1986), although, some
investigators have demonstrated residual effects in specific behaviors up to 24-hoursafter
drug (Leirer, Yesavage, & Morrow, 1991). More research is needed to define the onset,
magnitude, and duration of marijuana’s behavioral effects, especially following long
term, frequent use o f the drug.
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Long-term Residual Effects o f Marijuana Use on Neuropsychological Functioning
Findings in Brain Imaging Studies

Neuroimaging studies illustrate that differential patterns o f cortical activation exist in
chronic marijuana users. Two types of paradigms have been employed in the
neuroimaging studies. These include the resting paradigm and the cognitive challenge
paradigm. In the resting condition, the subject is instmcted to lie down, relax and not to
think whereas, in the challenge condition, the subject is engaged with a task.
Resting paradigm studies employing different techniques (e.g., regional cerebral
blood flow (rCBF), positron emission tomography (PET), single photon emission
computed tomography (SPECT), functional magnetic resonance imaging (fMRI)), have
shown subnormal cerebral blood flow (Mathew et al., 1998; Tunving et al., 1986) or
lower cerebellar metabolism (Amen & Waugh, 1998; Volkow et al., 1996) in long-term
marijuana users who were assessed within one week of cessation o f use. For example,
Lundqvist et al. (2001) measured brain blood flow levels after cessation o f marijuana use
(mean 1.6 days). The findings showed significantly lower mean hemispheric blood flow
values and significantly lower frontal values in the marijuana subjects compared to
normal controls. Block et al. (2000) found that after 26 hours of controlled abstinence,
young frequent marijuana users showed hypoactivity relative to controls in a large region
of the bilateral posterior cerebellar hemispheres, vermis and in the left and right ventral
prefrontal cortex (Brodmann’s area 11). Compared with average whole brain activity in
controls, marijuana users showed nine percent lower values. Block et al. (2000) also used
magnetic resonance imaging (MRI) to investigate brain structures in young currently
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frequent marijuana users. The users showed no evidence of cerebral atrophy or global or
regional changes in tissue volumes compared to controls.
Cognition in an everyday situation demands cognitive effort. It is therefore necessary
to involve studies, which have a challenge within their paradigm. Yurgelun-Todd et al.
(1999) assessed chronic marijuana smokers twice with fMRI after 24-hours and 28 days
of abstinence, on a visual working memory task. The control subjects produced
significant activation in the dorsolateral prefrontal cortex (DLPFC) during the task.
Marijuana smokers who completed 24-hours o f washout showed diminished activation in
this region. The effect remained diminished after 28 days o f washout, although some
increase in the DLPFC activation was noted relative to the 24-hour time point. In
contrast, smokers produced increased activation in the cingulate during both washout
conditions, whereas controls did not. These results indicate that even after an extended
washout period, specific differential patterns o f cortical activation exist in subjects with a
history o f heavy marijuana use.
Block et al. (2002) measured cerebral blood flow during the performance o f verbal
memory recall tasks and during a selective attention task. Memory-related blood flow in
frequent marijuana users showed decreases relative to controls in prefrontal cortex,
increases in memory-relevant regions of the cerebellum, and altered lateralization in the
hippocampus. The greatest differences between users and controls occurred in brain
activity related to episodic memory encoding.
Eldreth and colleagues (2004) used PET imaging and a modified version of the
Stroop task to determine if 25 day abstinent heavy marijuana users have persistent
deficits in executive function and brain activity. The 25 day abstinent marijuana users
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showed no deficits in performance on the modified version of the Stroop task when
compared to the comparison group. Despite the lack of performance differences, the
marijuana users showed hypoactivity in the left anterior cingulate cortex and the left
lateral prefrontal cortex and hyperactivity in the hippocampus bilaterally, when compared
to the comparison group. Eldreth and colleagues (2004) results suggest that marijuana
users display persistent metabolic alterations in brain regions responsible for executive
fimction. They have suggested that it may be that marijuana users recruit an alternative
neural network as a compensatory mechanism during performance on a modified version
of the Stroop task.
Kanayama et al. (2004) found in an fMRI study that heavy long-term marijuana
abusers displayed greater and more widespread brain activation than normal subjects
attempting to perform a spatial working memory task. This observation suggests that
heavy long-term marijuana abusers may experience subtle neurophysiological deficits
and that they compensate for these deficits by “ working harder,” that is, calling upon
additional brain regions to meet the demands of the task.

Behavioral Findings Related to the Residual Effects o f Marijuana

Research into the neuropsychological impairments associated with the use of
marijuana developed a growing literature during the 1960s and 1970s, although these first
studies produced contradictory results. From the 1980s onwards, the increase in
methodological control and the progressive refinement of the experimental designs
provided a much more exact delimitation of the possible neuropsychological deficits that
may result from the use of marijuana (Pope et al., 1995).
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O f the studies conducted in the 1970s and at the beginning of the 1980s, none of
those that used controlled doses managed to detect significant differences between users
and non-users o f marijuana (e.g., Barrat et al., 1972; Cohen et al., 1976; Dombush et al.,
1972; Frank et al., 1976; Jones & Benowitz, 1976), whereas the assessment studies of
recreational users have yielded about the same number of positive results (e.g.,
Mendihiratta et al., 1978, Souief, 1976; Wig & Varma, 1977) as negative ones (e.g..
Culver & King, 1974; Grant et al., 1976; Mendelson et al., 1976). Carlin and Trupin
(1977) and Schaefer et al. (1981) even documented superior neuropsychological
performance among marijuana users.
During the 1980s, probably because o f the progressive increase in methodological
control, including supervised abstinence periods and matched control groups, several
studies began to detect neuropsychological deficits associated with the effects of
marijuana. Varma et al. (1988) conducted a study that supervised a 12-hour controlled
abstinence period prior to the neuropsychological evaluation. They detected deficits on
two of the tests used (Pencil Tapping, estimation of size and time). Page et al. (1988)
carried out a study in Costa Rica with subjects who had consumed marijuana for more
than 25 years and with a non-supervised abstinence interval o f between 12- and 24-hours.
They observed significantly impaired performance in the marijuana users on information
processing, attention and memory compared to a control group.
This same sample o f Costa Rican marijuana users was the object of a large
prospective study, which included different groups of young and adult users (Fletcher et
al., 1996). Fletcher and colleagues (1996) detected memory deficits on free recall tasks
and on learning lists of words, as well as on selective and divided attention tasks. Their

91

results suggested deterioration in functions like attention or memory could be more
lasting over time than those in more basic functions.
Solowij and colleagues (1993; 1992) assessed the relationships between degree of
impairment and the frequency and duration of marijuana use. Thirty-two marijuana users
were divided into four groups of equal size (N - 8) defined by frequency (light: two or
fewer times per week versus heavy: more than three times per week) and duration (short:
four or fewer years of use versus long: five or more years of marijuana use). Subjects
were matched to a group of nonuser controls (N = 16). The marijuana users performed
worse than the controls and the greatest impairment was in the heavy user group. The
long duration user group found it harder to ignore irrelevant stimuli than the short
duration users and controls that did not differ. This impairment increased with the
number o f years of use but it was not related to frequency of use. There were no
differences between groups defined on frequency of use on this measure. Speed of
information processing was related to frequency of marijuana use but not to duration of
use.
Solowij et al. (2002) conducted a multi-site cross sectional study in the U.S. between
1997 and 2000 among 102 near daily marijuana users, 51 long-term users (mean - 2 3 . 9
years o f use), 51 shorter-term users (mean = 10.2 years) and 33 non-users. They assessed
attention, memory, and executive function from nine standard neuropsychological tests
prior to users’ entry into a treatment program and following a median 17 hour abstinence
period. Solowij and colleagues (2002) found that long-term marijuana users displayed
memory impairment, as measured by performance on the AVLT. Specifically, they
recalled fewer words and showed impaired learning, retention, and retrieval compared
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with controls and shorter-term users. Moreover, performance measures correlated
significantly with the duration o f marijuana use being worse with increasing years o f
regular marijuana use.
Similarly, Bolla and colleagues (2002) found as joints smoked per week increased,
performance decreased on tests measuring memory (AVLT) and executive function
(Wisconsin Card Sorting Test (WCST)) in 28 day abstinent heavy marijuana users. There
is also event related potential (ERP) data that shows that the degree of impairment
increases with the length of marijuana use. For instance, Solovrij (1995) assessed whether
these ERP changes in long-term marijuana users persisted after extended abstinence fi’om
marijuana. She studied 32 former users who had used marijuana for a mean of nine years
and who had been abstinent for a mean of two years. Some partial recovery of
fimctioning was found, that is, the speed of information processing was not reduced in the
ex-users but their ability to ignore irrelevant stimuli remained impaired. These findings
corroborate earlier evidence provided by a NIDA-funded study by Struve et al. (1993).
These researchers observed larger changes in electroencephalogram (EEG) frequency,
primarily in the frontal-central cortex, in daily marijuana users of up to 30 years duration
compared to shorter-term users and nonusers.
Similarly, Pope and Yurgelun-Todd (1996) compared heavy marijuana users (N = 65)
cognitive functioning to that o f a comparison group of light users (N = 64). Subjects in
both groups had smoked marijuana for at least two years and none had smoked regularly
for more than a decade. To ensure that the subjects did not smoke marijuana or use other
illicit drugs or alcohol during the study, researchers monitored them for 19- to 24-hours.
Then the subjects performed a battery of standard tests designed to assess their ability to
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pay attention, leam, and recall new information. The tests indicated that heavy marijuana
users had more difficulty than light users in sustaining and shifting attention and hence in
registering, organizing, and using information. Heavy users exhibited these cognitive
deficits by being less able than light users to leam word lists, by making a greater number
of errors in sorting cards by different characteristics, such as by color or shape, and by
making more errors when the rules for sorting the cards were changed without warning.
Men in the heavy users group showed somewhat greater impairment than women in the
same group.
More recently, Ehrenreich and co-workers (1999) administered a computer-assisted
battery for the assessment of a wide spectrum of attentional functions to a sample o f 99
pure marijuana users and 49 healthy controls. They reported on the relationship between
impairments in visual-attentional processing and the early use of marijuana (before 16
years o f age). Divided attention was also impaired in marijuana users, but not related to
earlier onset o f abuse, whereas flexibility and working memory functions were not
impaired in these users.
Croft et al. (2001) compared the performance of 18 pure marijuana users, 11 MDMAmarijuana users and 31 normal controls on neuropsychological tests of memory,
attention, and executive and motor functions. They showed that impairments in memory
and verbal fluency were more related to marijuana consumption in concurrent ecstasy
users. Tapert et al. (2002), in a follow-up study that administered an extensive
neuropsychological battery to a sample of 65 adolescent abusers and 40 community youth
controls showed cumulative marijuana use was related to attentional functioning
impairments.
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Nevertheless, recent studies have suggested that the marijuana-related
neuropsychological impairments may be largely due to the residual effects of the
substance, rather than to long-term effects. In this sense. Pope et al. (2001) compared the
neuropsychological performance of a group o f 45 former heavy users and a group o f 63
current users who were asked to abstain over a period o f 28 days, with 72 normal controls
on a neuropsychological battery designed to assess general intelligence, memory,
attention and executive function. Results showed subtle impairments in several cognitive
domains of the current marijuana user group during the first week o f abstinence, which
were related to the urinary concentrations of the THC metabolite. However, at the end of
the 28-day abstinence period, neuropsychological performance o f current users was
indistinguishable from former long-term users or normal controls.
A recent meta-analytic study (Grant et al., 2003), which included most of the studies
mentioned above has also failed to find a significant detrimental effect o f marijuana use
on several neuropsychological functions. These researchers calculated effect sizes for
each neuropsychological test administered within the 11 studies that were analyzed. Then
within each of the studies, the individual effect sizes were linearly combined by subsets
into one of eight neurocognitive ability domains. These domains were simple reaction
time, attention (e.g., WAIS-R Digit Span, Digit Vigilance), verbal/language (e.g., WAISR Vocabulary, Verbal Fluency), abstraction/executive function (e.g., WCST, Raven’s
Progressive Matrices), perceptual motor (e.g., WAIS-R Block Design, WAIS-R Object
Assembly), simple motor (e.g.. Grooved Pegboard, Finger Tapping), learning (CVLTLeaming Trials, AVLT-Leaming Trials), and forgetting/retrieval (e.g., CVLT-Recall,

95

AVLT-Delayed Recall). The only significant effect of long-term heavy marijuana use
was subtle selective memory impairment for learning and forgetting.
In summary, it appears that the long-term heavy use of marijuana does not produce
severe, grossly debilitating impairment in cognitive function that is found for example
with chronic, heavy alcohol use. Electrophysiological and neuropsychological studies
show that marijuana produces subtle impairments in attention, executive function, and
memory performance.
The longer marijuana has been used, the more pronounced the cognitive impairment.
The impairments are subtle, so it remains unclear how important they are for everyday
functioning and whether they are reversed after an extended period of abstinence. Early
studies that suggested gross structural brain damage with heavy use have not been
supported by better controlled studies with better methods.

Is Marijuana Neurotoxic?

Although there have been claims that chronic marijuana use may permanently
damage the brain, there is little scientific evidence to support these claims (e.g., Hollister,
1998; Zimmer & Morgan, 1997). As mentioned earlier, some studies have revealed a
modestly impaired ability to focus attention and filter out irrelevant information, as well
as an impairment in learning and remembering in ex-marijuana users (e.g., Bolla et al.,
2002; Solowij et al., 2002; Solowij et al., 1998), while others have failed to find
impairments in cognitive function (e.g.. Pope et al., 2001).
Animal studies have yielded conflicting results. Treatment o f rats with high doses of
THC given orally for three months (Scallet et al., 1991) or subcutaneously for eight
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months (Landfield et al., 1988) were reported to lead to neural damage in the
hippocampal CA3 zone, with shrunken neurons, reduced synaptic density and loss of
cells. However, in another study the potent synthetic cannabinoid WIN 552122 was
administered twice daily (2 mg/kg) to rats and led to an apparent increase in hippocampal
granule cell density and increased dendritic length in the CA3 zone. In perhaps, the most
severe test of all, rats and mice were treated with THC five days each week for two years
and no histopathological changes were observed in brain tissue, even after administration
of large doses THC (50 mg/kg/day in rats and 250 mg/kg/day in mice) (Chan et al.,
1996). Although claims were made that exposure of marijuana smoke in a small number
of rhesus monkeys led to structural changes in the septum and the hippocampus (Heath et
al., 1980), subsequent larger scale studies failed to show any marijuana-induced
histopathology in the monkey brain (Scallet et al., 1991).
Studies of the effects of cannabinoids on neurons in vitro have also yielded
inconsistent results as well. Exposure of rat cortical neurons to THC was reported to
decrease their survival, with twice as many cells dead after two hours of exposure to 5
pM THC than in control cultures (Downer et al., 2001). Significant effects were also
demonstrated with low concentrations of THC (O.I pM). The effects of THC were
accompanied by release of cytochrome C, activation of caspase-3 and DNA
fragmentation, suggesting an apoptotic mechanism. All of the effects of THC could be
blocked by the synthetic cannabinoid antagonist AM-251 or by pertussis toxin,
suggesting that they were mediated through CBi receptors.
Toxic effects of THC have also been reported on hippocampal neurons in culture,
with 50 percent o f cell death after two hours of exposure to 10 pM THC or after five days
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exposure to 1 pM THC drug (Chan et al., 1998). THC caused the shrinkage o f cell bodies
and nuclei of neurons and also caused genomic DNA strands to break. The synthetic
cannabinoid antagonist rimonabant blocked these effects, but not pertussis toxin. Chan et
al. (1998) proposed a toxic mechanism involving arachidonic acid release and formation
of free radicals. However, other authors failed to observe any damage in rat cortical
neurons exposed for up to 15 days to 1 pM THC (e.g., Sanchez et al., 1998).
In a remarkable study, injections of THC into solid tumors of C6 glioma in rodent
brain led to increased survival times and a complete eradication of the tumors was
evident in 20 to 35 percent of the treated animals (Galve-Roperh et al., 2000). The anti
proliferative effects of cannabinoids suggest a potential utility for use in cancer treatment
(Guzman et al., 2001).
Other studies have reported neuroprotective actions of cannabinoids. For example,
administration o f WIN 552122 was found in vivo to reduce neuronal damage in the rat
hippocampus and cerebral cortex following global ischemia or focal ischemia (Nagayama
et al., 1999). Subsequently, Panikashvili and colleagues (2001) found the
endocannabinoid 2-AG protected against damage elicited by closed head injury in the
mouse brain. Van der Stelt et al. (2001) observed THC had a similar effect in vivo in
protecting against damage elicited by ouabain (ouabain is a poisonous cardiac molecule
that is used by researchers for in vitro studies to block the sodium-potassium pump).
Furthermore, rat hippocampal neurons in tissue culture were protected against glutamatemediated damage by low concentrations of WIN 552122 or CP 55940 and these effects
were mediated through CB, receptors (Shen & Thayer, 1998).
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Not all of the neuroprotective effects seem to require mediation via cannabinoid
receptors. For example, Zhuang and colleagues (2005) findings suggest that cannabinoids
prevent cell death by initiating a time and dose dependent inhibition of adenylyl cyclase,
which outlasts direct action at the CBi receptor. Also, Nagayama et al. (1999) reported
protective effects of WIN 552122 that did not require either cannabinoid receptor in
cortical neurons exposed to hypoxia. Similar findings were reported for the protective
actions of anandamide and 2-AG in cortical neuron cultures (Sinor et al., 2000).
Subsequently, both THC and cannabidiol, which is not active on cannabinoid receptors
protected rat cortical neurons against glutamate toxicity (Hampson et al., 1998). The
authors suggested that the protective effects of THC in their studies might be due to the
antioxidant properties of these polyphenolic molecules, which have redox potentials
higher than those of known antioxidants (e.g., vitamins C and E).
Further support for the antioxidant properties of cannabinoids is provided in a recent
study by Morley et al. (2004). These researchers investigated whether co-administered
cannabinoids and MDMA affected the long-term neurotoxic properties o f MDMA in rats.
They found that co-administration of THC or CP 55940 (synthetic cannabinoid)
prevented hyperthermia. Hyperthermia has been found to induce oxidative stress which
results in excessive free radical formation and abnormal free radical reactions (Green et
al., 2003).
In addition to reversing hyperthermia, Morley et al. (2004) found that THC partially
attenuated the long-term serotonin depletion produced by MDMA. Rats given either THC
or the higher dose of CP 55940 in conjunction with MDMA displayed serotonin and 5HIAA levels in the hippocampus, prefrontal cortex and amygdala that were intermediate
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between MDMA treated rats. The lower co-administered dose of THC and CP 55940 (0.1
mg/kg) was largely ineffective in preventing MDMA-induced serotonin depletion,
suggesting that the protective effect o f cannabinoids requires relatively large co
administered doses.
Morley et al. (2004) attributed the underlying protective effects of cannabinoids to
their antioxidant properties. This conclusion was based on the finding that the selective
antagonist SR 141716, while reversing the cannabinoid agonist effects on MDMAinduced hyperthermia did not change the partial protection against serotonin depletion.
This finding indicated a CB]-independent mechanism was responsible for the
neuroprotection.
Morley and colleagues (2004) posited that the cannabinoids (THC and CP 55,940)
acted as antioxidants and may have counteracted the oxidative stress produced by
MDMA. Cannabinoids contain a phenolic structure typical of many antioxidants isolated
from plants. In contrast, the synthetic cannabinoid WIN 552122 lacks the structural
moieties that chemically define the antioxidative activity (Chen & Buck, 2000).

Summary

The neurocognitive changes that may be attributed to chronic marijuana use are subtle
and may depend on prolonged and heavy levels of consumption. That is, marijuana does
not produce severe impairment of cognitive function like that observed with heavy
alcohol use. Daily marijuana use over many years may produce subtle impairments in
learning and memory, attention and executive function. Impairment seems to be reversed
by an extended period of abstinence.
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Moreover, well-controlled studies, using sophisticated methods of investigation (e.g.,
fMRI, PET) have failed to demonstrate gross structural change in the brains of heavy,
long term marijuana users. These negative results are consistent with the evidence that
cognitive effects o f chronic marijuana use are subtle, and hence unlikely to be manifest as
gross structural changes in the brain.
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CHAPTER 3

METHOD
Aim o f the Proposed Study

As concomitant marijuana and other polydrug use have been deemed a possible
confound in previous ecstasy research, the primary aim of this study was to evaluate
auditory verbal learning and memory performance, as measured by the Auditory Verbal
Learning Test (ÀVLT) (Rey, 1964; Schmidt, 1996), in ecstasy users while controlling for
the extent of marijuana and other illicit drug use. Marijuana use was controlled for by
enrolling marijuana-only users and, subsequently, by specifying the extent of marijuana
use, in both the ecstasy and marijuana-only user groups. Marijuana use was categorized
as either heavy or light, with heavy use defined as using marijuana five or more times per
week and light marijuana use defined as using marijuana less frequently than five times a
week.
To minimize polydrug use among the user groups, the apriori exclusionary criteria
established for other illicit drug use stated that the frequency of other illicit drug use
(except alcohol and nicotine) was not to exceed more than ten occasions in a participant’s
lifetime. This criterion was relaxed post-hoc to not more than 15 lifetime uses for each of
the drugs inventoried in this study. This was done in order to include a few participants
who reported greater than 10 lifetime uses of one or two of the multiple drugs surveyed.
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Moreover, this had the advantage of increasing the power of the statistical analyses by
increasing the number of participants in the drug user groups.
Additionally, alcohol use was accounted for by not including participants who
reported regular heavy alcohol use. Regular heavy alcohol use was defined as severe
drunkenness occurring at a frequency of at least twice a month over six months or longer
within the last two years.

Participants

One hundred and nine undergraduate university students ages 18 years and older with
a history of ecstasy and/or marijuana use were recruited from introductory psychology
courses via an announcement placed in the psychology department subject pool,
Experimetrix. Students without a regular history of drug use were also recruited to
participate. All groups were matched for age, education level, and verbal intellectual
ability. While there were not an equal number of females and males in the groups, there
was not a statistically significant difference in the gender ratio among the groups.
To optimize data collection and reduce participant attrition rates, experimental testing
was conducted over one session, under laboratory conditions. Consequently, participants
were notified via the Experimetrix recruitment announcement to abstain from all illicit
drug use for at least 24-hours prior to reporting for experimental testing. This measure
was necessary to ensure that participants were free of acute residual drug effects.
Written informed consent was obtained to ask participants about their drug use within
the last 24-hours. Participants that provided verbal confirmation of adherence to the 24hour abstinence period were permitted to begin experimental testing. Alternatively,
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participants that reported they had not adhered to the 24-hour abstinence criterion were
given the option of either receiving half a research credit and no longer being eligible for
future participation in the study, or reporting back for testing at a later date when they
were able to meet the abstinence criterion and be eligible to receive full credit for
completion of the entire experimental protocol.
Once it had been established that a participant was eligible for experimental testing,
written informed consent was obtained for the experimental protocol. The experimental
testing session was comprised of two parts: neuropsychological assessment and
completion of the drug use history questionnaire.
Neuropsychological testing was conducted first and began with the evaluation of
verbal learning and memory performance using the AVLT (Rey, 1964; Schmidt, 1996).
The first portion of the BFLT-E was administered during the AVLT 20-minute delay
(i.e., learning trials 1 through 5, interference List B, recall of List B designs, immediate
recall of List A designs). The remaining trials on the BFLT-E (delayed recall after a 20minute delay and recognition), were administered following completion of the 20-minute
delay. Intellectual function (IQ) was assessed within the BFLT-E 20-minute delay and
immediately after AVLT testing was complete. The verbal subtest of the Wechsler Adult
Intelligence Scale, Third Edition (WAIS-III) was used to infer verbal intellectual
functioning (Wechsler, 1997).
In the second part of the experimental testing session, participants were asked to
complete a dmg use history questionnaire, in which prior levels of drug use for the
previous week, month, year, and lifetime were recorded (see Appendix E). The drug use
questionnaire data were used retrospectively to assign participants to one of five
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experimental groups. Data collected on participants who did not meet the inclusion
criteria were not included in any o f the statistical analyses.

Experimental Groups
Marijuana-Only Users. Marijuana-only users were separated into two groups. The

only difference between the two marijuana-only user groups was the extent of marijuana
use. The groups were labeled marijuana-only light users (M l) and marijuana-only heavy
users (M h). Categorization of marijuana users as light or heavy was based on the selfreport data collected from the drug use history questionnaire and resembled the criterion
used by Fried, Watkinson, James, and Gray (2002). Specifically, heavy marijuana use
was defined as using marijuana five or more times per week and light marijuana use was
defined as using marijuana fewer than five times a week.
Additional inclusion criteria for the marijuana-only user groups included: (1)
consistent use of marijuana over the past year, (2) no prior use of ecstasy, (3) no current
or prior history o f regular illicit drug use other than marijuana (the frequency o f using
other illicit drugs could not exceed more than 15 occasions in the participant’s lifetime),
and (4) no regular heavy alcohol use (defined as severe drunkenness occurring at a
frequency o f at least twice a month over six months or longer within the last two years)
(Daumann et al., 2003; Gouzoulis-Mayfrank et al., 2000; Gouzoulis-Mayfrank et al.,
2003; Yip & Lee, 2005).
Fifty participants met these criteria and were retrospectively assigned to either the M l
user group or M h user group. The M l user group was comprised of 28 participants, 12
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females and 16 males, while 22 participants, 8 females and 14 males, were assigned to
the M h user group.
Ecstasy-Marijuana Users. Like the marijuana-only users, there were two concomitant

ecstasy-marij uana user groups. One group of ecstasy users was classified as ecstasymarijuana light users (E + M l) if they reported using marijuana fewer than five times per
week, while the other ecstasy user group was defined as concurrent heavy marijuana
users (E + M h) if they used marijuana five or more times per week. In accordance with
other ecstasy investigations (e.g.. Von Geusau et al., 2004; Bedi & Redman, 2006;
Lamers et al., 2006; Parrott et al., 1998; Rizzo et al., 2005), participants were eligible for
inclusion into the ecstasy user groups if they had used ecstasy on a minimum of at least
10 occasions, with at least one occasion in the most recent year.
Based on these criteria, 34 participants were assigned to either the E + M l user group
or the E + M h user group. Fifteen participants, 8 females and 7 males, were assigned to the
E + M l user

group and 19 participants, 6 females and 13 males, were assigned to the

E + M h user

group.

While the issue of impurity in illicit ecstasy tablets was a problem for researchers
in the early 1990s (Spruit, 2001), impurity is far less of an issue now (Parrott, 2006). For
instance, during the late 1990s, the proportion of ecstasy tablets containing MDMA
increased to around 80 to 90 percent. The latest reports suggest that non-MDMA tablets
are very infrequent, with purity levels between 90 and 100 percent being the norm
(Parrott, 2004a). Moreover, many of the psychological effects reported by illicit ecstasy
users is similar to those reported by participants in clinical MDMA studies (Cami et al.
2000; Grob et al. 1996; Vollenweider et al., 1998a). Increases in positive mood, energy,
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difficulty concentrating, and alterations in perception have been documented in both
retrospective and clinical studies. Taken together, these findings suggest that the
recreational ecstasy user is probably consuming MDMA and so using data from
recreational ecstasy users to estimate the human neuropsychological consequences of
repeated MDMA exposure is considered herein to be reasonable.
Like the criterion for the marijuana-only user groups, participants were not included
in the combined ecstasy and marijuana user groups if their frequency of other illicit drug
use exceeded more than 15 occasions in their lifetime and/or they reported regular, heavy
alcohol use.
Non-Drug Using Controls. The fifth group of participants consisted of non-drug using

controls. The inclusion criteria for assignment to this group included: (1) no prior use of
ecstasy, (2A) no previous use of marijuana, (2B) no previous or current history o f other
illicit dmg use, such as hallucinogens, cocaine, stimulants, or opiates (the frequency of
using other illicit dmgs should not exceed more than 15 occasions in the participant’s
lifetime), and (3) no regular heavy alcohol use (defined as severe drunkenness occurring
at a frequency o f at least twice a month over six months or longer within the last two
years). The control group (C) consisted o f 25 participants, 15 females and 10 males. The
only dmg use reported by the C group was alcohol and nicotine.
Similar to many of the well-controlled ecstasy studies (e.g., Croft et al., 2001 ; Curran
& Verheyden, 2003; Fox et al., 2001; Gouzoulis-Mayfrank et al., 2000; GouzoulisMayfrank et al., 2003; Lamers et al., 2006; McCardle et al., 2004; Quednow et al., 2006;
Reneman et al., 2001; Reay et al., 2006; Rizzo et al., 2005; Semple et al., 1999; Simon &
Mattick, 2002; Thomasius et al., 2003), participants in each group were not included if
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they had: (1) a current or previous history of an Axis I psychiatric disorder (except for
drug abuse in the user groups), (2) any organic brain disorder, (3) a history o f head injury
with loss o f consciousness requiring hospitalization, (4) a medical or neurological
condition that might affect cognitive function, or (5) regularly used legal or illegal
psychotropic drugs such as opiates or benzodiazepines (the frequency o f using other
psychotropic drugs should not exceed more than 15 occasions in the participant’s
lifetime).

Dependent Measures
Verbal Learning and Memory. The AVLT (Rey, 1964; Schmidt, 1996) was used to

evaluate auditory verbal learning and memory performance. The AVLT is a standard
neuropsychological test o f explicit memory that measures delayed recall performance for
lists of unrelated words. Explicit long-term memory tasks have been shown to rely
critically on the hippocampus. This is supported by a review o f 147 case studies of
amnesia patients involving hippocampal damage, which found that all cases showed
severe deficits in conscious retrieval (i.e., explicit memory), but intact non-conscious
retrieval (i.e., implicit memory) (Spiers, Maguire, & Burgess, 2001). Also, in functional
magnetic resonance imaging (fMRI) studies, explicit memory has been found to be
associated with neural activation of the hippocampus, as well as activation of sensory
areas o f the cortex (Thiel, 2003).
Explicit memory tests, such as the AVLT, are particularly sensitive to hippocampal
functioning because the filled delay prohibits the retention of words in working memory
between study and test. In addition, memory for unrelated words involves less elaborative
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and/or associative processing than other memory tasks, such as the verbal pairedassociates task. The elaborative and/or associative processing of words has been shown in
functional neuroimaging studies to activate specific parts of the prefrontal cortex in
addition to the hippocampus (Posner, Peterson, Fox, & Raichle, 1988; Roskies, Fiez,
Balota, Raichle, & Peterson, 2001; Schreckenberger et al., 1998). This distinction served
as the basis for selection of the verbal learning memory task used in this investigation.
Additionally, the AVLT has been utilized in several ecstasy and marijuana
investigations (e.g., Bolla et al., 1998; Curran et al., 2003; Fox, Toplis, et al., 2001;
Gouzoulis-Mayfrank et al., 2000; Lamers et al., 2006; McCardle et al., 2004; Quednow et
al., 2006; Reneman et al., 2000; Solowij et al., 2002; Thomasius et al., 2003; Yip & Lee,
2005) and was selected so that direct comparisons could be made between the findings in
these previous studies and those obtained in this study.
The QPSS computerized version o f the AVLT-AB was used to enable real-time
recording and scoring o f the test (Poreh, 2004). The QPSS software utilizes the same set
of standardized instructions and is administered in the same manner as the paper and
pencil version of the AVLT.
The software was installed on two laptop computers. The experimenter was seated in
front o f the computer and controlled the presentation of the instructions and the stimuli.
Additionally, the experimenter was responsible for recording participants’ responses. All
instructions and stimuli (i.e., words) were read by a pre-recorded voice on the computer.
On each trial, a configuration of buttons that correspond to the AVLT words was
displayed on the computer screen. Once the participant started to verbalize a response
(i.e., recall a word from the word list), the experimenter used the mouse to click on the
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corresponding word-picture button. If the participant responded with a word that did not
appear in the list, the experimenter recorded the word as either a confabulation or as an
association. Error confabulations were defined as words unrelated to those in the stimulus
list, whereas error associations were defined as words that were semantically or
phonemically related to those in the stimulus list.
For the recognition trial on the AVLT, a word appeared one at a time on the computer
screen. The experimenter saw the word, while the participant heard it played by the
computer. Participants’ were asked to verbally answer either “yes” if the word they just
heard was from List A or “no” if it was not. The experimenter clicked on the “yes” button
if the participant answered yes or on the “no” button if the participant responded no.
There was an undo function, in the event the experimenter clicked on the wrong wordpicture, yes-no button, or incorrectly typed in a word that was not on the stimulus list.
The AVLT required participants to leam a list o f 15 words (List A) across five
successive trials (trials 1 through 5). All words from the list were concrete nouns and
were presented at the rate of one word every two seconds (inter-trial interval = 20
seconds). The order of word presentation was the same on each trial and the same for all
participants. At the end o f each trial, participants were required to recall as many words
from the list as possible. Additionally, participants were instructed that the order in which
they recalled the words did not matter.
Following the fifth learning trial, a second list o f 15 unrelated words from List B was
presented to participants across a single trial (trial B). After recall of the interference list,
participants were asked to recall the List A words (trial 6). This trial represented
participants’ short-delay or immediate recall performance. Following a 20-minute delay,
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participants were asked again to recall the List A words (trial 7). This trial represented
participants’ long-delay or delayed recall performance.
A recognition test followed the 20-minute delayed recall trial. Participants were asked
to identify as many words as possible from the first list (List A) when presented with a
list of 50 words containing items from both Lists A and B, as well as words that were
semantically related or phonemically similar to words on Lists A and/or B. Participants
heard each word one at a time and were asked to verbalize a response of “yes” if the word
was from List A or “no” if the word was not from List A.
Memory scores were calculated for each individual trial and reflected the number of
words correctly recalled. The number of words recalled after the first presentation of List
A was defined as immediate word span or supraspan. Supraspan reflects attentional
processes related to the acquisition o f information prior to storage (Fox, Toplis et al.,
2001; Lezak, 2004).
Like trial 1 o f List A, the interference trial (List B) involved initial mnemonic
processes on a new word list. However, unlike trial 1, the interference trial assessed
participants’ supraspan ability immediately following learning.
A score for total acquisition was calculated by summing the number of words
recalled on trials 1 through 5. Error confabulations (words unrelated to those in the
stimulus list) and error associations (words semantically and phonemically linked to
those in the stimulus list) were recorded along with intrusion errors fi'om List A to B and
vice versa. A high number of intrusion errors is usually associated with confabulation,
which is often interpreted as an inability to accurately evaluate any retrieved information
(Burgess & Shallice, 1996). High levels o f confabulation errors are predominantly
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reported in patients who have frontal cortical lesions (Mayers & Daum, 1997). In
contrast, an increase of association errors is indicative of retrieval problems, such as the
“tip-of-the-tongue” syndrome, where participants reveal that they know the correct word
but are unable to actually recall it (Brown & McNeill, 1966).
Non-Verbal Distracter Task. The Biber Figure Learning Test-Extended (BFLT-E) is

pattemed after the AVLT (Glosser, Cole, et al., 2002). The paper-pencil version of the
BFLT-E was employed as a distracter task and was administered during the 20-minute
delay o f the AVLT. The basis for selection of this distracter task was that it takes
sufficient concentration to effectively to prohibit the continuous rehearsal of words
between the study- test phases of the AVLT. Also, the use of non-verbal stimuli was
intended to minimize the opportunity for interference between the distracter task and the
AVLT stimuli.
In the BFLT-E, participants completed five trials in which 15 designs from List A
were presented at a rate o f one every three seconds. After each trial, participants were
asked to recall as many of the 15 designs as they could in any order by drawing the
designs. Following figure recall on the fifth trial, a second set o f designs was presented
from List B (interference trial). After the recall of List B designs and without additional
exposure, participants were asked to draw the original 15 designs from List A (immediate
recall).
Following a 20-minute delay, recall and recognition memory were tested. For the
recall portion, participants were asked to reproduce the designs presented in List A. The
recognition trial consisted o f 45 designs, the original 15 designs seven designs from the
distracter list (List B) and 23 foils (i.e., designs that had not been presented before). The
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45 designs were shown one at a time. Participants were asked to verbalize a response of
“yes” if the design was from List A or “no” if the design was not from List A.
Memory scores were calculated for each individual trial and consisted o f the number
o f designs correctly recalled. The number o f designs recalled after the first presentation
of List A will specifically be defined as immediate span or supraspan. Similar to trial 1 of
List A, List B also involved initial mnemonic processes on a new word list. However,
unlike trial 1, List B assessed participants supraspan ability immediately following
learning. The number o f designs recalled on trial 6 (the trial immediately following recall
of designs from interference List B) represented participants immediate recall scores,
while the number of designs recalled on trial 7 (after a 20-minute delay) was referred to
as participants’ delayed recall scores. Also, the number of designs correctly identified on
the recognition trial was calculated and scores for total acquisition were calculated by
summing the number o f designs recalled on trials 1 through 5.
Verbal Intelligence (IQ). To control for pre-existing differences in general cognitive

capacity among groups, IQ was assessed from performance on the vocabulary subtest of
the Wechsler Adult Intelligence Scale, Third Edition (WAIS-III) (Wechsler, 1997). In
order to permit time for neuropsychological testing, an estimate o f Full Scale IQ (FSIQ)
was derived from the vocabulary subtest.
Sattler (2001) maintains that the vocabulary short form has been substantiated
statistically, as this subtest has a moderate correlation with FSIQ (r = .80) and high
reliability (r = .93) (The Psychological Corporation, 1997). Ringe, Saine, and Cullum
(1999) provide further evidence supporting the use of the vocabulary subtest as an
estimate o f FSIQ. These researchers observed an excellent correlation (r = .94) between
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estimated IQ from the vocabulary subtest and FSIQ in a population o f mixed neurological
and psychiatric patients (n = 63). Moreover, they conducted multiple regression analyses
which demonstrated that the vocabulary subtest accounted for 90 percent of the variance
in FSIQ scores among the sample. The internal consistency reliability for the vocabulary
subtest was high (r = .93) (The Psychological Corporation, 1997).
The WAIS-III vocabulary subtest assesses word knowledge by requiring the subject
to verbally provide a dictionary style definition for 33 words that increase in order of
difficulty. The examiner read the question, “What does

mean?” The easiest word in

the test is “bed,” but administration began with the fourth word, “winter,” which is the
normal procedure (Lezak, 2004). The test continued until the participant failed six words
consecutively or until the list was exhausted. The most difficult word on the WAIS-III is
“tirade.” A score of either zero, one, or two points was given depending on the accuracy,
precision, and aptness of each definition. This measure is heavily influenced by formal
education and literacy, as well as age and gender. The vocabulary test took approximately
15- to 20-minutes to administer.
Vocabulary subtest raw scores were converted to age-corrected standard scaled scores
based on normative data provided in the WAIS-III manual. The age-corrected scaled
scores were then summed and converted into an estimated FSIQ based on the method and
tables established by Sattler (2001).
Drug Use History Questionnaire. All participants completed the drug use history

questionnaire (see Appendix II). The questionnaire consisted of two parts. The first part
consisted o f items pertaining to demographic and health information. Details of age,
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gender, level of education, past or present history of a medical illness, and prior diagnosis
o f a major psychiatric (Axis I) disorder were obtained.
The second part of the questionnaire was composed o f items that probed for previous
patterns of drug use. Specifically, the questionnaire was used to evaluate the age o f onset,
fi'cquency (consumption episodes in a given week, month, and year), and duration of use
o f a number of often abused psychoactive drugs. For every substance a participant had
actually consumed, the following information was requested: (1) the total lifetime
consumption o f each drug, (2) the frequency o f consumption episodes per week and
month, (3) the age of onset of use, and (4) the number of years that have elapsed since the
onset o f use. In addition to these items, participants who reported ecstasy use were asked
to provide information regarding (1) the average number of pills used in each episode and
(2) the largest number of pills ingested in an episode of use.

Procedure

No biological screening for drug use was carried out. However, it was requested that
participants abstain from using ecstasy and other drugs for at least 24-hours prior to
testing. Notice to abstain from all drug use was specified in the study advertisement
placed in Experimetrix. Individuals who reported for testing that had not met this
requirement were not allowed to participate at that time.
It was emphasized in the informed consent form that neither the experimenter nor the
University condoned illicit drug use. Additionally, it was emphasized that this
investigation should not be seen as approval or encouragement for the use of ecstasy and
marijuana or other illegal drugs, particularly since they could have serious side effects. It
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was also stated in the informed consent form that taking part in this study was voluntary
and that a participant could withdraw from the study at anytime without giving a reason.
Participants were informed that the data would be treated as strictly confidential. A
participant’s name never appeared on the drug history questionnaire nor was it used to
code files associated with the experimental tests. Rather, a six digit numerical code
created by the random number generator function in Microsoft Excel was assigned to
each participant following completion o f the informed consent form. The master list of
participant names and the numerical code assigned to each of them was deleted promptly
after credit was assigned to the participant, which occurred immediately following the
completion of the protocol. This was done in order to ensure that there was no record
which could link data to a particular participant. Furthermore, electronic data obtained
from the computerized version of the AVLT and the drug use history questionnaire were
promptly removed from the hard drive and stored on a master disk which was locked in a
filing cabinet along with the other participant data.
All neuropsychological testing and completion of the drug history questionnaire were
administered under laboratory conditions, in one experimental session. Experimental
testing lasted approximately two hours. Data collected on participants who completed
testing but did not meet the study’s inclusion criteria were not included in any of the
statistical analyses. Participants received one research credit for each hour they
participated in the experiment. All participants ran through the entire experimental
protocol and, consequently, received two credits for participation.
Participants reported one at a time to the UNLV Psychopharmacology Laboratory and
experimental testing was conducted in a quiet room, by either the primary investigator or
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an undergraduate research assistant. The research assistants received extensive training
on administration of the experimental protocol by the principal investigator. Training
included verbal explanations and hands-on familiarization with the administration of the
neuropsychological tests (WAIS-III vocabulary subtest, AVLT, BFLT-E), drug use
history questionnmre, informed consent forms and information or debriefing sheet.
Moreover, a written set o f instructions regarding the protocol administration was
provided. Each research assistant was evaluated by the principal investigator prior to
conducting experimental testing and periodically throughout data collection to ensure
reliability.

Predictions
Additive Effects. One possible outcome hypothesized in this study was that combined

use o f ecstasy and marijuana would have negative additive effects on AVLT word recall
performance. Additive effects are the simplest case of combined drug action and indicate
that each drug acts independently to produce its own effects. The effects of the drugs
simply summate, that is, the combined effect of the two drugs equals the sum of their
individual effects in isolation.
Figure 2 provides an example of possible negative additive effects of both ecstasy and
marijuana use on AVLT recall performance. In the example, examination of the
difference between marijuana-only users and the combined ecstasy-marijuana users, at
each level of marijuana use should reveal that the addition of ecstasy decreased word
recall by two units [(M l- E+M l) = (10 - 8 ) = 2 = (Mh - E+Mh) = (6 - 4) = 2].
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Additive Effects

No Ecstasy (marijuana-only)
Ecstasy
•6

».oo

I

M arijuana Use

Figure 2.
Predictions for additive effects of ecstasy and marijuana use on the number
of words recalled on the AVLT. The effect of marijuana is independent o f the effect of
ecstasy. The differences between marijuana only light users and ecstasy-marijuana light
users (10 - 8 = 2) and the marijuana-only heavy users with ecstasy-marij uana heavy users
(6 - 4 = 2) is equal.

Positive Synergistic Effects (Neuroprotection). Another possible outcome observed in

this study is that marijuana interacts with ecstasy in such a way that marijuana reduces
the impact o f ecstasy’s effects on verbal learning and memory performance. The extent to
which marijuana minimizes the reduction of recall scores will depend upon the extent of
marijuana use. This prediction is based on Morley and colleagues (2004) findings in rats,
which suggest that cannabinoids attenuate the long-term neurotoxic effects caused by the
addition o f MDMA, especially at high doses o f marijuana. If Morley et al.’s (2004)

animal findings are applicable to human verbal learning and memory performance then
marijuana use in the combined user groups should reduce the rate of decline in the
number of words recalled on the AVLT, with the greatest minimization o f deficits
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occurring in the heavier marijuana users. Moreover, heavy marijuana use will attenuate
the effect of ecstasy, making it comparable to the performance of the marijuana-only
users. Figure 3 provides an example of positive neuroprotective effects of marijuana on
ecstasy. From this example, the difference between the marijuana light groups is greater
than the marijuana heavy groups [(M l- E + M l) = (1 0 -9 ) = 1 > (M h - E + M h ) = (6 - 6) =
0 ].

Positive Synergistic Effects-Neuroprotection

■No Ecstasy (marijuana-only)
■Ecstasy

I
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Figure 3.
Predictions for positive synergistic effects between ecstasy and marijuana
use on the number of words recalled on the AVLT. Ecstasy and marijuana use are not
independent, rather marijuana acts synergistically with ecstasy to minimize recall deficits
caused by the addition o f ecstasy use. The reduced effect of ecstasy is even greater in the
marijuana heavy condition.

Negative Interactive Effects (Negative Synergistic Effects). The other potential

outcome that could occur is that marijuana interacts synergistically with ecstasy to
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produce memory impairment that is greater than that observed by the sum of the deficits
produced by either ecstasy or marijuana alone (see Figure 4 for an example). This
prediction is based on Young et al.’s (2005) findings in rats, which demonstrated
synergistic disruption in working memory performance in rats that were co-administered
MDMA and THC. The amount o f synergistic disruption produced was dependent upon
the dose o f marijuana, such that greater synergistic disruption was observed under high
marijuana dose conditions compared to lower marijuana dose conditions.

Negative Synergistic Eflects

No Ecstasy (marijuana-only)
g

Ecstasy
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M arijuana Use

Figure 4.
Predictions for negative synergistic effects between ecstasy and marijuana
use on the number o f words recalled on the AVLT.

Marijuana and ecstasy use do not act independently to impair performance, rather
ecstasy interacts synergistically with marijuana to produce greater impairment than that
observed by the sum o f the deficits produced by each drug alone. The magnitude of the
impairment depends on the extent of marijuana use. A greater synergistic disruption of
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recall performance is seen in ecstasy-marijuana heavy users versus ecstasy-marij uana
light users.
If these data are applicable to human verbal memory performance, then among the
drug users in this study, the combined ecstasy-marij uana users should exhibit more
impaired word recall than the marijuana-only users. Moreover, the magnitude of
impairment observed in the ecstasy-marijuana heavy users would be greater than that
observed in the ecstasy-marijuana light users [(M l- E + M l) = (1 0 -7 ) = 3 < (M h E + M h)

= (6 - 2) = 4].

Statistical Analyses

Statistical analyses were performed using SPSS 15.0 software for Windows (SPSS
Inc., Chicago, IL). An alpha level of 0.05 was used for all analyses. A Multivariate
Analysis of Variance (MANOVA) was conducted on the descriptive statistics of the
participants’ age, gender, education level, and verbal intelligence scores as measured by
the WAIS-III vocabulary subtest, with group assignment as the single between-subject
factor (i.e., C, M l, M h, E + M l, and E + M h). Similarly, a MANOVA was performed on the
participants’ drug use characteristics and included age of onset of use, frequency of use
episodes, per week and per month, total lifetime use, and the number of years that have
elapsed since the onset of use. Two additional drug use characteristics were computed for
ecstasy: a) the average number o f pills taken in an episode, and b) the largest number of
pills taken in an episode.
Two separate sets of Multivariate Analyses o f Covariance (MANCOVAs) were
performed on the AVLT and the BFLT-E data, with group assignment as the single
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between-subject factor. The first set of MANCOVA analyses treated age, education, and
verbal intelligence scores as covariates. It is well established that these factors affect
verbal learning and memory performance (Lezak, 2004). Furthermore, since visual
memory tests correlate with performance on tests of verbal learning and memory these
same factors were also treated as covariates in the BFLT-E analyses (Lezak, 2004).
In addition to age, education, and verbal intelligence, the second set o f MANOCVA
analyses o f the word and figure data treated monthly use of alcohol and nicotine and
cumulative lifetime use of drugs other than ecstasy and marijuana as covariates. Selection
o f these drugs specifically was based on MANOVA findings that indicated the use of
these drugs was significantly different among the groups. In particular, cumulative
lifetime uses o f the following drugs were accounted for; cocaine, mushrooms, LSD,
solvents, heroin, oxycontin (hyrdrocodone), muscle relaxers, xanax, percocet, valium,
ritalin/adderall, ambien/lunesta, morphine, methadone, and demerol.
Separate Analyses of Covariances (ANCOVAs) were calculated for each of the
dependent measures that reached significance in both the first and second sets of
MANCOVA analyses. Scheffe post-hoc tests and simple effects analyses via ANCOVAs
were performed on the AVLT and BFLT-E dependent measures that reached significance
in each of the MANCOVA analyses.
The AVLT dependent measures examined were the total number o f words recalled on
trial 1 (supraspan), trials 2-4, trial 5 (final acquisition level), interference (trial B), trial 6
(immediate recall), and trial 7 (delayed recall). Additionally, total acquisition (sum of the
number o f words recalled on trial 1 through trial 5), the amount learned in five trials (trial
5 - trial 1), proactive interference (trial 1 - trial B), retroactive interference (trial 5 - trial

122

6), number of repetitions (words that were repeated), sum of error associations across
trials 1 through 7 and trial B (words semantically or phonemically related to those in the
stimulus list), and sum of error confabulations (words unrelated to those in the stimulus
list) were measured.
Also, AVLT recognition hits and recognition errors were measured. Specifically, the
types o f recognition errors that were observed included: semantic association with either
a List A (SA) or B (SB) word, phonemic association with either a List A (PA) or B (PB)
word, and semantic-phonemic association with either a List A (SPA) or B (SPB) word.
The dependent measures examined on the BFLT-E included the number of figures
recalled on trial 1 (supraspan), trials 2 - 4 , trial 5 (final acquisition level), interference
distracter trial (List B figures), trial 6 (immediate recall), trial 7 (delayed recall). In
addition, recognition performance, the sum of figures recalled on trials 1 through trial 5
(total acquisition), the amount learned in five trials (trial 5 - trial 1), scores on the
reproduction trials, and extraneous responses were included in the MANCOVA analyses.
Extraneous responses were summed for all of the BFLT-E trials, except the
recognition trial. Both perseverations and extraneous responses constituted extra
responses. Perseverations were defined as the repetition of a design, whereas, an extra
response meant drawing a design that was unrelated to those in the stimulus list.
In the first MANCOVA analyses, where age, education, and WAIS-III vocabulary
scores were covaried, the AVLT dependent measures that were significantly different
among the groups were total acquisition, interference, immediate recall, delayed recall,
and recognition. Also, gender X drug group interactions were observed for interference
(trial B), proactive interference (trial 1 - trial B), and error associations. The BFLT-E
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dependent measures that reached statistical significance on the first MANCOVA analyses
were immediate recall and extra responses. No interactions were observed on the BFLTE data.
The second MANCOVA analyses, which additionally controlled for cumulative
lifetime use of other illicit drugs (i.e., drugs other than ecstasy and marijuana), yielded
the same set of significant outcomes on the AVLT measures as the first analyses, except
for one the gender X drug group interaction for interference. Thus, significant findings
were observed for total acquisition, interference, immediate recall, delayed recall, and
recognition. Subsequently, gender X drug group interactions were observed for proactive
interference and error associations on the AVLT. In contrast, none of the BFLT-E
dependent measures that reached significance in the first MANCOVA analyses yielded
significance in the second MANCOVA analyses.
Regression analyses were used to predict the contribution of drug use as reported by
poly drug users in this study to memory performance on both the AVLT and BFLT-E.
Total lifetime drug consumption as indicated by the total number o f times a drug was
used was selected as the parameter of interest since lifetime consumption of cocaine and
methamphetamine, for example, has previously been observed to correlate negatively
with both immediate and delayed recall scores on the AVLT (Croft et al., 2001 ; Reneman
et al., 2001 ; Thomasius et al., 2003).
In addition, regression analyses were used to examine the relationship o f weekly and
monthly marijuana use, and the average and largest dose o f ecstasy consumed in an
episode, to memory performance. The current frequency of regular use o f ecstasy and
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marijuana were thought to indicate most effectively the extent of pattern of use, with
higher frequencies of use more likely to impart an influence on memory function.
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CHAPTER 4

RESULTS
Descriptive Statistics

Descriptive statistics including means, standard deviations, range, and gender ratios
for the groups are shown in Table 5. MANOVA analyses conducted on these data
indicated that the groups did not differ with respect to age, education, or verbal IQ (p >
1). Additionally, the ratio of males to females was not statistically different among the
groups. However, there were approximately half as many females to males in the M h and
E+Mh user groups compared to the M l and E +M l user groups who were more evenly

matched (see Table 5).

Table 5

Demographic characteristics in the control group and the drug user groups.

Ç

Ml

Mh

E+Mi

E+My

N

25

28

22

15

19

Age in years (SD)
r= range

20 (2.6)
r= 18-27

20(1.8)
r= 18-25

20(1.7)
1=18-23

21 (2.1)
1=18-25

21 (2.9)
1=18-29

Gender

15 F/IOM

12F/16M

8F/14M

8F/7M

6F/13M

Education in years (SD)
r=range

14(1.3)
r=12-16

14(1.4)
r=12-18

14(1.5)
r=13-17

15 (2.0)
1=12-20

15(2.1)
1=12-19

13 (2.4)
Estimated IQ (SD)
12 (2.4)
11 (2.6)
12(2.1)
12 (2.8)
Means and standard deviations were computed for age, education, and estimated IQ. The range (r) is also
reported for age and education. The number o f females (F) and males (M) in each group is reported in the
row labeled gender.
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Information pertaining to drug use is reported in Table 6 (see Appendix I). The means
and standard deviations represented in Table 6 are based on the total number of
participants in each group who reported use of a particular drug. In some instances, only
one participant in a group reported using the drug and so just that participant’s individual
data are reported. For example, only one participant in the M h group reported
methamphetamine-amphetamine use, so the subsequent data for that group in Table 6
represent the drug use by that one participant only.
Because o f the exclusionary criteria used to establish group membership the only
drug use reported by participants assigned to the control group (C) was alcohol and
nicotine. MANOVA analyses of the drug use data across groups yielded a main effect of
group for the following alcohol use characteristics; number of years used, F’(l,4) = 3.163,
p < 0.017, weekly use, F (\A ) - 4.671,/? < 0.002, and monthly use, F(\,A) = 5.016,/? <

0.001. For nicotine, the drug use characteristics that were significantly different among
the groups were age o f onset, F(\,A) = 7.627,/? < 0.001, number of years used, F(\,A) =
5.957,/? < 0.001, weekly use, F(\,A) = 5.711,/? < 0.001, and monthly use, F(l,4) = 3.831,
p < 0.006.

Scheffe post-hoc tests conducted on the drug use characteristics related to alcohol
showed the C group had used alcohol for a lesser number of years (p < 0.022) and
consumed fewer alcoholic beverages on both a weekly (p < 0.003) and monthly (p <
0.002) basis than the E+Mh group. None of the other group comparisons were significant.
For nicotine, Scheffe post-hoc tests indicated that the C group started using cigarettes
at a significantly older age than the M l users (p < 0.010), E +M l users (p < 0.042), and
the E+Mh users (p < 0.010). The E+Mh users had smoked for a longer period of time (p <
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0.010) and smoked more cigarettes a month (p < 0.007) than the C group. Weekly use of
cigarettes was greatest among the combined user groups (i.e., E + M l and E+Mh) (p <
0.010 for both).
With regard to ecstasy use, participants retrospectively assigned to either the E + M l or
E+M h

groups all exceeded the apriori criterion for assignment to the ecstasy use groups,

which was consumption of at least ten ecstasy tablets within the past year. As expected,
the MANOVA analyses yielded a significant main effect of group for all ecstasy drug use
characteristics.
Scheffe post-hoc tests confirmed the ecstasy user groups (E + M l and E + M h) were
similar on every aspect o f ecstasy use, except the largest number of pills taken in an
episode. The E + M h users reported taking a significantly larger number of pills in an
episode (mean = 3.5 pills) compared to the E + M l users (mean = 2.2 pills) (p < 0.028).
Participants assigned to either the combined ecstasy-marijuana user groups or the
marijuana-only user groups reported consistent marijuana use over the past year. Recall
that participants were classified as light marijuana users if they reported use of marijuana
fewer than five times per week, whereas participants who reported using marijuana five
or more times per week were classified as heavy marijuana users. None o f the
participants assigned to the marijuana-only user groups reported ever using ecstasy.
For marijuana use, the MANOVA analyses indicated significant main effects o f
group, as expected from the group assignments, for age of onset, F(\,A) = 289.506,/? <
0.001, number of years used, F(\,A) = 19.093,/? < 0.001, time since last use, F(\,A) =
10.631,/? < 0.001, cumulative lifetime use, F(\,A) = 6.780,/? < 0.001, weekly use, F(\,A)
= 15.154,/? < 0.001, and monthly use, F(\,A) - 16.398,/? < 0.001. Scheffe post-hoc
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comparisons showed that both the M l and E + M l user groups smoked less marijuana a
week and less a month compared to the M h and E + M h user groups {p < 0.001; p <
0.001). Moreover, the comparisons of marijuana use between the M l and E + M l users and
the M h and E + M h users were not significant (p > 1), which indicated that these groups
frequency of marijuana use was similar to each other.
Marijuana abstinence periods (i.e., time since last use in weeks) were significantly
longer in the M l users compared to both the M h and the E + M h user groups (p < 0.001 ; p
< 0.001) indicating that the heavier marijuana user groups used marijuana more recently
than the lighter user groups. There was not a significant difference in the time since last
marijuana use in the M l and E + M l users (p > 1).
The M l and E +M h users also differed significantly with regard to the number o f years
they had used marijuana (p < 0.001) and in the total number of times that they had used
in their lifetime (p < 0.004). The E + M h group smoked marijuana for a longer period of
time (p < 0.007) and smoked far more times in their lifetime than the M l users (p <
0.005). None of the marijuana user groups differed significantly from each other with
respect to the age at which they began smoking marijuana.
With respect to other drug use (i.e., drugs other than marijuana and/or ecstasy),
participants in the drug user groups reported use of the following drugs in the drug use
questionnaire; cocaine, mushrooms, methamphetamine/amphetamine, LSD, solvents,
heroin, oxycontin (hyrdrocodone), muscle relaxers, xanax, percocet, valium,
ritalin/adderall, ambien/lunesta, morphine, methadone, and demerol. While data were
collected for each of these drugs and drug use characteristics, cumulative lifetime use was
used to assess the quantity of drug use among the groups because this measure reflected
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the total number o f times a drug was used in a participant’s lifetime. Furthermore,
cumulative drug use is one o f the most widely used drug use characteristic evaluated in
drug investigations. For example, there is evidence that shows cumulative use of cocaine
for example is closely associated with deficits on AVLT trial 7 (Fox et al., 2001;
Thomasius et al., 2004).
The MANOVA and subsequent ANOVA analyses conducted on cumulative lifetime
uses o f other drugs showed that there were significant differences in the total number of
times the drug user groups had taken cocaine (F(l,3) = 10.051,p < 0.001), LSD (Ffl,3) =
5.060,p < 0.003), oxycontin (hydrocodone) (F(l,3) = 2.962, p < 0.037), percocet (Ffl,3)
= 2.780,p < 0.046), and xanax (F(l,3) = 2.886,p < 0.041). The M l user group consumed
the least amount o f cocaine compared to the other drug user groups (M h,P < 0.039;
E+ML, P < 0.007, E+M h,P < 0.001). The Mh users and the E +M l users’ lifetime cocaine

use did not differ but cocaine use was greater in the E+Mh users compared to the Mh
users.
Participants in the E+Mh users also had taken a significantly greater amount o f LSD
across their lifetime than each of the other groups (M l,p < 0.001; E + M l,p < 0.003;
E+M h,p < 0.004). Hyrdocodone use was greater in the Mh (p < 0.007) and E+ Mh user

groups (p < 0.036) compared to the M l user group. No differences were observed in the
E+M l user group. The cumulative use of percocet was significantly higher in the E+Mh

user group relative to the M l users (p < 0.026) and E+M l users (p < 0.040). Furthermore,
with respect to cumulative use of xanax, the Mh users reported a significantly greater
lifetime use o f xanax compared to the M l (p < 0.013) and E +M l (p < 0.049) user groups.
There were no significant difference in cumulative use of xanax among the Mh users and
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E+M h users (p > 1). When these findings are taken together, they indicate that the E+M h
user group consumed both a wider variety of other drugs, as well as a greater amount of
those drugs, relative to the other drug user groups.
With the exception o f hydrocodone and xanax use in the M h users, the mean total
number of times drugs other than marijuana and/or ecstasy were used did not exceed the
apriori exclusionary criterion of not more than ten uses o f any drug other than alcohol
and nicotine in a lifetime. This criterion was relaxed post-hoc to not more than 15
lifetime uses for each of the drugs inventoried in this study. This was done in order to
include a few participants who reported greater than ten lifetime uses of one or two of the
dmgs surveyed. Moreover, this had the advantage of increasing the power of the
statistical analyses by increasing the number of participants in the drug user groups.

A VLT Task Data
Total Acquisition. Group means and standard deviations for total acquisition are

reported in Table 7. The first column in Table 7 reflects the observed group means and
standard deviations, that is, the means for each group prior to the treatment of factors as
covariates in the MANCOVA and subsequent ANCOVA analyses. The second column
represents the group means and standard deviations after age, education, and verbal IQ
scores were treated as covariates. The third column reflects the group means and standard
deviations after monthly use of alcohol and nicotine and cumulative lifetime use of other
drugs were added as covariates (in addition to age, education, and verbal IQ).
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As mentioned earlier, the initial MANCOVA analyses conducted on the AVLT data
treated age, education, and verbal IQ as covariates. The results indicated that there was a
significant main effect o f group for total acquisition scores, F(\,A) = 4.133,p < 0.004.

Table 7
Mean total acquisition scores on the AVLT for each group (standard
deviations are in parentheses)
Observed
Adjusted
Adjusted
Means*
Group
Means***
Means**
58.120(4.2)
C
57.558 (2.3)
58.073 (2.7)
56.071 (6.5)
57.081 (2.4)
56.965 (2.2)
Ml
53.773 (6.4)
53.660 (2.4)
52.629 (2.8)
Mh
52.773 (6.7)
52.135 (3.0)
51.236 (3.2)
E+M l
52.316(5.7)
52.342 (2.6)
53.396 (3.5)
E+M h
Notes; * = means before the covariate analyses; ♦* = means after age, education, and verbal IQ were
treated as covariates; *♦♦ = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use of other drugs were treated as covariates.

Figure 5 illustrates group mean total acquisition scores and standard errors before the
adjustment for covariates. Subsequent Scheffe post-hoc tests showed that the sum of
words recalled across trials 1 through 5 was significantly higher for group C and the M l
users compared to the M h ip < 0.020 ;p < 0.044), E + M l ip < 0.005; /? < 0.011), and
E +M h users (p <
E + M l,

0.004; p < 0.008). Total acquisition scores were similar among the M h,

and E + M h users (p > 1).
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Mean AVLT total acquisition scores and standard errors for each group.

When monthly use o f alcohol and nicotine and cumulative lifetime use of other drugs
were added as covariates in the MANCOVA analyses, the pattern o f findings was
identical to that given above. A main effect o f group was observed, F(\,A), = 3.403, p <
0.013, where the sum o f the words recalled on trials 1 through 5 was highest for group C
(M h, P

< 0.008; E + M l,/? < 0.003; E + M h, p < 0.006) and M l users (M h, p < 0.023;

E + M l, p

< 0.006; E + M h, p < 0.001). AVLT total acquisition scores were similar among

the M h, E + M l, and E + M h users (p> 1).
Taken together, these findings showed a dose response effect o f marijuana use and a
possible neuroprotective effect of ecstasy on marijuana. Heavier or more frequent use of
marijuana affected word learning more profoundly than lighter marijuana use. This was
evidenced by the difference in total acquisition scores between the M l and M h users.
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In contrast, when ecstasy use was present, the dose response effect for marijuana was
attenuated. The lack of difference between total acquisition scores in the combined user
groups (E + M l and E + M h) might reflect a “basement effect.” However, since the E + M l
and E + M h user groups were matched on every aspect of ecstasy use and differed with
respect to their marijuana use, it is possible that ecstasy use attenuated the degree to
which heavy marijuana use produced the observed impairment in the acquisition of words
across five learning trials. Finally, the lack of significant differences in total acquisition
scores among group C and the M l users (p > 1) suggests that the M l users particular
pattern o f marijuana use was not sufficient to impact adversely the ability to learn a list of
words.
Interference Trial. Scores on interference trial B represented the number of words

recalled following a single presentation of a new word list (List B). List B assessed
participants’ supraspan ability immediately following learning, that is, the attentional
processes related to the acquisition of information prior to storage. Group means and
standard deviations for the interference trial are presented in Table 8.

Table 8
Mean number of words recalled on the interference trial for the groups
(standard deviations are included in parentheses)
Group
C
Ml
Mh
E+M l
E+M h

Observed
Mean*
6.800(1.9)
7.321 (2.1)
6.046(1.7)

Adjusted
Means**
6.611 (0.7)
7.514(0.7)
6.042(1.3)

Adjusted
Means***
6.540 (0.8)
7.545 (0.7)
5.764 (0.9)

6.667(1.5)

6.501 (0.9)

6.108(1.0)

5.895 (1.6)
6.676(1.1)
5.994 (0.8)
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use o f other drugs were treated as covariates.
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The initial MANCOVA and subsequent ANCOVA analyses showed that there were
significant group differences in the number of words recalled on List B, F(\ ,4) = 3.034 ,
p < 0.021. The number of words recalled from the interference list (List B) was similar

for group C and each o f the drug user groups. However, the M l users recalled
significantly more words on the interference trial than the Mh users {p < 0.004) and the
E+Mh users (p < 0.004). Figure 6 displays the observed mean number of words recalled
on the interference trial for the groups.
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Figure 6
Mean number of words recalled on the interference trial (List B) of the
AVLT for each group.

These findings along with a lack of significant differences between the M h users and
the E +M l and E+Mh users indicates that heavier marijuana use and not ecstasy use, is
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more closely associated with producing a decrease in the number of words recalled or
disruptions in attentional processes needed to learn a new list of words.
The first analyses also indicated there were differences in the number of words
recalled by males and females on the interference trial. This was supported by
MANCOVA-ANCOVA findings of a significant gender X group interaction, F(l,4) =
2.512,/? < 0.047. Interference trial means and standard deviations for males and females
in the groups are reported in Table 9.

Table 9
Interference scores for males and females in each group (means and
standard deviations)
Observed
Adjusted
Adjusted
Means*
Means**
Means***
Females
Females
Males
Females
Males
Males
Group
C
6.200(1.9) 7.700(1.6) 6.009 (0.9) 7.987(1.1) 6.034(1.0) 7.949(1.2)
7.846(1.9) 6.867(2.1) 7.696(1.0) 6.997(1.0) 7.228(1.2) 7.402(1.1)
Ml
6.250(1.4) 5.928 (1.9) 6.123(1.2) 6.001 (0.9) 6.168(2.1) 5.975(1.4)
Mh
7.250(1.8) 6.000 (0.8) 6.771 (0.9) 6.547 (0.9) 7.034(1.1) 6.247 (1.2)
E+M l
5.714(1.4) 6.000 (1.8) 5.369 (1.5) 6.201 (1.1) 6.175(0.8) 5.733 (0.9)
E+M h
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use o f other drugs were treated as covariates.

Tests o f simple effects conducted via ANCOVA analyses revealed that females in
group C recalled significantly fewer words than males (/? < 0.010). Figure 7 illustrates the
gender differences in interference performance. The finding o f poorer recall performance
in the females assigned to the C group was tmexpected, since females tend to perform
better on tests of verbal learning and memory than males (Lezak, 2004).
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Figure 7
Observed means and standard errors for females and males in each group on
the interference trial of the AVLT.

When monthly and cumulative use of other drugs were added as covariates, in the
second MANCOVA-ANCOVA analyses, the main effect of group remained significant
for interference scores, F(l,4) = 2.577 , p < 0.043. Likewise, post-hoc tests confirmed the
dose response effect of marijuana use. This was demonstrated by the finding that the M l
users recalled more words from interference List B than the Mh users (p < 0.004).
Unlike the post-hoc findings in the first analyses, however, the E + M h user group’s
word recall performance was no longer significantly worse than the M l users’ (p > 1).
This result demonstrates that other drug use is associated with the word recall deficit
observed for interference in the E + M h users and highlights the importance o f accounting
for polydrug use in ecstasy research.
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An effect o f ecstasy use on AVLT interference performance was also observed in the
second analyses. This was demonstrated by the fact the E + M l users recalled significantly
fewer words from interference List B compared to the Ml users (p < 0.028). Given that
these groups were matched for marijuana use and that other drug use was treated as a
covariate, the increased impairment observed in the E + M l users is likely attributable to
ecstasy use. It is possible that ecstasy use affected word recall in the E + M h users, too, but
may have been masked by the effects generated from taking other drugs. Finally, the
gender x drug group interaction for interference observed in the initial analyses was not
observed in the second set of analyses.
Proactive Interference. Proactive interference scores were calculated for each

participant by subtracting the sum of words recalled on interference trial B from the sum
of words recalled on trial 1 (trial 1 - trial B). This measure reflects the extent to which
List A learning interfered with the ability to learn words from List B. Greater word recall
scores in trial 1, compared to trial B (e.g., +1.1) indicate a more pronounced effect of
proactive interference, while scores of zero or lower (e.g., -1.1) indicate that List A
learning did not interfere with word learning in List B or that no proactive interference
effect was obtained.
Table 10 contains the observed means and standard deviations calculated for AVLT
proactive interference for each group. There were significant differences in the amount of
proactive interference exhibited among males and females within a group. This was
confirmed in the first set o f MANCOVA-ANCOVA analyses by a significant gender X
group interaction, F(l,4) = 2.512,/? < 0.047.
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Table 10
Proactive interference scores for males and females in each group (means
and standard deviations)
Adjusted
Observed
Adjusted
Means* **
Means*
Means**
Group
Females
Males
Males
Females
Males
Females
C
1.133 (2.0) 0.100 (1.4) 1.256 (0.9) -0.084(1.1) 1.617(1.1) 0.146(1.3)
-0.692(2.1) 0.267 (2.2) -0.591 (1.1) 0.179 (1.0) -0.152(1.1) 0.113(1.0)
Ml
0.625 (2.2) 1.214(1.7) 0.750 (1.4) 1.143(1.0) 0.675(1.5) 0.785(1.2)
Mh
-0.750 (2.4) 0.714(1.5) -0.424(1.4) 0.342(1.6) -0.218(1.5) 0.698(1.6)
E+Ml
1.714 (2.1) 0.417(2.3) 2.695 (1.8) -0.155(1.3) 2.733 (1.9) -1.091 (1.5)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; ♦♦• = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use of other drugs were treated as covariates.

Figure 8 illustrates proactive interference scores on the AVLT for females and males
in each group. Scheffé post-hoc comparisons after the first set of analyses showed that
females in the E + M h user group had greater difficulty learning List B words because o f
interference created by List A learning than males (p < 0.004).
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Figure 8
Observed means and standard errors calculated for proactive interference
for each group.
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The gender X group interaction for proactive interference scores remained significant
after accounting for other drug use, F(\,A) = 3 .4 8 7 ,< 0 .0 1 1 . Likewise, post-hoc tests
also showed that the female E +M h users experienced more proactive interference from
List A learning than the males {p < 0.001) which indicates that females showed a
decreased ability to suppress previous List A learning during the acquisition of List B
words.
Trial 6 (Immediate Recall). Scores on trial 6 of the AVLT reflect the number of

words recalled from List A, immediately following a single presentation and recall of
interference List B. Group means and standard deviations for the number o f words
recalled on AVLT trial 6 are displayed in Table 11. The initial MAN CO V A-AN COV A
analyses showed there were significant group differences in the number of words recalled
on trial 6, F("l ,4) = 3.112 ,/? <0.018.

Table 11
AVLT trial 6 (immediate recall) scores for each group (means and standard
deviations are reported)
Observed
Adjusted
Adjusted
Group_________Means*_____ ________ Means**
Means***
12.972(1.1)
12.959 (2.3)
c
13.040(1.6)
12.643(1.0)
12.214 (2.2)
12.436(1.0)
Ml
10.096(1.2)
11.011 (1.0)
11.000(3.4)
Mh
11.148 (1.4)
11.333 (2.4)
11.071 (1.3)
E+Ml
11.650(1.5)
11.000(2.7)
10.974(1.1)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use o f other drugs were treated as covariates.

Figure 9 displays the group means and standard errors for the AVLT immediate recall
trial. Post-hoc tests showed that immediate recall performance for groups C and M l were
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similar (p > 1). However, group C recalled significantly more words after the
presentation of the interference list than the M h ip < 0.023), E+M l ip < 0.044) and E+M h
user groups (p < 0.011).
Additionally, a dose response effect of marijuana use was demonstrated by the fact
that the M l users recalled significantly more words after the presentation o f the
interference list than the Mh users (p < 0.047). Immediate recall performance in the M l
users was also significantly higher than the E+M l ip < 0.024) and E+M h user groups (p <
0.012). There were no observed differences in scores on trial 6 among the Mh users and
either o f the combined user groups (E+M l and E+M h) (for both p > 1).
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Mean number o f words recalled on AVLT trial 6 for each group.

When cumulative use of other drugs were controlled for in the second MANCOVAANCOVA analyses, group main effects remained significant for trial 6, F(\,A) = 3.448,p
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< 0.012. However, the post-hoc comparisons that reached significance were different in
the second set o f analyses. For instance, neither of the combined user groups (E + M l and
E + M h)

no longer recalled significantly fewer words than group C or M l users (for both p

> 1), which indicates that the word recall deficits observed in the E + M l and E + M h user
groups in the first set o f analyses are probably more appropriately attributed to the use of
other drugs. The Mh users recalled fewer words from List A following the interference
trial than M l users ip < 0.002) suggesting that there may be a dose response effect for
marijuana use on immediate recall.
Trial 7 (Delayed Recall). Group means and standard deviations for trial 7 of the

AVLT are displayed in Table 12. The groups differed with respect to the number of
words recalled after a 20-minute delay. This was evidenced by a main effect for group in
the first MAN COVA-AN COVA analyses, F (\,4) = 5.119 ,p < 0.001.

Table 12
deviations)

Trial 7 (delayed recall) scores for each group (means and standard

Adjusted
Adjusted
Observed
Group
Means**
Means***
Means*
13.361 (0.9)
13.200(1.0)
C
13.440 (1.4)
12.464 (2.0)
12.706(0.8)
12.818(0.9)
Ml
11.243 (1.0)
11.639(0.9)
11.636(2.6)
Mh
11.109(1.2)
10.936(1.1)
11.200(2.3)
E+Ml
11.322(1.3)
11.000(2.8)
10.954(1.0)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use o f other drugs were treated as covariates.

Figure 10 illustrates the differences between the groups performance on AVLT trial
7. Group C recalled more words after the 20-minute delay than the Mh ip < 0.007), the
E + M l (p

< 0.001), and E + M h user groups ip < 0.001). The M l users recalled significantly
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more words after the long delay than the E+M l users (p < 0.013) and the E+Mh users (p <
0.008).
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Figure 10 Mean number of words recalled on trial 7 of the AVLT for each group.

The main effect of group remained significant in the second MANCOVA-ANCOVA
analyses, F (\,4) = 2.925,p < 0.026. Post-hoc tests indicated that group C recalled more
words after the 20-minute delay than the M h (p < 0.008), the E+M l (p < 0.011), and
E+M h users (p < 0.037). Moreover, the M l users recalled significantly more words than

the M h users (p < 0.026) and the E+M l users (p < 0.024) on trial 7. The comparison
between the E+M h users and the M l users delayed recall performance was not far from

approaching significance (p < 0.067).
Taken together, these findings suggest that the fi-equency of marijuana use primarily
affects delayed recall performance. Heavier marijuana use was associated with greater
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reductions in the number of words recalled on trial 7 than lighter use. While ecstasy use
also had a negative impact on delayed recall scores, its effects tended to be less robust.
Recognition. Group means and standard deviations for hits or the number of words

accurately discriminated as List A words on the AVLT recognition trial are reported in
Table 13. There were significant differences among the groups with respect to hits on the
recognition trial. This was confirmed in the initial MANCOVA and subsequent
ANCOVA analyses yielded a main effect o f group, F(l,4) = 3.181 ,p < 0.017 on
recognition scores.

Table 13

Recognition scores for each group (means and standard deviations)

Adjusted
Observed
Adjusted
Means*
Means***
Group
Means**
C
14.880 (0.4)
14.809 (0.4)
14.805 (0.4)
14.544 (0.1)
14.429 (0.8)
14.539 (0.3)
Ml
14.015 (0.4)
14.318(0.7)
14.293 (0.4)
Mh
13.858 (0.5)
13.867(1.5)
13.821 (0.5)
E+Ml
14.656 (0.5)
14.368(1.0)
14.364 (0.4)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use o f other drugs were treated as covariates.

Figure 11 graphically displays group performance on the AVLT recognition trial. The
C group accurately recognized more words from List A than the Mh users (p < 0.043)
and E + M l users (p < 0.001). Recognition performance was also significantly better in the
M l users

than in the E + M l users (p < 0.013). There were no detectable differences among

the M h users, E + M l users, and E + M h users (p > 1).
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Figure 11
Observed group means and standard errors for hits on the AVLT
recognition trial.

Group differences remained significant when other drug use was controlled in the
second MANCOVA-ANCOVA analyses, F (\,4) = 3.680 , p < 0.008. Scheffé post-hoc
tests showed that group C recognized more words than the Mh users (p < 0.006) and the
E + M l users (p <

0.003) The M l users recognized more words than the E + M l users (p <

0.019), which illustrates a negative impact o f ecstasy use given these groups were
matched for marijuana use and other drug use was treated as a covariate. Interestingly,
the E + M h users recognized more words than the E + M l users (p < 0.018) and did not
differ statistically from the other groups (p > 1). No obvious reason for this result is
apparent in the data.
Error Associations. An error association was defined as the recall o f a word that

was either semantically or phonemically related to a word in the stimulus list. An
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increase in association errors is indicative of retrieval problems such as “tip-of-thetongue” syndrome,_where participants’ reveal they know the correct word but are unable
actually to recall it (Brown & McNeil, 1966). Error associations were summed for AVLT
trials 1 through 7 and the interference trial.
In the initial set of MANCOVA-ANCOVA analyses, a significant gender X group
interaction was observed for AVLT error associations, F (\,4) = 3.478,p < 0.011,
demonstrating that there were differences in the number of associations committed by
males and females in a group. Error association means and standard deviations for males
and females in each group are reported in Table 14.

Table 14
Error association scores for males and females in each group (means and
standard deviations)
Observed
Adjusted
Adjusted
Means*
Means**
Means***
Females Males
Group
Females Males
Females Males
0.1 (0.3) 0.9 (1.6)
C
0.0 (0.6) 0.9 (0.7)
0.1 (0.9) 0.8 (1.1)
0.5 (0.7) 0.4 (0.8)
0.5 (0.4) 0.3 (0.4)
0.6 (0.9) 0.4 (1.0)
Ml
0.1 (0.4) 1.0 (1.3)
0.1 (1.2) 0.7 (1.0)
0.2 (0.7) 1.0 (0.5)
Mh
0.8 (1.5) 2.0 (3.0)
0.6 (1.2) 2.3 (1.3)
0.7 (2.0) 2.0 (2.1)
E+Ml
2.1 (3.6) 0.3 (0.6)
2.8 (2.1) 0.2 (1.5)
2.7 (1.5) 0.2 (1.2)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; ♦•♦ = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use of other drugs were treated as covariates.

Figure 12 illustrates the mean number of associations made by males and females in
the groups. Tests of simple effects revealed that the females in the E+M h user group
made significantly more error associations on the AVLT than the male E+M h users (p <
0.050) suggesting that ecstasy use combined with heavier marijuana use produced greater
difficulty with word retrieval in females.
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Figure 12
Mean number of error associations made by males and females in each
group on the AVLT.

Similarly, the gender X group interaction for AVLT error associations was observed
in the second analyses, Ffl,4) = 4.513, p < 0.050. Tests o f simple effects revealed the
males in the E + M l user group made significantly more AVLT error associations than
females in the E + M l group (p < 0.049). Alternatively, females in the E + M h user group
made significantly more association errors than the male E + M h users (p < 0.048).
BFLT-E Tasks
Trial 6 (Immediate Recall). Like the AVLT, trial 6 of the BFLT-E represents

immediate recall, that is, the number o f figures recalled from List A following the
presentation of a new list of figures (List B). The initial MANCOVA-ANCVOA analyses
that treated age, education, and verbal IQ scores as covariates yielded a main effect of
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group for BFLT-E immediate recall scores, F(\,A) = 2.676,p < 0.014. The observed and
adjusted group means and standard deviations for the immediate recall trial on the BFLTE are reported in Table 15.

Table 15
deviations)

BFLT-E immediate recall scores for each group (means and standard

Adjusted
Adjusted
Observed
Group
Means*
Means**
Means***
39.571 (2.3)
39.905(1.3)
39.320 (5.3)
C
38.362 (2.2)
37.750 (5.9)
37.873 (1.2)
Ml
37.847 (2.4)
37.738(1.4)
37.727 (4.5)
Mh
35.871 (3.0)
37.571 (1.6)
36.933 (6.8)
E+Ml
33.638(1.7)
34.573 (2.6)
35.105 (6.7)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use o f other drugs were treated as covariates.

Figure 13 illustrates BFLT-E immediate recall performance for each o f the groups.
Scheffé post-hoc tests showed that the E+M h user group recalled significantly fewer
figures from List A following the presentation and recall of a new list o f figures
compared to group C (p < 0.005) and the M l user group (p < 0.028). None of the other
comparisons were significant.
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Figure 13
recall trial.

Observed group means and standard errors for the BFLT-E immediate

When monthly use of alcohol and nicotine and the cumulative use of other drugs were
added as covariates in the second set of MANCOVA-ANCOVA analyses, immediate
recall scores were no longer significantly different between the groups (p > 1). This
indicates that the use of other drugs accounted for a significant proportion of the
immediate recall impairment observed in the E + M h drug user group in the first set of
analyses.
Extra Responses. Extra responses were summed for all of the BFLT-E trials, except

the recognition trial. Both perseverations and extraneous responses constituted extra
responses. Perseverations were defined as the repetition of a design, whereas, an extra
response meant drawing a design that was unrelated to those in the stimulus list. Means
and standard deviations for BFLT-E extra response data for each group are presented in
Table 16.
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Table 16

BFLT-E extra responses for each group (means and standard deviations)

Observed
Adjusted
Adjusted
Means***
Group
Means*
Means**
C
0.231 (1.6)
0.483 (0.9)
0.200 (0.4)
1.598 (0.8)
1.464(2.8)
1.144(1.5)
Ml
2.454(1.7)
2.321 (1.0)
2.546 (5.2)
Mh
2.667 (6.8)
3.256 (2.0)
E+Ml
2.968(1.1)
4.211 (6.7)
3.663 (1.2)
4.282(1.8)
E+Mh
Notes: * = means before the covariate analyses; ** = means after age, education, and verbal IQ were
treated as covariates; *** = means after age, education, verbal IQ, monthly alcohol and nicotine, and
cumulative lifetime use of other drugs were treated as covariates.

Initial MANCOVA-ANCOVA analyses conducted on the BFLT-E extra response
scores yielded a main effect o f group, F (\,4) ~ 3.454, p < 0.011, demonstrating that there
were significant differences in the number o f extra responses made across the groups.
Post-hoc tests confirmed that the ecstasy-marijuana user groups (E + M l and E + M h) made
more extra responses than group C (p < 0.022; p < 0.001). Also, the E + M h users
committed more errors on this BFLT-E measure than the M l users (p < 0.009). Figure 14
displays the differences in the number of BFLT-E extra response committed for each
group.
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Figure 14
The observed mean total number of extra responses made on BFLT-E trials
1 through 7 and on interference trial B for each group.

In contrast, the main effect of group for the BFLT-E extra response data did not reach
significance in the second set of MANCOVA-ANCOVA analyses (p >1). This suggests
that the group differences initially observed in the first set of analyses were closely
associated with the consumption of drugs other than ecstasy and marijuana.
Taken together, the second set of analyses conducted on the immediate recall and
extra response data emphasize the importance of accounting for polydrug use in
recreational ecstasy users. Moreover, these findings call into question the conclusions
drawn in previous studies that did not take into account the use of dmgs other than
ecstasy.
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Regression Analyses

Two standard multiple regression analyses were conducted to examine the degree to
which ecstasy, marijuana, and other drug use predicted performance on the AVLT
dependent measures that were significant in the MANCOVA-ANCOVA analyses which
treated age,_education, verbal IQ, and other drug use as covariates. In both regression
analyses, the following AVLT dependent measures were treated as criterion variables:
total acquisition, interference, immediate recall, delayed recall, and recognition.
In the first regression analysis, one drug use characteristic for ecstasy and six drug
use characteristics for marijuana were used as predictor variables. The drug characteristic
used as a predictor for ecstasy was cumulative lifetime use. This decision was based on
regression analyses conducted earlier on all eight ecstasy use characteristics (refer to
Table 6 for the drug use characteristics associated with ecstasy) which revealed
cumulative lifetime ecstasy use was the only significant predictor, R^ = .030, F (l, 101) =
2.10,p < .05. The following marijuana use characteristics were treated as predictors: age
of onset, number of years used, time since last use, amount of weekly use, amount of
monthly use, and cumulative lifetime use.
The seven predictors accounted for 16.3 percent of the variance in total acquisition
scores on the AVLT, R^ = .163, F (\, 101) = 2.80,p < .05. The simultaneous solution
suggested that the number of years marijuana had been used was the primary predictor
that explained AVLT total acquisition scores, P = -.374, /(lOl) = -3.07,p = .003. This
indicates that more deficits were observed in word learning performance with longer use
o f marijuana. Furthermore, none of the other marijuana use or ecstasy use predictors were
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found significantly to explain the variance for the other AVLT dependent variables:
interference, immediate recall, delayed recall, and recognition.
The second multiple regression analysis treated monthly use of alcohol and nicotine
and cumulative use of cocaine, LSD, oxycontin (hydrocodone), xanax, and percocet as
predictors to examine the contribution that these drugs had on verbal learning and
memory performance on the same significant AVLT dependent measures evaluated in the
first regression analysis. These drugs were selected as predictor variables because prior
MANOVA analyses conducted on the drug use data revealed the groups differed
significantly with respect to the total number of times these drugs had been used.
Collectively, the seven predictor variables accounted for 4.5 percent o f the variance
of AVLT total acquisition scores, ^ = .045, F (\, 95) = 5.08, p < .05. This indicates that
more deficits were observed in word learning performance when total lifetime uses of
cocaine, LSD, oxycontin (hydrocodone), xanax, and percocet were greater. No one
predictor contributed significantly to the variance of the total number o f words recalled
on the first five AVLT learning trials, although, cumulative LSD use was found to
approach significance, ^ = -.170, t(95) = -1.81, p = .072.
Likewise, the seven predictors together accounted for 11 percent o f the variance in
delayed recall scores on the AVLT,

= .110, F ( \ , 95) = 5.08,p = .05. The most

important predictor observed was cumulative LSD use, P = -.304, t(95) = -2.92, p < .05,
which is consistent with previous findings (Croft et al., 2001 ; Fox et al., 2001). These
findings demonstrate that greater lifetime uses of cocaine, oxycontin (hydrocodone),
xanax, percocet, and especially LSD are associated with reductions in the number of
words recalled after a long delay. None o f the other predictors were found to be
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significant for interference, immediate recall, or delayed recall performance on the
AVLT.
In summary, the regression analyses corroborated findings obtained in the secondary
AVLT MANCOVA-ANCOVA analyses, which showed effects o f ecstasy, marijuana,
and other drug use on total acquisition and delayed recall performance. With respect to
total acquisition, more deficits were observed in word learning performance with longer
use o f marijuana and to a lesser extent, with greater lifetime use o f ecstasy. Still further,
larger deficits were observed for total acquisition when total lifetime uses of cocaine,
LSD, oxycontin (hydrocodone), xanax, and percocet were greater. The fact that
cumulative LSD use approached significance in the regression analyses suggests that
total LSD use may affect word learning to a greater extent than the other drugs examined.
Finally, greater reductions in word recall after a long delay were observed with greater
lifetime use of other drugs, especially LSD use.
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CHAPTER 5

DISCUSSION
The primary goal o f the present study was to investigate the extent to which word
learning and memory deficits, previously observed in studies of recreational ecstasy
users, are associated with concomitant marijuana use and/or the use of other drugs rather
than ecstasy per se. The results that emerged from this study both complement and
contradict the findings of earlier studies that have investigated the effects of ecstasy use
on verbal learning and memory performance.
The results in the present study demonstrate that verbal learning and memory
deficits occurred on the AVLT in the combined ecstasy-marijuana users relative to non
drug using controls, which is consistent with a number of previous memory studies of
recreational ecstasy users (e.g., Croft et al., 2001; Dafters et al., 1999; Fox et al., 2001;
Gouzoulis-Mayfrank et al., 2000; Klugman et al., 1999; Lamers et al., 2006; McCann et
al., 1998; McCardle et al., 2004; Morgan, 1999; Parrott & Lasky, 1998;Parrott et al.,
1998; Quednow et al., 2006; Reneman et al., 2001; Thomasius et al., 2003; Verkes et al.,
2001; Wareing et al., 2000; Yip & Lee, 2005). Similarly, greater word recall deficits were
observed in heavier marijuana users than in non-drug using controls (e.g.. Block &
Ghoneim, 1993; Bolla et al., 1998; Bolla et al., 2002; Croft et al., 2001; Dafters et al.,
2004; Fletcher et al., 1996; Gouzoulis-Mayfrank et al., 2000; Kanayama et al., 2004;
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Lamers et al., 2006; Pope et al., 2001; Pope & Yurgelxm-Todd, 1996; Solowij et al.,
2002).
O f more direct relevance to the primary research question was the finding that,
generally speaking, verbal learning and memory impairments in the concurrent ecstasymarijuana user groups resembled those in the heavy marijuana-only user group,
indicating that the deficits observed in the combined ecstasy-marijuana users may be
more attributable to marijuana use than ecstasy use. Moreover, marijuana’s negative
effects on word learning and memory were dose dependent, which is consistent with
other published findings (e.g., Accordino et al., 2006; Bolla et al., 2002; Bolla et al.,
1998; Fletcher et al., 1996; Fried et al., 2002; Hall et al., 2004; Kouri et al., 1995; Solowij
et al., 1998). In this context, it should also be noted that the illicit use of psychoactive
substances other than ecstasy or marijuana also negatively impacted word recall in the
drug user groups.
More specifically with regard to the use of marijuana, dose response effects were
demonstrated for total acquisition, interference, immediate recall, and delayed recall trials
on the AVLT. On each of these dependent measures, heavier marijuana-only users
experienced greater difficulty learning two lists of words and subsequently retrieving
words from those lists than lighter marijuana-only users. Subsequently, heavier marijuana
use disrupted the ability to freely recall words from List A both immediately after list
presentation (immediate recall) and 20-minutes following List A presentation (delayed
recall). In contrast, to its effects on free recall, marijuana has no effect on recognition of
previously presented words within a list of old and new words. As previously mentioned,
these dose-response effects of marijuana are in agreement with other published findings.
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For example. Block and Ghoneim (1993) have reported that relative to a matched group
of non-dmg using controls, heavy marijuana users had significant impairments in
memory retrieval along with deficits in verbal expression and mathematical reasoning.
Similarly, a large prospective study using younger and older populations o f Costa Rican
marijuana users and matched controls found that prolonged use o f marijuana is associated
with deficits in free recall and list learning tasks (Fletcher et al., 1996).
The results also imply that lighter marijuana users are not impaired to an extent that
would interfere with memory functioning in their daily lives. The M l drug user group
performed similarly to the non-drug control group on total acquisition, immediate recall,
delayed recall, and recognition trials o f the AVLT. The M l users reported smoking
marijuana 243 times in their lifetime, an average of once a week over a period of three
years, with two weeks elapsing since the time of their last use. In contrast, the M h user
group reported using marijuana a total of 2,241 times in a four year period, smoking an
average o f 12.5 times a week, with less than half a week elapsing since they had last used
marijuana.
Two lines o f evidence suggest that the deficits in the combined ecstasy-marijuana
drug user groups were not related primarily to ecstasy consumption. The first is that if
ecstasy or the combination o f ecstasy and marijuana were responsible for the cognitive
deficits seen on the AVLT, then it would be expected that the participants who used both
ecstasy and marijuana would perform more poorly than those who had used only
marijuana, whereas if marijuana were primarily responsible for the deficits then there
should be no difference between the groups. Thus, the present finding that neither of the
ecstasy-marijuana user groups performed worse than the heavier users of just marijuana
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on total acquisition, interference, immediate recall, and delayed recall trials suggests that
the deficits obtained in the combined user groups were not primarily associated with
ecstasy use. Second, that the number o f years of marijuana use was the best predictor of
AVLT total acquisition performance in the regression analyses further substantiates
marijuana’s contribution to the word learning and memory deficits observed in the
current work.
Further support for the argument that ecstasy use is not predominantly responsible for
poorer word recall performance can be derived from the second set of MANCOVAANCOVA analyses, which treated other drug use as a covariate (i.e., monthly use of
alcohol and nicotine and the cumulative lifetime use of cocaine, amphetaminemethamphetamine mushrooms, LSD, solvents, heroin, oxycontin (hyrdrocodone), muscle
relaxers, xanax, percocet, valium, ritalin/adderall, ambien/lunesta, morphine, methadone,
and demerol). This other drug use was responsible for a significant proportion o f the
differences among the drug user groups on interference, immediate recall, and delayed
recall scores on the AVLT. Moreover, the regression analyses showed that other drug use
explained 4.5 percent of the differences in total acquisition scores on the AVLT, with
LSD falling just short of approaching significance as the best predictor o f total
acquisition performance. Indeed, LSD accounted for the largest proportion of the
variance observed in delayed recall scores among the drug user groups. Similarly, other
illicit drug use was strongly associated with figure recall deficits and errors committed on
the BFLT-E dependent measures.
Although heavier marijuana and other illicit drug use were closely associated with the
observed word learning and retrieval failures in the present study, subtle negative effects
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o f ecstasy use were, in fact, found. For example, E + M l users exhibited greater difficulty
learning new sets of words, as shown by lower total acquisition and interference scores,
than the M l users. Moreover, female E + M h users experienced a greater inability to
suppress previous List A learning while trying to acquire List B words than male E + M h
users. Additionally, males in the E + M l user group and females in the E + M h user group
made significantly more errors of association than the corresponding marijuana-only user
groups. Finally, the E + M l users also had more difficulty with word retrieval after the 20minute delay and with word recognition than the M l users.
Taken together, the above articulated subtle effects of ecstasy do not invalidate the
robust verbal learning and memory deficits reported in other ecstasy research, they just
were not observed in the present study. Differences in word recall performance were
primarily associated with heavier marijuana use and the illicit use of other psychoactive
substances. To some extent, ecstasy use negatively affected word learning rates, free
recall abilities, and the number o f errors committed on the AVLT. However, the extent of
ecstasy’s contribution to verbal impairment seems far less reaching than that of marijuana
and other drugs.
The disparity between the results observed in this study and other published research
on ecstasy may be, in part, explained by differences in participants’ ecstasy use
characteristics. The total number of ecstasy tablets taken among the ecstasy-marijuana
user groups in this study was substantially less than in previous studies (see Table 3 in
Appendix I). For example, in this study, the ecstasy-marijuana user groups reported a
mean cumulative lifetime use of 30.3 (E + M l) and 33.4 (E + M h) ecstasy tablets compared
to ecstasy users in the Thomasius et al. (2003) study, who reported a mean cumulative
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use o f 1,033 ecstasy tablets and relative to the ecstasy users in the Quednow et al. (2006)
study who had used 457 ecstasy pills in their lifetime.
It should be noted that heavy marijuana smokers (M h and E + M h) reported a higher
rate o f use o f other drugs, which is consistent with findings from other investigations
(Bolla et al., 1998; Hall et al., 1995; Kouri et al., 1995; Pope et al., 2001; Solowij et al.,
2002). Both of the heavier marijuana groups used a wider variety o f drugs and more of
them. Other studies show that as polydrug use widens, it also intensifies, with polydrug
users being also the heaviest users of alcohol, tobacco, and other stimulants (e.g., Kouri
et al., 1995; Milani et al., 2000; Parrott et al., 2001).
The present study extends the existing ecstasy literature related to cognitive and
memory function. This study dealt with the methodological shortcomings and
confounding variables that have plagued a number of earlier ecstasy-related
investigations by adequately matching participants with regard to intellectual function,
education level, gender and age. Moreover, specific consideration for the concomitant use
of other illicit drugs by ecstasy users, specifically marijuana, was controlled.
Given that the cause o f the learning and memory deficits obtained in this research
seems to lie primarily at the feet o f marijuana, it seems appropriate to devote the balance
of this discussion to a number of potential neurochemical explanations for the observed
verbal learning and memory impairments in heavy marijuana users, whether or not they
are concurrently using ecstasy. In so doing, this researcher does not intend to imply that
ecstasy and other psychoactive drugs do not have adverse effects on learning and
memory but instead that the effects of marijuana in this context seem to be pervasive and
deserving o f further consideration.
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The serotonin (5-HT) system is a diverse and intricate system composed o f at least 14
identified receptor subtypes (Barnes & Sharp, 1999). Serotonergic nerve fibers originate
in the raphe nuclei of the hindbrain and project widely throughout the brain innervating
almost every major brain structure (Abrams et al., 2004). One interesting aspect of the
serotonin system is the reciprocal interactions many of its receptors have with one
another. For example, 5-HTia and 5-HTiA receptors appear to exhibit opposing roles
(Araneda & Andrade, 1991; Darmani et al., 1990). Specifically, activation of 5-HT,A
receptors typically results in cellular hyperpolarization and inhibition of cell firing,
whereas activation of 5-HT2a receptors induces cellular depolarization and increased cell
firing (Araneda & Andrade, 1991). Additionally, these two receptors appear to elicit
opposing behavioral responses, with 5-HT ia receptor activation inducing hyperphagia,
increased male sexual behavior, anxiolysis, and hypothermia, whereas activation o f the 5HT2Areceptor induces hyperthermia, reduced male sexual behavior, anxiogenesis, and
hypophagia (Abdel-Fattah et al., 1995). Concomitant activation o f one serotonin receptor
results in functional inhibition of another. This suggests that the net effect of serotonergic
activity is delicately regulated by the balance of serotonin receptors (Hill et al., 2003).
The endocannabinoid system is a neuromodulatory system in the brain that shares a
high level o f overlap with the serotonergic system in terms of the physiological processes
it regulates. For example, both the serotonergic and endocannabinoid systems regulate
body temperature, feeding behavior, sleep and arousal, and emotional processes
(Chaperon & Thiebot, 1999; Hill et al., 2005).
In vitro and in vivo work has suggested that cannabinoids might influence 5-HT
release. Cannabinoid receptor (CB|) agonists suppress electrically- and calcium -
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stimulated 5-HT release from cortical slices (Nakazi et al., 2000) and THC inhibits the
release o f 5-HT in the hippocampus (Egashira et al., 2002). This suppression of
serotonergic neurotransmission by cannabinoids is believed to be involved in the memory
deficits produced by THC. Pretreatment with a 5-HT precursor, 5-hydroxytryptophan (5HTP), or a 5-HT reuptake inhibitor, clomipramine, reverses these THC-induced deficits
(Egashira et al., 2002).
Biochemical work has further suggested that endocannabinoids may enhance 5-HT ia
receptor-mediated responses but attenuate 5-HT2a receptor-mediated responses (Boger et
al., 1998). This finding is supported by behavioral studies that have found that both short
and prolonged administration of potent CBi receptor agonists potentiated 5-HT2a
behaviors while reducing 5-HT%A receptor behaviors (e.g.. Cheer et al., 1999; Darmani,
2001; Gorzalka et al., 2005; Hill et al., 2003).
Shifting our consideration to another neurotransmitter, cannabinoids increase
dopamine neurotransmission in the nucleus accumbens (Di Chiara & Imperato, 1988;
Nestler, 2002; Wise, 2002). Cannabinoids participate in the regulation of dopamine
synthesis, release and turnover (Gardner & Vorel, 1998). It is possible that the negative
memory effects observed in the present study were associated with the sustained use of
marijuana which is known to produce decreased dopamine neural transmission via
systemic down regulation of dopamine receptors in the hippocampus, especially D 2
receptors (Fujishiro et al., 2005).
Hippocampal dopamine neurons project fi’om the ventral tegmental area, with some
of dopamine fibers in the posterior hippocampus originating from the substania nigra
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(Vemey et al., 1985). In fact several studies have shown that disturbances in
dopaminergic systems induce learning and memory in rats (Fujishiro et al., 2005).
Herkenham and colleagues (1990) demonstrated that cannabinoid receptors (CB,) are
located throughout the brain by using a synthesized ligand (CP 55940) that is structurally
similar to THC. They found that this ligand exhibited high density binding to CB|
receptors in the cerebellum, basal ganglia, cerebral cortex and hippocampus. The finding
that CBi receptors are located in the hippocampus and that the THC-like ligand readily
binds to these receptors correlates with marijuana's negative effects on learning and
memory fimction.
The hippocampus is located in the inferior medial temporal lobe. It has been shown to
be involved in memory functioning through studies with brain-damaged patients who, in
extreme cases, suffer anterograde amnesia, which is the inability to form new long-term
memories due to damage to the bilateral hippocampus (Gazzaniga et al. 1998). Rather
than the hippocampus actually storing or retrieving memories, it is critical in the transfer
of short-term memories into long-term memories by encoding and consolidating new
information.
Chan and colleagues (1998) have investigated the neurotoxicity o f THC on cultured
rat hippocampal neurons and slices. THC not only caused the shrinkage o f cell bodies
and nuclei o f neurons, but also caused genomic DNA strands to break. Neuronal toxicity
was found even with low doses, which were comparable to normal human consumption,
by Chiang & Barnett (1984). As expected, the rate of cell death increased with THC
concentration. There is speculation, which is consistent with findings of Herkenham et al.
(1990), that THC targets hippocampal neurons because there is an abundance o f CB,
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receptors in the hippocampus. When THC binds to these CBj receptors, it sets off
transcriptional-dependent cell death. It would seem to follow that there would also be
neurotoxicity of cells in the basal ganglia, cerebellum, and the cerebral cortex, since CBi
receptors have also been found in abundance there. However, Chan et al. (1998) found
that hippocampal neurons are more sensitive to THC than other cultured cortical neurons.
Chan et al. (1998) proposed that because THC is hydrophobic, neuronal death may be
due to interactions with membrane lipids rather than with the CBj receptors. However,
they found that the CBi receptor antagonist SR141716A completely inhibited neuronal
death, which led Chan and colleagues to conclude that the actual binding of THC to
cannabinoid CBi receptors in hippocampal neurons was responsible for the observed
neuronal death.
Although Chan et al.’s (1998) research was well-controlled and informative; this
experiment was done on rat hippocampal neurons in vitro, which begs the question of
whether it can be extrapolated to human hippocampal neurons in vivo. Even if this
extrapolation were accepted, it needs still to be determined in humans whether permanent
memory loss would occur due to the neuronal death of these cells by THC because
previous human data suggests that the effects of marijuana use on learning and memory
are reversible (e.g.. Pope et al., 2001; Solowij et al., 2002; Sullivan, 2006).
Brain imaging studies have also tried to pinpoint the neural physiological alterations
induced by marijuana use. For example. Amen and Waugh (1998) attempted to find a
correlation between chronic marijuana usage and changes in localized brain activity using
single photon emission computer tomography (SPECT). SPECT measures changes in
cerebral blood flow by radioactive decay, which can then be visualized and interpreted as
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metabolically active regions in the brain. In Amen and Waugh's (1998) study, patients
diagnosed with attention deficit/hyperactivity disorder (ADHD) were compared with
other ADHD patients who used marijuana. The ADHD controls showed only a decreased
perfiision in the prefrontal cortex but no abnormalities in the temporal lobes. In contrast,
the ADHD-marijuana smokers exhibited a greater, dose related, decrease in activity of
the prefrontal cortex and decreased perfusion in the temporal lobes. Based on these
results. Amen and Waugh concluded that chronic marijuana usage changed the cerebral
perfusion pattern of the brain, specifically in the temporal lobe region. In this context, it
should be noted that Kandel and Schwartz (1985) had previously demonstrated that
memory deficits were associated with abnormal activity in the temporal lobes.
While Amen and Waugh's study was thorough, their reasoning behind using only
ADHD subjects can be questioned. Their justification for not studying a normal group of
marijuana users with a normal control group was that even a normal group adds an
element of uncertainty because so many marijuana users have additional diagnoses. This
is a weak argument since it seems ADHD patients who smoke marijuana will have the
complication of not only having ADHD, but additional diagnoses, since they too are
marijuana users. Nonetheless, their work sets the stage for future imaging studies to
examine the degree to which heavy marijuana use changes the brain physiologically with
respect to memory.
In a study of hippocampal lesioned patients. Drew et al. (1980) used a test battery
consisting o f a series of psychometric tests including Babock Story Recall, Digit Span,
Paired-Associate Learning, and Murdock Retention Test. These tests were used to assess
recent memory function where the standard procedure was to provide a list o f items that
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marijuana intoxicated subjects first memorized and then were asked to recall immediately
and after a delay. During the delay, the subject was engaged in another mental activity
(i.e., counting backwards in three's) to prevent rehearsal.
Drew and colleagues (1980) results showed that acute marijuana intoxication did not
affect memory retrieval from short term/working memory when the list was recalled
immediately after learning. However, after the delay period the number of items recalled
by the intoxicated subjects significantly decreased compared to the control group. The
interesting portion o f this study here is that the performance of marijuana- intoxicated
subjects was also compared with hippocampal brain damaged patients. The results
indicated that these two groups performed similarly on the test battery. These findings
suggest that being under the influence of marijuana may be similar to creating a
temporary lesion in the hippocampus with respect to impaired memory function.
Given the range o f possible reductive mechanisms that might underlie the behavioral
data obtained in the present study, more research is clearly needed to evaluate the long
term, and possibly permanent, effects of marijuana use on memory. Future experiments
should examine acute users, chronic users, and ex-users of marijuana, and the effect of
the length and frequency of marijuana use on memory functions. Furthermore, behavioral
studies and brain imaging investigations should prove beneficial in more adequately
pinpointing the physiological aspects that lead to functional memory impairments in
marijuana users. A direct benefit of understanding fully the memorial effects of
marijuana is that it would permit a better understanding of the combined effects of
marijuana and other psychotropic dmgs, starting with the combined effects of marijuana
and ecstasy.
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APPENDIX I

TABLES
Table 1
Studies investigating explicit long-term verbal learning and memory in
ecstasy users with relatively strong control over the influence of drugs apart fi'om ecstasy
Investigation

Immediate
Recall
.ns#

Delayed
Recall
ns

Curran &
Verheyden
(2003)

.ns

sig.+DD

RBMT Prose
Recall &
Buschke Selective
Reminding Task

Dafters, Hoshi,
& Talbot
(2004)

.ns#

.ns#

Fox, Toplis et
al. (2001)

slg.+DD

sig.+DD

RBMT
Immediate &
Delayed Passage
Recall
AVLT

GouzoulisMayfrank et al.
(2000)

sig.+DD

sig.

VLMT-German
version AVLT

Halpem et al.
(2004)

.ns

.ns

Lamers et al.
(2006)

.ns#

.ns

WMS-Verbal
Paired
Associates/CVLT
AVLT

McCardle et al.
(2004)

sig.

sig.

AVLT

compared MDMA and polydrug

Montgomery,
Fisk,&
Newcombe
(2005)

sig.

Verbal Paired
Associates

users; statistically controlled for
cannabis use; matched for IQ
compared MDMA and polydrug
users matched on other drug use
and IQ; covariate analyses revealed
cannabis use affected performance

Croft et al.
(2001)

.ns

Memory Test

Variables Controlled

Coughlan List and
Design Learning
Test

compared MDMA-cannabis users,
cannabis-only controls and non
drug users; matched on cannabis
and IQ; performed covariate
analyses for total cannabis, total
MDMA, frequency of cannabis and
MDMA use
compared male ex- and currentMDMA; users with male polydrug
controls matched for cannabis use
and IQ and non-drug users;
manipulated MDMA
use in MDMA-cannabis groupheavy/light; matched on cannabis
and IQ; performed; covariate
analyses for other drug use
compared short-term and long-term
MDMA; users and polydrug
controls; statistically; controlled for
other drug use; matched for IQ
compared MDMA-cannabis,
cannabis-only and non-drug users;
matched for cannabis use; cannabis
use was associated with some
VLMT measures
compared MDMA and polydrug
users
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compared MDMA-cannabis and
cannabis only users with non-drug
users

Table 1 continued
Investigation

Immediate Recall

Variables
Controlled
Quednow et al.
.ns
sig.+DD; recall
German versioncompared
(2006)
AVLT
abstinent MDMA
consistency;
recognition,
users cannabisonly users, and
retroactive
interference
non-drug users;
statistically
controlled for
cannabis use
Reneman, Majoie sig.+DD
.ns
AVLT
SERT densities
et al. (2001)
were lower in
recent ecstasy
users but not in
abstinent ecstasy
users
.ns
CVLT
compared
Semple et al.
ns+DD
MDMA users and
(1999)
non-users; after
controlling for IQ
results were .ns;
lifetime doses of
MDMA was
associated; with
memory
impairment
.ns
Simon & Mattick
.ns
WMS-111
regression
(2002)
Auditory
analyses
Memory
approached sig.
for the effect of
current frequency
of cannabis use
Thomasius et al.
sig.+DD
sig.+DD
AVLT
compared ex- and
(2003)
current-MDMA
users; ex-users
memory was
worse than
current users;
SERT availability
was reduced only
in current users
compared “pure”
Yip & Lee (2005) sig.
sig.+DD
Chinese versionAVLT;
MDMA users and
non- drug users;
recognition
matched IQ
Note, sig, = significant deficit in ecstasy uses compared to controls. Unless otherwise stated, the findings shown are in
comparison to a control group of drug users who don’t use ecstasy, .ns = no significant difference between ecstasy
users and controls, p > .05. .ns# = no difference between ecstasy users and other drug users, but significantly different
from non-drug using controls. DD = Dose Dependence to some measure of ecstasy use.
Delayed Recall
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Memory Test

Table 2
Verbal learning and memory studies that exercised less control over the
influence of drugs apart from ecstasy and other possible covariates
Investigation

Immediate
Recall
.ns

Delayed
Recall
.ns

sig.+DD

sig. +DD

RBMT-Prose
recall

Bolla et al.
(1998)

sig.+DD

.ns

AVLT

Curran &
Travill (1997)

sig.

sig.

Prose recall

Fox, Parrott et
al. (2001)

.ns

ns

Krystal et al.
(1992)

sig.

sig.

Morgan (1999)

sig.

sig.

Parrott & Lasky
(1998)

sig.

sig.

24 single words
drawn from 6
semantic
categories
WMS Initial &
delayed
paragraph
RBMT-Story
recall
Auditory word
recall

Reneman,
Lavalaye et al.,
(2001)
Rodgers (2000)

.ns

sig.

AVLT

sig.

sig.

WMS-Verbal

ns

ns

Paired
Associative/
Logical
Memory
Word recognition

Back-Mad ruga
et al. (2003)
Bhattachery &
Powell (2001)

Verkes et al.
(2001)

Memory Test
AVLT

Notes
no drug use exclusion criteria
were applied to controls
compared novice-, regular-,
abstaining MDMA users and non
drug users; matched on IQ;
differed on frequency of cannabis
use over past month
no statistical control over the
influence of cannabis or other
drugs; controlled for IQ
compared MDMA users and
alcohol drinkers; no statistical
control over the influence of
cannabis use or other potential
covariates
no statistical control of cannabis
or other drugs

compared MDMA users to agematched normative data
statistical differences between
groups on IQ and other drug use
compared novice- and regular MDMA users with non-drug
users; no statistical control over
cannabis use or IQ
no statistical control over the
influence of cannabis use or other
possible covariates
compared MDMA-cannabis and
cannabis only and non-drug users
groups; considerable cannabis use
among both user grps; MDMA use
was light (20 tabs)

compared moderate- and heavyMDMA users with non-drug
users; no statistical control over
the influence of cannabis use or
other potential covariates
RBMT-Story
longitudinal study (over 1 yr) of
Zakzanis&
sig.
sig.
Young (2001)
15 MDMA users; memory
recall
declined from baseline to followup; MDMA use increased as did
other drug use
Note. sig. = significant deficit in ecstasy uses compared to controls. Unless otherwise stated, the findings shown are in
comparison to a control group of drug users who don’t use ecstasy, .ns = no significant difference between ecstasy
users and controls, p > .05. .ns# = no difference between ecstasy users and other drug users, but significantly different
from non-drug using controls. DD = Dose Dependence to some measure of ecstasy use.
.ns

sig.
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Table 3
Cumulative lifetime dose (unless otherwise specified) o f MDMA and
cannabis use in studies investigating explicit long-term verbal memory performance in
ecstasy users
Investigation
Back-Madruga et al. (2003)

Bollaetal. (1998)
Croft et al. (2001)

Curran & Travill (1997)

Curran & Verheyden (2003)

Ecstasy/MDMA Use
M = 74.6 (SD = 100.6) MDMA
users
M = not reported for non-drug
users
M = 60 MDMA users
M = 0 non-drug users
M = 41.9 (SD = 49.3) MDMA
users
M = 0.6 (SD = 1.3) Cannabisonly users
M = 0 non-drug users
M = not reported MDMA users
M = not reported non-drug
users
M = 4.33 (2.89) yrs of use
current MDMA users
M = 3.49 (2.63) yrs of use exMDMA users
M = 0 non-drug users

Dafters et al. (2004)

less than 50 tabs MDMA lightcannabis users
50 or more tabs MDMA heavycannabis users
M= 0 Cannabis-only users
M = 0 non-drug users

Fox, Parrot et al. (2001)

M = 364.6 MDMA users
M = 0 Polydrug users
M = 8II.5 (SD = 981.8) Long
term MDMA users
M = 223.9 (SD = 387.3) Short
term MDMA users
M = 0.6 ± 0.9 Polydrug users

Fox, Toplis et al. (2001)

Gouzoulis-Mayfrank et al.
(2000)

M = 93.4 (SD = 119.9) MDMA
users
M = 0 Cannabis-only users
M = 0 non-drug users

Halpem et al. (2004)

M = not reported MDMA users
M = not reported non-drug
users
M = 133.8 (SD= 101.3)
MDMA users
M = not reported MDMA

Krystal et al. (1992)

Lamers et al. (2006)

users
M = 0 Caimabis-only users
M = 0 non-drug users
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Marijuana/Cannabis Use
M = not reported MDMA users
M = not reported for non-drug
users
M = not reported MDMA users
M = not reported non-drug users
M = 10,964.9 (SD= 13,235.5)
MDMA users
M = 7762.4 (SD = 14,480.9)
Cannabis-only users
M = 0.5 (SD = 0.8) non-drug
users
M = not reported MDMA users
M = not reported non-drug users
M = 6.7 (4.2) yrs of use current
MDMA users
M = 7.2 (5.1) yrs of use exMDMA users
M = 7.4 (6.7) yrs of use non
drug users
M = 1252.9 (SD= 1078.1)
MDMA light-cannabis users
M = 1680.7 (SD = 838.2)
MDMA heavy-cannabis users
M = 1023.1 (SD = 670.7)
Cannabis-only users
M = 0 non-drug users
M = not reported MDMA users
M = not reported Polydrug users
M = 10,306.8 (SD = 22,119.5)
Long-term MDMA users
M = 1617.3 (SD = 2898.4)
Short-term MDMA users
M = 447.3 (SD= 629.2) Polydrug
users
M = 650 (SD = 635) avg daily
dose mg MDMA users
M = 724 (SD = 608) avg daily
dose mg Cannabis-only users
M = 0 non-drug users
M = not reported MDMA users
M = not reported non-drug users
M = not reported MDMA users

M = 932.4 (SD = 873)
MDMA users
M = 1581.6 (SD = 1432.5)
Cannabis-only users
M = 1.2 (SD = 2.1) non-drug

Table 3 continued
Investigation
McCann et al. (1999)

McCardle et al. (2004)

MDMA Use
M = 215(SD = 33) MDMA
users
M = 0 non-drug users
M = 30 MDMA users
M = 0 non-drug users

Morgan (1999)

M = not reported MDMA users
M = 0 Polydrug users
M = 0 non-drug users

Montgomery, Fisk, &
Newcombe (2005)

M = 315.30 (SD = 330.10)
MDMA users
M = 0 non-drug users

Parrott & Lasky (1998)

M = not reported MDMA users
M = not reported Non-drug
users
M = 457.9 (SD = 433.9)
MDMA users
M = 6.7 (SD = 24) Cannabisonly users
M = 485 (SD = 598) Current
MDMA users
M = 268 (SD = 614) ExMDMA users
M = 0 non-drug users

Quednow et al. (2006)

Reneman et al. (2001)

Rodgers (2000)

M = 20 times (over a 5-yr
period) MDMA users
M = 0 Cannabis-only users
M = 0 non-drug users

Semple et al. (1999)

M = 672 (SD = 647)
M = 0 Polydrug users

Simon & Mattick (2002)

M = 258 (SD = 574) MDMA
users
M = 5 Cannabis-only users

Thomasius et al. (2003)

M = 1,033.77 (SD= 1702.44)
Current Male users
M = 600.42 (SD = 565.28)
Current Female users
M= 987.31 (SD = 824.50) ExMale users
M = 533.80 (SD = 317.22) ExFemale users
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Cannabis Use
M = not reported MDMA users
M = not reported non-drug
users
M = smoke occasionally; not
specifically reported MDMA
users
M = 0 non-drug users
M = 13.74 (SD = 11.6) joints
consumed per week MDMA
users
M = 9.28 (SD = 11.5) joints
consumed per week Polydrug
users
M = 0 non-drug users
M = 2,128.71 (SD = 2,401.96)
MDMA users
M = 1,082.54 (SD = 1,439.33)
non-drug users
M = not reported MDMA users
M = not reported Non-drug
users
M = 547.1 (SD = 502.7)
MDMA users
M = 1033.4 (SD = 1348.6)
Cannabis-only users
M = 326.9 (SD = 514.9) joints
in past year Current MDMA
users
M =456.7 (SD = 881.9) joints
in past year Ex-MDMA users
M = 15.3 (SD = 16) joints in
past year non-drug users
M = 4 days per week (over a
10-yr period) MDMA users
M = 4 days per week (over a
11-yr period) Cannabis-only
users
M = 0 non-drug users
M = not reported MDMA users
M = not reported Polydrug
users
M = 67.9 joints per month
MDMA users
M = 62.6 joints per month
Cannabis-only users
M = 566.78 (SD= 1187.98)
Current MDMA users
M = 2132.91 (SD = 2199.77)
Ex-MDMA Users
M = 1247.66 (SD= 1290.57)
Polydrug Users

Table 3 continued
Investigation
Verkes et al. (2000)

MDMA Use
M = 741 Heavy MDMA users
M = 169 Moderate MDMA
users
M = 0 non-drug users

Yip & Lee (2005)

M = 35.84 (SD =13.21) ExMDMA users
M = 0 non-drug users
M = 19 MDMA users (at
baseline)
M = 55 MDMA users (at
follow-up)

Zakzanis & Young (2001)
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Cannabis Use
M = 1,850 Heavy MDMA
users
M = 1,890 Moderate MDMA
users
M = 0 non-drug users
M = 0 Ex-MDMA users
M = 0 non-drug users
M = 14% of MDMA users
reported cannabis use (at
baseline)
M = 15% of MDMA users
reported cannabis use (at
follow-up)

Table 6
Patterns of drug use by drug in the drug user groups and the control group
(means and standard deviations)
Ecstasy

Group
C
M i.
M„
E+ Ml
E+ Mh

Age of
Onset
0
0
0
18.1
(1.4)
18.8

.... (1:7)

#of
Times
Used a
Month
0
0
0
0.7
(2.1)
1.6
(4.6)

Lrgest
#of
Pills
Taken
in an
Episode
0
0
0
2.2
(1.5)
3.5
(2.4)

Time
Since
Last Use
0
0
0
34.5
(61.8)
14.3
(11.0)

Total #
of
Times
Used
0
0
0
30.3
(71.4)
33.4
(43.2)

Age of
Onset
0
16.1
(2.6)
15.6
(2.1)

# of Yrs
Used
0
3.3
(2.5)
4.3
(2.9)

Time
Since
Last
Use
0
1.9
(1.8)
0.3
(0.5)

Total # of
Times
Used
0
242.9
(564.6)
2241.2
(4261.6)

# ofTimes
Used a
Week
0
1.3
(0.9)
12.5
(13.6)

#of
Times
Used a
Month
0
5.2
(3.6)
49.9
(54.3)

16.0
(2.0)
15.3
(2.4)

4.4
(2.8)
6.1
(3.0)

1.4
(2.3)
0.3
(0.4)

509.5
(437.3)
3178.9
(3700.1)

2.0
(1.3)
16.8
(15.9)

8.3
(5.0)
65.2
(55.9)

Age of
Onset
0
18.3
(2.1)

# of Yrs
Used
0
1.5
(1.3)

Time
Since
Last
Use
0
96.3
(44.4)

Total # of
Times
Used
0
1.0
(0.0)

# ofTimes
Used a
Week
0
0.0
(0.0)

# ofTimes
Used a
Month
0
0.0
(0.0)

# of Yrs
Used
0
0
0
2.6
(2.1)
2.1
(2.0)

# of
Times
Used a
Week
0
0
0
0.1
(0.5)
0.3
(1.2)

Avg
# of
Pills
Taken
in an
Episode
0
0
0
1.6
(0.7)
1.9
(1.0)

Marijuana

Group
C
Ml

% of
Users in
Each
Group
0
100%

Mh

100%

E+ Ml

100%

E+ Mh

100%

Group
C
Ml

% of
Users in
Each
Group
0
14%

Cocaine

Mh

50%

17.8
(1.3)

0.8
(0.9)

43.6
(43.9)

3.8
(2.9)

0.0
(0.0)

0.5
(1.2)

E+ Ml

40%

18.3
(2.5)

2.0
(1.6)

15.8
(27.7)

6.8
(3.1)

0.0
(0.1)

0.0
(0.0)

E+ Mh

68%

19.0
(2.0)

1.7
(1.6)

43.4
(72.9)

0.0
(0.0)

0.2
(0.4)
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7.2
(2.9)

Table 6 continued
Methamphetamine/Amphetamine

Group
C
Ml

% of
Users in
Each
Group
0
11%

Mh
E+ Ml

5%
20%

E+ Mh

21%

Age of
Onset
0
17.3
(2.5)
15
19.0
. (3.0)
19.5
(4.0)

# of Yrs
Used
0
1.3
(1.5)
3
2.0
(1.0)
1.2
(0.9)

Time Since
Last Use
0
93.7 (54.0)

Total #
ofTimes
Used
0
1.0 (0.0)

# ofTimes
Used a
Week
0
0.0 (0.0)

#of
Times
Used a
Month
0
0.0 (0.0)

108
89.3 (57.9)

10
1.3 (0.6)

0
0.0 (0.0)

0
0.0 (0.0)

139.0(83.4)

6.8 (2.2)

0.0 (0.0)

0.0 (0.0)

# ofTimes
Used a
Week
0
0.0 (0.1)

#of
Times
Used a
Month
0
0.1 (0.4)

Mushrooms

Group
C
Ml

% of
Users in
Each
Group
0
25%

Mh

41%

E+ Ml

53%

E+ Mh

79%

Group
C
Ml
Mh

% of
Users in
Each
Group
0
0
5%

E+ Ml
E+ Mh

7%
37%

Age of
Onset
0
17.1
(2.3)
18.6
(1.9)

# of Yrs
Used
0
2.5
(2.0)
1.1
(1.2)

Time Since
Last Use
0
81.9(135.7)

Total #
ofTimes
Used
0
6.9 (5.5)

33.8 (42.5)

3.3 (3.5)

0.0 (0.0)

0.0 (0.0)

18.0
(0.9)
18.5
(2.9)

2.6
(1.8)
1.9
(2.0)

70.0 (60.9)

5.1 (3.0)

0.0 (0.0)

0.0 (0.0)

87.5 (105.6)

4.7(3.1)

0.0 (0.0)

0.0 (0.0)

Total #
ofTimes
Used
0
0
4

# ofTimes
Used a
Week
0
0
0

#of
Times
Used a
Month
0
0
0

1
4.6 (4.0)

0
0.0 (0.0)

0
0.3 (0.5)

LSD
Age of
Onset
0
0
17

# of Yrs
Used
0
0
1

Time Since
Last Use
0
0
16

18
19.9
(4.1)

4
0.7
(0.4)

208
133.9
(153.3)
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Table 6 continued
Solvents

Group
C
Ml

% of
Users in
Each
Group
0
14%

Mh

18%

E+M l

13%

E+ Mh

32%

Group
C
Ml
M„
E+M l
E+M h

% of
Users in
Each
Group
0
0
0
7%
5%

ofTimes
Used a
Week
0
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)

#of
Times
Used a
Month
0
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)

Age of
Onset
0
17.8
(3.3)
17.0
(2.6)
18.0
(0.0)

# of Yrs
Used
• 0
1.6
(2.9)
2.3
(2.1)
2.0
(2.8)

Time Since
Last Use
0
98.5
(69.5)
72.5
(40.1)
55.0
(69.3)

Total #
ofTimes
Used
0
1.5
(1.0)
5.5
(4.2)
2.0
(1.4)

18.0
(2.1)

1.5
(1.6)

104.8
(156.1)

3.0
(1.5)

0.0
(0.0)

0.0
(0.0)

Time Since
Last Use
0
0
0
104
1

Total #
ofTimes
Used
0
0
0
10
1

# ofTimes
Used a
Week
0
0
0
0
0

# of
Times
Used a
Month
0
0
0
0
0

Total #
ofTimes
Used
0
5.4
(5.2)
12.8
(8.0)

# ofTimes
Used a
Week
0
0.0
(0.0)
0.0
(0.0)

#of
Times
Used a
Month
0
0.1
(0.4)
0.3
(0.5)

0.0
(0.0)
0.0
(0.0)

0.3
(0.5)
0.2
(0.6)

#

Heroin

Age of
Onset
0
0
0
19
19

# of Yrs
Used
0
0
0
3
0

Hydrocodone

Group
C
Ml

% of
Users in
Each
Group
0
25%

Mh

50%

E+ Ml

60%

E+ Mh

68%

Age of
Onset
0
17.0
(2.1)
17.8
(1.1)

# of Yrs
Used
0
2.3
(2.0)
2.0
(1.7)

Time Since
Last Use
0
91.9
(74.2)
33.2
(50.7)

17.2
(1.9)
18.0
(1.6)

3.2
(1.4)
4.2
(6.1)

94.3
(101.4)
69.4
(99.3)
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7.8
(8.4)
7.9
(5.7)

Table 6 continued
Muscle Relaxers

Ml

% of
Users in
Each
Group
0
7%

Mh

5%

18

1

4

10

0

1

E+ Ml

13%

18.0
(0.0)

1.0
(0.0)

10.5
(13.4)

3.0
(1.4)

0.0
(0.0)

0.0
(0.0)

E+ Mh

21%

18.0
(1.4)

1.8

51.0
(37.7)

8.3
(3.5)

0.0
(0.0)

0.0
(0.0)

Time Since
Last Use
0
95.3
(65.4)
39.0
(50.6)
156.0
(52.0)
92.8
(121.4)

Total #
ofTimes
Used
0
2.7
(2.1)
13.7
(8.9)
2.7
(2.1)
9.5
(6.2)

# ofTimes
Used a
Week
0
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)
0.0
(0.0)

#of
Times
Used a
Month
0
0.0
(0.0)
0.2
(0.4)
0.0
(0.0)
0.2
(0.4)

Time Since
Last Use
0
69.7
(59.5)
30.2
(32.9)
0
93.0
(141.1)

Total #
# ofTimes
ofTimes
Used a
Used
Week
0
0
0.0
1.3
(0.0)
(0.6)
8.2
0.0
(8.7)
(0.0)
0
0
6.1
0.0
(3.0)
...... i0:0) ....

Group
C

Age of
Onset
0
16.5
(0.7)

# of Yrs
Used
0
3.5
(0.7)

Time Since
Last Use
0
130.0
(36.8)

Total #
ofTimes
Used
0
6.5
(4.9)

...(1:8)

# ofTimes
Used a
Week
0
0.0
(0.0)

#of
Times
Used a
Month
0
0.0
(0.0)

Xanax

Group
C
Ml

% of
Users in
Each
Group
0
11%

Mh

27%

E+ Ml

20%

E+ Mh

32%

Group
C
Ml

% of
Users in
Each
Group
0
11%

Age of
Onset
0
16.7
(0.6)
17.7
(1.6)
17.7
(2.1)
18.8
(1.0)

# of Yrs
Used
0
2.7
(1.5)
1.5
(0.8)
1.7
(2.1)
2.0
(1.3)

Percocet

Mh

23%

E+ Ml
E+ Mh

0
37%

Age of
Onset
0
17.0
(1.0)
18.0
(1.9)
0
17.9
(1.8)

# of Yrs
Used
0
3.3
(0.6)
1.8
(2.5)
0
5.2
(8.3)
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#of
Times
Used a
Month
0
0.0
(0.0)
0.0
(0.0)
0
0.0
(0.0)

Table 6 continued
Valium

Ml

% of
Users in
Each
Group
0
4%

Mh

9%

E+ Ml.
E+ Mh

7%
11%

Group
C

# ofTimes
Used a
Week
0
0

# of
Times
Used a
Month
0
0

Age of
Onset
0
16

# of Yrs
Used
0
4

Time Since
Last Use
0
104

Total #
ofTimes
Used
0
5

16.0
(0.0)
17
18.0
(1.4)

1.0
(1.4)
4
2.5
(0.7)

79.5
(108.2)
208
87.0
(89.1)

6.0
(5.7)
5
7.5
(3.5)

0.0
(0.0)
0
0.0
(0.0)

0.0
(0.0)
0
0.0
(0.0)

Time Since
Last Use
0
0
108
114.0
(132.9)
78.2
(97.0)

Total #
ofTimes
Used
0
0
4
1.0
(0.0)
5.0
(8.5)

# ofTimes
Used a
Week
0
0
0
0.0
(0.0)
0.0
(0.0)

# of
Times
Used a
Month
0
0
0
0.0
(0.0)
0.4
(0.9)

Time Since
Last Use
0
0
52
0
0

Total #
ofTimes
Used
0
0
2
0
0

# ofTimes
Used a
Week
0
0
0
0
0

# of
Times
Used a
Month
0
0
0
0
0

Time Since
Last Use
0
0
0
0
14.0
(15.6)

Total #
ofTimes
Used
0
0
0
0
4.5
(4.9)

# ofTimes
Used a
Week
0
0
0
0
0.0
(0.0)

#of
Times
Used a
Month
0
0
0
0
0.0
(0.0)

Ritalin/Adderall

Group
C
Ml
Mh
E+ Ml

% of
Users in
Each
Group
0
0
5%
13%

E+ Mh

26%

Age of
Onset
0
0
16
19.0
(1.4)
19.0
(1.7)

# of Yrs
Used
0
0
2
0.5
(0.7)
0.2
(0.4)

Ambien/Lunesta

Group
C
Ml
Mh
E+M l
E+ M h

% of
Users in
Each
Group
0
0
5%
0
0

Age of
Onset
0
0
18
0
0

# of Yrs
Used
0
0
0
0
0

Morphine

Group
C
Ml
Mh

E+ M l
E+ M h

% of
Users in
Each
Group
0
0
0
0
11%

Age of
Onset
0
0
0
0
20.0
(1.4)

# of Yrs
Used
0
0
0
0
0.5
(0.7)
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Table 6 continued
Methadone

Group
C
Ml
Mh
E+ Ml
E+M h

% of
Users in
Each
Group
0
0
0
0
5%

Group
C
Ml
Mh
E+ Ml
E+ Mh

% of
Users in
Each
Group
0
0
0
0
5%

Age of
Onset
0
0
0
0
21

#

of Yrs
Used
0
0
0
0
1

Time Since
Last Use
0
0
0
0
52

Total#
ofTimes
Used
0
0
0
0
6

# ofTimes
Used a
Week
0
0
0
0
0

#of
Times
Used a
Month
0
0
0
0
0

Time Since
Last Use
0
0
0
0
3

Total #
ofTimes
Used
0
0
0
0
5

# ofTimes
Used a
Week
0
0
0
0
0

#of
Times
Used a
Month
0
0
0
0
1

Demero
Age of
Onset
0
0
0
0
22

# of Yrs
Used
0
0
0
0
1

Alcohol

Group
C

% of
Users in
Each
Group
84%

Ml

84%

Mh

91%

E+ Ml

100%

E+ Mh

100%

Age of
Onset
16.9
(2.3)
15.3
(2.1)
15.7
(2.2)
15.9
(1.3)
15.1
(2.2)

# of Yrs
Used
3.2
(3.7)
4.5
(2.9)
4.5
(2.5)
4.6
(2.7)
6.1
(3.4)

Time Since
Last Use
21.9
(39.9)
1.8
(2.7)
2.8
(6.9)
29.8
(107.0)
1.6
(2.4)

Age of
Onset
15.7

# of Yrs
Used
3.7
(4.0)
3.6
(3.2)
3.4
(1.7)
5.2
(3.2)
5.3
(3.6)

Time Since
Last Use
89.3

# ofTimes
Used a
Week
1.2
(2.3)
4.3
(4.3)
4.3
(3.7)
4.3
(3.3)
6.2
(6.2)

# ofTimes
Used a
Month
4.7
(8.9)
18.0
(19.5)
17.3
(14.4)
17.6
(13.0)
24.6
(21.0)

Nicotine

Group
C

% of
Users in
Each
Group
12%

(1.5)

Ml

61%

Mh

50%

E+ Ml

60%

E+ M h

84%

15.4
(2.8)
16.0
(1.9)
15.8
(1.9)
16.1
(2.1)

(105.1)

45.4
(120.0)
9.6
(20.9)
0.4
(1.3)
34.4
(129.6)
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# ofTimes
Used a
Week
0.7
(1.2)
22.9
(44.8)
15.7
(20.7)
26.2
(22.2)
52.5
(57.6)

# ofTimes
Used a
Month
3.3
(5.8)
94.8
(185.9)
132.5
(252.0)
104.7
(89.0)
212.5
(234.6)

APPENDIX II

DRUG USE HISTORY QUESTIONNAIRE
Instructions
Part I: Demographic and Health Information

Now we will complete the drug use history questionnaire. The questionnaire is
divided into two parts. For the first part, I will ask you to provide me with basic
demographic and health information. There are 11 questions for this portion. For some of
the questions, if you answer yes, you will be asked to provide additional information. For
the last item on this portion o f the questionnaire, I will ask you if you’re currently taking
any prescribed medications. Please report only those medications that a doctor has
specifically prescribed to you and you are taking in the recommended manner. 1 will ask
you to report illicit prescription drug use in the second portion of the drug use
questionnaire.

Part II: Drug Use Inventory

In the second portion o f the questionnaire, 1 will ask you to report your drug use
history for a variety of drugs. For each drug that you have taken, 1 will ask you: at what
age did you begin using the drug, how many times have you used in your lifetime,
weekly and monthly usage, and time since last use. Specific to ecstasy, 1 will also ask you
how many pills you take on average per drug episode and what was the largest number of
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pills you ever used in an episode. On the last item on this portion of the questionnaire, I
will ask you if you have ever illicitly used prescription drugs. Illicit prescription drug use
refers to taking a medication that was not specifically prescribed to you and/or taking a
medication that was prescribed to you, but not in the manner it was prescribed (e.g.,
taking more than was prescribed).

Demographic and Health Information

1. Age
2. Gender
3. Years o f Education

4. Do you have a history of head
injury with loss of consciousness
requiring hospitalization?
5. Do you have a past or present
history o f medical illness?
If yes, please explain.
6. Have you ever been diagnosed
with a major psychiatric disorder?
If yes, please explain.
7. Have you ever been diagnosed
with a learning disorder? If yes,
please explain.
8. Is your health good?
P. Are you currently taking any prescribed medications?
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Drug Use Inventory

Drug

Age
of
Onset

#of
Yrs
Used

Time
Since
Last
Use

Total
#of
Times
Used

Ecstasy
Marijuana
Cocaine
Methamphetamine/
Amphetamine
LSD
Mushrooms
Heroin
Solvents
Alcohol
Nicotine
Prescription Drugs

Prescription Drugs

Prescription Drugs

Prescription Drugs
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#of
Times
Used
a
Week

# of
Times
Used
a
Month

Average
# of
Pills
Taken
in an
Episode

Largest
#of
Pills
Taken
in an
Episode
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